WO2001072728A2 - Novel piperazine derivatives - Google Patents

Novel piperazine derivatives Download PDF

Info

Publication number
WO2001072728A2
WO2001072728A2 PCT/IB2001/000375 IB0100375W WO0172728A2 WO 2001072728 A2 WO2001072728 A2 WO 2001072728A2 IB 0100375 W IB0100375 W IB 0100375W WO 0172728 A2 WO0172728 A2 WO 0172728A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
amino
aryl
alkylamino
alkylsulfonylamino
Prior art date
Application number
PCT/IB2001/000375
Other languages
French (fr)
Other versions
WO2001072728B1 (en
WO2001072728A3 (en
WO2001072728A9 (en
Inventor
Laura Cook Blumberg
Matthew Frank Brown
Molly Ann Mcglynn
Christopher Stanley Poss
Ronald Paul Gladue
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP01914083A priority Critical patent/EP1268455A2/en
Priority to HU0300567A priority patent/HUP0300567A3/en
Priority to CA002404626A priority patent/CA2404626A1/en
Priority to IL15192301A priority patent/IL151923A0/en
Priority to SK1365-2002A priority patent/SK13652002A3/en
Priority to EEP200200567A priority patent/EE200200567A/en
Priority to KR1020027012974A priority patent/KR20020084273A/en
Priority to APAP/P/2002/002637A priority patent/AP2002002637A0/en
Priority to AU2001239469A priority patent/AU2001239469A1/en
Priority to JP2001570640A priority patent/JP2003528867A/en
Priority to BR0109703-2A priority patent/BR0109703A/en
Priority to MXPA02009645A priority patent/MXPA02009645A/en
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Priority to PL01358618A priority patent/PL358618A1/en
Priority to UA2002097590A priority patent/UA73553C2/en
Priority to NZ521290A priority patent/NZ521290A/en
Priority to EA200200873A priority patent/EA006079B1/en
Priority to DZ013306A priority patent/DZ3306A1/en
Publication of WO2001072728A2 publication Critical patent/WO2001072728A2/en
Publication of WO2001072728A3 publication Critical patent/WO2001072728A3/en
Priority to IS6546A priority patent/IS6546A/en
Priority to BG107091A priority patent/BG107091A/en
Priority to NO20024649A priority patent/NO20024649D0/en
Priority to HRP20020785 priority patent/HRP20020785A2/en
Publication of WO2001072728A9 publication Critical patent/WO2001072728A9/en
Publication of WO2001072728B1 publication Critical patent/WO2001072728B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings

Definitions

  • the present invention relates to novel piperazine derivatives, methods of use and pharmaceutical compositions containing them.
  • the compounds of the invention are potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
  • the CCR1 receptor is also sometimes referred to as the CC- CKR1 receptor.
  • autoimmune diseases such as rheumatoid arthritis, type I diabetes (recent onset), lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis
  • acute and chronic inflammatory conditions such as osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis
  • allergic conditions such as asthma and atopic dermatitis
  • infection associated with inflammation such as viral inflammation (including influenza and hepatitis) and Guillian-Barre
  • chronic bronchitis such as xeno-transplantation, transplantation tissue
  • Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1 , as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1 , including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1 , HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex).
  • CMV cytomegalovirus
  • Herpes viruses Herpes zoster and Herpes simplex
  • TNF inflammatory cytokines
  • TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria.
  • MIP-1 and RANTES are soluble chemotactic peptides (chemokines) which are produced by inflammatory cells, in particular CD8+ lymphocytes, polymorphonuclear leukocytes (PMNs) and macrophages, J.Biol. Chem,, 270 (30) 29671-29675 (1995). These chemokines act by inducing the migration and activation of key inflammatory and immunomodulatory cells.
  • chemokines soluble chemotactic peptides
  • chemokines have been found in the synovial fluid of rheumatoid arthritis patients, chronic and acute rejecting tissue from transplant patients and in the nasal secretions of allergic rhinitis patients following allergen exposure (Teran , et al,, L Immunol., 1806-1812 (1996), and Kuna et al., J. Allergy Clin. Immunol. 321 (1994)).
  • Antibodies which interfere with the chemokine/receptor interaction by neutralizing MIP1 ⁇ or gene disruption have provided direct evidence for the role of MIP-1 ⁇ and RANTES in disease by limiting the recruitment of monocytes and CD8+ lymphocytes (Smith et al., J.
  • the present invention also relates to a compound of the 1 Formi
  • a is 1 , 2, 3, 4 or 5;
  • b is O, 1 , 2, 3 or 4;
  • c is 0 or 1 ;
  • d is 1 , 2, 3, 4 or 5;
  • e is 0 or 1 ;
  • j is 1 , 2, 3, or 4;
  • X is C(O), C(S) or CH 2 ;
  • Y is CH 2 , or if e is 0, Y is CHR 8 wherein R 8 is hydrogen, (C 6 -C 10 )aryl or NR 9 R 10.
  • Z is oxygen, NR 9 or CR 11 R 12 ; each R 1 is independently selected from hydrogen, hydroxy, hydroxysulfonyl, halo, (C C 6 )alkyl, mercapto, mercapto(C 1 -C 6 )alkyl, (C 1 -C 6 )a)kylthio l (C r C 6 )alkylsulfinyl, (C r C 6 )alkylsufonyl, (CrC 6 )alkylthio(C C 6 )alkyl, (C 1 -C 6 )alkylsulfinyl(C 1 -C 6 )alkyl, (C r C 6 )alkylsulfonyl(C r C 6 )alkyl, (CrC 6 )alkoxy, (C 6 -C 10 )aryloxy, halo(C r C 6 )alkyl, trifluoromethyl, formy
  • C 6 )alkylaminocarbonyl ((C ⁇ -C 6 )alkyl) 2 aminocarbonyl, (C 6 -C 1 o)arylaminocarbonyl, (C 6 - C 10 )aryl(C 1 -C 6 )alkylaminocarbonyl, carboxy(C ⁇ -C 6 )alkyl, (C 1 -C 6 )alkoxycarbonyl(C 1 -C ⁇ )alkyl, (C 6 -C 10 )aryl(C 1 -C 6 )alkoxycarbonyl(C 1 -C 6 )alkyl, aminocarbonyl(C C 6 )alkyI, (C r
  • R 4 is (R 5 ) f (R 6 ) g (C 6 -C 10 )aryl, (R 5 ) f (R 6 ) g (C 3 -C 10 )cycloalkyl, (R 5 ) f (R 7 ) h (C 2 -C 9 )heteroaryl, or (R 5 ) f (R 7 ) h (C 2 -C 9 )heterocycloalkyl, wherein f is 1 , 2, 3 or 4; ,g and h are each independently 0, 1 , 2 or 3; R 5 is one to three groups independently selected from (C 2 -
  • C 6 alkylcyanoguanidino, aminocarbonyl(CrC 6 )alkylamino, (C 1 -C 6 )alkylsulfonylamino(C 1 - C 6 )alkylamino, (C ⁇ -C 6 )alkoxycarbonylamino(C 1 -C 6 )alkylamino, aminosulfonyl(C
  • C 6 )alkylcarbonylamino(C ⁇ -C 6 )alkyl cyano(C 1 -C 6 )alkylcarbonylamino(C 1 -C 6 )alkyl, amino(C C 6 )alkylaminocarbonylamino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylamino(C 1 -
  • C 6 )alkyl cyanoguanidino(C ⁇ -C 6 )alkylureido(C ⁇ -C 6 )alkyl, halo(C 1 -C 6 )alkylsulfonyIamino(C 1 - C 6 )alkyl, amino(CrC ⁇ )alkylsulfonylamino(C- ⁇ -C 6 )alkyl, (C ⁇ -C 6 )alkylamino(C ⁇ -
  • R 6 is one to three groups independently selected from hydrogen, hydroxy, hydroxysulfonyl, halo, (C ⁇ -C 6 )alkyl, mercapto, mercapto(
  • C s alkylthio(C 1 -C 6 )alkyl, hydroxy(C 2 -C 6 )alkenyl, hydroxy(C 2 -C 6 )alkenyl, hydroxy(C 2 -C 6 )alkynyl, (C C 6 )alkoxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 6 -C 10 )aryl(C 1 -C 6 )alkyl, aryloxy(C r C 6 )alkyl, (C 6 - C 10 )aryl(C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, amino, (C C 6 )alkylamino, ((C 1 -C 6 )alkyl) 2 amino, (C 6 - C 10 )arylamino, (C 6 -C 10 )aryl(C r C 6 )alkylamino, amino(C
  • C 6 )alkyl 2 amino(C C 6 )alkyl, hydroxy(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, (C 6 -C 10 )arylamino(C C 6 )alkyl, (C 6 -C 1 o)aryl(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, (C C 6 )alkylcarbonylamino(C C 6 )alkyl, (C 6 -C 10 )arylcarbonylamino(C 1 -C 6 )alkyl, ((C r C 6 )alkylcarbonyl)( (C 1 -C 6 )alkyl)amino(C 1 -C 6 )alkyl, C 3 -C ⁇ o)cycloalkyl(C 1 -C 8 )alkyl)amino(C 1 -C 6 )alky], (C C 6
  • C 9 heteroarylamino(C C 6 )alkyl, (C CeJalkoxycarbonyl, (C 6 -C 10 )aryl(C 1 -C 5 )alkoxycarbonyl, (C ⁇ -C 6 )alkylcarbonyl, (C 6 -C 10 )arylcarbonyl, (C 6 -C o)aryl(C 1 -C 6 )alkylcarbonyl, hydroxy(C r C 6 )alkoxycarbonyl, (C C 6 )alkoxycarbonyl(C 1 -C 6 )alkyl, (C 6 -C 10 )aryl(C 1 -C 6 )alkoxycarbonyl(C 1 - C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkylcarbonyloxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C
  • C 6 )alkyl 2 aminocarbonyloxy(C C 6 )alkyl, (C 1 -C 6 )alkylcarbonyl(C 1 -C 6 )alkyl, (C 6 -
  • C 6 )alkyl glycinamido, (C C 6 )alkylglycinamido, aminocarbonylglycinamido, (C 1 -C 6 )alkoxy(C 1 - C 6 )alkylcarbonylglycinamido, (aminocarbonyl)((C r C 6 )alkyl)glycinamido, ((C
  • R 7 is one to three groups independently selected from hydrogen, hydroxy, halo, (C C 6 )alkyl, (C 1 -C 6 )alkylsulfonyl, (C 6 -C 10 )arylsulfonyl, (C C 6 )alkoxy, hydroxy(CrC 6 )alkoxy, halo(C 1 -C 3 )alkyl, fomyl, nitro, cyano, halo(C 1 -C 6 )alkoxy, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 6 - C 10 )aryl, (C 6 -C 10 )aryl(C r C 6 )alkyl, amino, (C r C 6 )alkylamino, ((C 1 -C 6 )alkyl) 2 amino, (C 6 - C 10 )arylamino, (C 6 -C 1 o)ary
  • C 6 )alkyl 2 amino(C C 6 )alkyl, (C 1 -C 6 )alkylcarbonylamino(C 1 -C 6 )alkyl, (C 6 - C 10 )arylcarbonylamino(C ⁇ -C 6 )alkyl, ((C C 6 )alkylcarbonyl)( (C C 6 )alkyl)amino(C 1 -C 6 )alkyl, (C C 6 )alkoxycarbonylamino(C 1 -C 6 )alkyl, (C ⁇ -Ce)alkoxycarbonyl, (Ce-C ⁇ Jary ⁇ d-
  • C 6 )alkylaminocarbonylamino(C 1 -C 6 )alkyl ((C 1 -C 6 )alkyl) 2 aminocarbonylamino(C 1 -C 6 )alkyl, C 6 )alkyl, ((C 1 -C 6 )alkyl) 2 amino(C C 6 )alkyl, carboxy(CrC 6 )alkyl, (C 1 -C 6 )alkoxycarbonyl(C 1 - C 6 )alkyl, aminocarbonyl(C C 6 )alkyl and (C C 6 )alkylaminocarbonyl(CrC 6 )alkyl.
  • Preferred compounds of formula I include those wherein R 1 is hydrogen, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C ⁇ -C 6 )alkyl, hydroxy or (C C 6 )alkylcarbonyloxy.
  • R 2 and R 3 are each independently selected from (C r C 6 )alkyl, (C 3 -C 8 )cycloalkyl, amino(CrC 6 )alkyl, amino(C 3 - C 8 )cycloalkyl, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, (C ⁇ -C 3 )alkylamino(C 3 -C 8 )cycloalkyl, hydroxy(C C 6 )alkyl, (C 1 -C 6 )alkoxycarbonylamino(C 1 -C 6 )alkyl, ureido(C r C 6 )alkyl, (C 1 -C 6 )alkyureido(C 1 - C 6 )alkyl, (C 2 -C 9 )heteroaryl(C 1 -C 6 )alkyl or (C 2 -C 9 )heter
  • Other preferred compounds of formula I include those wherein c is 1 ; X is C(O); d is 2; Y is ethylene; and e is 0.
  • Other preferred compounds of formula I include those wherein c is 1 ; X is C(O); d is 1 ; Y is CH 2 ; e is 1 ; and Z is NR 9 wherein R 9 is hydrogen or (C 1 -C 6 )alkyl.
  • Other preferred compounds of formula I include those wherein c is 1 ; X is CH 2 ; d is 2;
  • Y is ethylene; and e is 0.
  • Other preferred compounds of formula I include those wherein c is 1 ; X is C(O); d is 1 ; Y is CHR 8 wherein R 8 is NR 9 R 10 ; R 9 and R 10 are each independently hydrogen, (C C 6 )alkyl or (CrCe ⁇ lkylcarbonyl; e is 1 ; and Z is CR 11 R 12 wherein R 11 and R 12 are hydrogen.
  • Other preferred compounds of formula I include those wherein c is 1 ; X is C(O); d is
  • Y is CHR 8 wherein R 8 is NR 9 R 10 ; R 9 and R 10 are each independently hydrogen, (C C 6 )alkyl or (CrC 6 )alkylcarbonyl; e is 1 ; and Z is NR 9 wherein R 9 is hydrogen or (C C 6 )alkyl.
  • Y is CHR 8 wherein R 8 is NR 9 R 10 ; R 9 and R 10 are each independently hydrogen, (C r C 6 )alkyl or (C C 6 )alkylcarbonyl; e is 1 ; and Z is oxygen.
  • Y is CHR 8 wherein R 8 is NR 9 R 10 ; R 9 and R 10 are each independently hydrogen, (C r C 6 )alkyl or (C r C 6 )alkylcarbonyl; e is 1 ; and Z is CR 11 R 12 wherein R 11 and R 12 are hydrogen.
  • R 4 is (R 5 ) f (R 6 ) g (C 6 - C 10 )aryl or (R 5 ) f (R 7 ) h (C 2 -C 9 )heteroaryl wherein f, g and h are independently 1 or 2.
  • R 5 is (C 2 - C 9 )heterocycloalkylcarbonyl, (C 2 -C 8 )heteroarylcarbonyl, (C 2 -C 8 )heteroaryl(C
  • R 5 is (C C 6 )alkylsulfonylamino(C 1 -C 6 )alkylcarbonylamino, cyanoguanidino(C 1 -C 6 )alkylcarbonylamino, (C 1 -C 6 )alkylcyanoguanidino(C 1 -C 6 )alkylcarbonylamino, ((C ⁇ -C 6 )alkyl) 2 cyanoguanidino(C
  • C 6 )alkylureido (C 1 -C 6 )alkylamino(C 1 -C 6 )alkylureido, ((C 1 -C 6 )alkyl) 2 amino(C 1 -C 6 )alkylureido, (C 2 -C 8 )heterocycloalkyl(CrC 6 )alkylureido, (C 2 -C 9 )heteroaryl(C ⁇ -C 6 )alkylureido, aminosulfonyl(C C 6 )alkylureido, aminocarbonyl(CrC 6 )alkylureido, (C
  • R 5 is amino(C ⁇ - C 6 )alkylsulfonylamino, (C ⁇ -C 3 )alkylamino(C 1 -C 6 )alkylsulfonylamino, ((C -C 6 )alkyl) 2 amino(C 1 - C 6 )alkylsulfonylamino, acetylamino(C ⁇ -C 6 )alkylsulfonylamino, (acetyl)((C ⁇ -C 6 )alkyl)amino(C C 6 )alkylsulfonylamino, ureido(C 1 -C 6 )alkylsulfonylamino, (C 1 -C 6 )alkylureido(C 1 - C 6 )alkylsulfonylamino, ((C ⁇ -C 6 )alkyl) 2 ureido(C
  • R 5 is cyanoguanidino, (C C 6 )alkylcyanoguanidino, ((C r C e )alkyl) 2 cyanoguanidino, (C 2 - C 9 )heterocycloalkylcyanoguanidino, (C 2 -C 9 )heteroarylcyanoguanidino, (C 2 -
  • R 5 is aminocarbonyl(C ⁇ -C e )alkylamino, (C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkylamino, (C r
  • R 5 is cyano(C C 6 )alkylaminoalkyl or aminocarbonyl(C ⁇ -C 6 )alkylamino(C 1 -C 6 )alkyl.
  • R 5 is acetylamino(C ⁇ - C 6 )alkylamino(C Ce)alkyl, (acetyl)((C 1 -C 6 )alkyl)amino(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl, (C C 6 )alkoxycarbonylamino(C r C 6 )alkylamino(C 1 -C 6 )alkyl, (C 2 -
  • C 6 )alkylamino(CrC 6 )alkyl ureido(C C 6 )alkylamino(C 1 -C 3 )alkyl, (CrC 6 )alkylureido(C C 6 )alkylamino(CrC 6 )alkyl, ((C 1 -C 6 )alkyl) 2 ureido(C ⁇ -C 6 )alkylamino(C 1 -C 6 )alkyl or aminocarbonyloxy(CrC 6 )alkylamino(CrC 6 )alkyl.
  • R 5 is acetylamino(C 1 - C 6 )aIkylcarbonylamino(C 1 -C 6 )alkyl, (acetyl)((C 1 -C 6 )alkyl)amino(C 1 -C 6 )alkylcarbonylamino(C 1 - C 6 )alkyl, aminocarbonyl(C 1 -C 6 )alkylcarbonylamino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylaminocarbonyl(C 1 - C 6 )alkylcarbonylamino(C 1 -C 6 )alkyl, ((C 1 -C 6 )alkyl) 2 aminocarbonyl(C 1 - C 6 )alkylcarbonylamino(C ⁇ -C 6 )alkyl, aminosulfonyl(C 1 -C 6 )alkylcarbonyla
  • R 5 is amino(C C 5 )alkylaminocarbonylamino(C C 6 )alkyl, (C ⁇ -C 6 )alkylamino(CrC 6 )alkylaminocarbonyl amino ⁇ rCsJalkyl, ((C 1 -C 6 )alkyl) 2 amino(C 1 -C 6 )alkylaminocarbonylamino(CrC 6 )alkyl, aminocarbonyl(C 1 -C 6 )alkylaminocarbonylamino(CrC 6 )alkyl, (C r C 6 ) alkylcarbonylamino(C 1 - C 6 )alkylaminocarbonylamino(C C 6 )alkyl, (C 1 -C 6 )alkylsulfonylamino(C 1 -
  • R 5 is amino(C C 6 )alkylsulfonylamino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylamino(C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkyl, ((C 1 -C 6 )alkyl) 2 amino(C ⁇ -C 6 )alkylsulfonylamino(C 1 -C 6 )alkyl, acetylamino(Cr
  • R 5 is cyanoguanidino(C r C 6 )alkyl, (C 1 -C 6 )alkyl(cyanoguanidino)(C 1 -C 6 )alkyl, ((C r C 6 )alkyl) 2 (cyanoguanidino)(C r C 6 )alkyl, (C 2 -C 9 )heterocycloalkyl(cyanoguanidino)(C C 6 )alkyl, (C CgJheteroary cyanoguanidinoJ ⁇ C ⁇ Jalkyl, (C 2 -C 9 )heterocycloalkyl(C r
  • C 6 alkyl(cyanoguanidino)(C C 6 )alkyl, ((C 1 -C 6 )alkyl) 2 amino(C 1 -C 3 )alkyl(cyanoguanidino)(C 1 - C 6 )alkyl, aminocarbonyl(C 1 -C 6 )alkyl(cyanoguanidino)(CrC 6 )alkyl, (C r
  • CeJalkylaminocarbony C CeJalky cyanoguanidinoJ ⁇ i-CeJalkyl or ((C r
  • C 6 )alkyl 2 aminocarbonyl(C 1 -C 6 )alkyl(cyanoguanidino)(C 1 -C 6 )alkyl.
  • R 5 is (C 2 - C g )heterocycloalkylsulfonyl, amino ⁇ CeJalkylaminosulfonyl, (CrC 6 )alkylamino(C r C 6 )alkylaminosulfonyl, ((C 1 -C 6 )alkyl) 2 amino(C 1 -C 6 )alkylaminosulfonyl, (C 2 -
  • R 6 and R 7 are each independently halo, halo(C C 6 )alkyl, (CrC 6 )alkyl, (C C 6 )alkoxy, trifluoromethyl, trifluoromethoxy, hydroxy, aminocarbonyl, cyano, ureido, (C C 6 )alkylsulfonylamino, (C C 6 )alkoxycarbonylamino or glycinamino.
  • the present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I.
  • the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, L , salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1 ,1 '-methylene-bis-(2-hydroxy-3- naphthoate)]salts.
  • pharmacologically acceptable anions such as the hydrochloride, hydrobromide, hydroiodide, nit
  • the invention also relates to base addition salts of formula I.
  • the chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds.
  • Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations ( g ⁇ , potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water- soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
  • the compounds of this invention may contain olefin-like double bonds. When such bonds are present, the compounds of the invention exist as cis and trans configurations and as mixtures thereof.
  • the present invention also relates to compounds of formula I wherein any of the hydrogens may optionally be replaced by deuterium.
  • alkyl, alkenyl and alkynyl groups referred to herein, as well as the alkyl moieties of other groups referred to herein (e j., alkoxy), may be linear or branched, and they may also be cyclic (e ⁇ j., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl) or be linear or branched and contain cyclic moieties.
  • halogen includes fluorine, chlorine, bromine, and iodine.
  • (C 3 -C 10 )Cycloalkyl when used herein refers to cycloalkyl groups containing zero to two levels of unsaturation such as cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, 1 ,3-cyclohexadiene, cycloheptyl, cycloheptenyl, bicyclo[3.2.1]octane, norbornanyl etc.
  • HeterocycloaIkyl when used herein refers to pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, oxiranyl, methylenedioxyl, chromenyl, barbituryl, isoxazolidinyl, 1 ,3-oxazolidin-3-yl, isothiazolidinyl, 1 ,3-thiazolidin-3-yl, 1 ,2-pyrazolidin-2-yl, 1 ,3-pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1 ,2-tetrahydrothiazin-2-yl, 1 ,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1 ,2-tetrahydrodiazin-2-y
  • (C 2 -C 8 )Heteroaryl when used herein refers to furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1 ,3,5-oxadiazolyl, 1 ,2,4- oxadiazolyl, 1 ,2,3-oxadiazolyl, 1 ,3,5-thiadiazolyl, 1 ,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1 ,2,3-triazinyl, 1 ,3,5-triazinyl, pyrazolo[3,4- bjpyridinyl, cinnolinyl,
  • ureido refers to an "amino-carbonyl-amino" moiety.
  • acetyl refers to an "alkyl-carbonyl" moiety wherein alkyl is defined as above.
  • cyanoguanidino refers to a functional group having the following formula
  • HET refers to a (C 2 -C 9 )heterocyloalkyl or (C 2 -C 9 )heteroaryl group and the nigrogen of said group is the place of attachment.
  • mercapto refers to a "HS-" moeity.
  • the compounds of this invention include all conformation al isomers ( g., cis and trans isomers) and all optical isomers of compounds of the formula I enantiomers and diastereomers), as well as racemic, diastereomeric and other mixtures of such isomers.
  • the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and sequelae
  • Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1 , as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1 , including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1 , HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex).
  • CMV cytomegalovirus
  • Herpes viruses Herpes zoster and Herpes simplex
  • TNF inflammatory cytokines
  • mammal preferably a human
  • an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier comprising an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
  • the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting chemokine binding to the receptor CCR1 in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting chemokine binding to the receptor CCR1 in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
  • disorders and conditions are those enumerated in the preceding paragraph.
  • the present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and sequelae associated
  • Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1 , as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1 , including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1 , HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex).
  • CMV cytomegalovirus
  • Herpes viruses Herpes zoster and Herpes simplex
  • TNF inflammatory cytokines
  • mammal preferably a human
  • administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
  • the present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
  • the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and sequelae
  • Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1 , as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1 , including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1 , HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex).
  • CMV cytomegalovirus
  • Herpes viruses Herpes zoster and Herpes simplex
  • TNF inflammatory cytokines
  • mammal preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoar ' thritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and
  • Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1 , as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1 , including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1 , HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex).
  • CMV cytomegalovirus
  • Herpes viruses Herpes zoster and Herpes simplex
  • TNF inflammatory cytokines
  • TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial me-nin ⁇ itiQ K ' a /P ak'i cvnrlmmo inf ⁇ rH-irtn DPI ito f ⁇ i tro K/m_ Hic ⁇ -c_
  • C 6 )alkylureido ((C 1 -C 6 )alkyl) 2 aminocarbonyl(C ⁇ -C 6 )alkylureido, acetylamino(C 1 -C 6 )alkylureido, (acetyl)((C 1 -C 6 )alkyl)amino(C 1 -C 6 )alkylureido, carboxy(C C 6 )alkylureido, halo(C C s )alkylsulfonylamino, amino(C C 6 )alkylsulfonylamino, (C ⁇ -C 6 )alkylamino(C
  • C 6 alkylcyanoguanidino, hydroxy ⁇ CeJalkylamino, aminocarbonyl(C r C 6 )aIkylamino, carboxy(C r C 6 )alkylamino, (C r C 6 )alkylsulfonylamino(C 1 -C 6 )alkylamino, (C C 6 )alkoxycarbonylamino(C 1 -C 6 )alkylamino, aminosulfonyl(C 1 -C 6 )alkylamino, (C 2 -
  • R 18 and R 19 together with the nitrogen to which they are attached is selected from the group consisting of (C 2 -C 9 )heteroaryl(C 1 -C 6 )alkylamino, (C 2 -C 9 )heterocycloalkyl(C 1 - C 6 )alkylamino, (C r C 6 )alkylsulfonylamino, (C ⁇ -C 6 )alkylsulfonylamino(C 1 -C 6 )alkylamino, ureido(C 1 -C 6 )alkylamino, (C Ce)alkylureido(C 1 -C 6 )alkylamino, ((CrC 6 )alkyl) 2 ureido(C C 6 )alkylamino, halo(C C 6 )alkylamino, aminosulfonyl(C 1 -C 6 )alkylamino, (C
  • C 6 )alkylcarbonylamino ((C 1 -C 6 )alkyl) 2 aminocarbonyl(C ⁇ -C 6 )alkylcarbonylamino, ureido(C C 6 )alkylcarbonylamino, (C 1 -C 6 )alkylureido(C 1 -C 6 )alkylcarbonylamino, ((C 1 -C 6 )alkyl) 2 ureido(C 1 - C 6 )alkylcarbonylamino, (C 1 -C 6 )alkoxycarbonylamino(C ⁇ -C 6 )alkylcarbonylamino, aminosulfonyl(C 1 -C 6 )alkylcarbonylamino, hydroxy(C 1 -C 6 )alkylamino(C 1 -
  • C 9 heteroarylamino, ureido(C 1 -C 6 )alkylamino, (C C 8 )alkylureido(CrCe)alkylamino, ((C C 6 )alkyl) 2 ureido(C C ⁇ )alkylamino, (C 1 -C 6 )alkylsulfonylamino(C 1 -C 6 )alkylamino, (C
  • reaction 1 of Preparation A the compound of formula XXXV, wherein b is 0, 1 or 2, is converted to the corresponding compound of formula XXXIV by reacting XXXV with an ethyldiamine compound of the formula, (R 3 ) j -ethyldiamin ' e, in the presence of an aprotic solvent, such as diethylether.
  • the reaction mixture is heated to reflux for a time period between about 1 hour to about 12 hours.
  • reaction 2 of Preparation A the compound of formula XXXIV is converted to the corresponding compound of formula XXXIII by reducing XXXIV with a reducing agent, such as sodium borohydride, in a refluxing protic solvent, such as ethanol.
  • a reducing agent such as sodium borohydride
  • reaction 3 of Preparation A the compound of formula XXXIII is converted to the corresponding compound of formula XXX by reacting XXXIII with a benzaldehyde compound of the formula
  • reaction mixture is stirred at room temperature for a time period between about 1 hour to about 4 hours, preferably about 2 hours.
  • reaction 1 of Preparation B the compound of formula XXII, wherein b is 0, 1 or 2, is converted to the corresponding compound of formula XXI by reacting XXIII with a benzaldehyde compound of the formula
  • reaction 2 of Preparation B the compound of formula XXI is converted to the corresponding compound of formula XX by first reacting a compound of the formula
  • reaction 3 of Preparation B the compound of formula XX is converted to the corresponding piperizine-2,5-dione compound of formula XIX by treating XX with trifluoroacetic acid in the presence of a polar aprotic solvent, such as methylene chloride.
  • a polar aprotic solvent such as methylene chloride.
  • reaction 4 of Preparation B the compound of formula XIX is converted to the corresponding compound of formula XVIII by reducing XIX with a reducing agent, such as lithium aluminum hydride.
  • a reducing agent such as lithium aluminum hydride.
  • the reaction is conducted at a temperature between about -10°C to about 10°C, preferably about 0°C, for a time period between about 10 minutes to about 90 minutes, preferably about 40 minutes.
  • reaction 1 of the Preparation C the compound of formula XXV is converted to the corresponding compound of formula XXIV by reacting XXV with an amine of the formula, NHR 18 R 19 , wherein R 18 and R 19 are each independently selected from hydrogen, a nitrogen containing (C 2 -C 9 )heterocycloalkyl or (C 2 -C 9 )heteroaryl group, or (C C 6 )alkyl optionally substituted by hydroxy, aminocarbonyl, (C r C 6 )alkylaminocarbonyl, ((C C 6 )alkyl) 2 carbonyl, carboxy, (CrC 6 )alkylsulfonylamino, (C ⁇ -C 6 )alkoxycarbonylamino, aminosulfonyl, (C C 8 )alkylaminosulfonyl, ((C C 8 )alkyl) 2 aminosulfonyl, (C 8 -C 10 )
  • reaction 2 of Preparation C the compound of formula XXIV is converted to the corresponding compound of formula XXIII by reacting XXIV with thiophenol in the presence of a base, such as sodium hydride, and a polar aprotic solvent, such as dimethylformamide.
  • a base such as sodium hydride
  • a polar aprotic solvent such as dimethylformamide
  • reaction 3 of Preparation C the compound of formula XXV is converted to the corresponding compound of formula XXXVIII by reacting XXV with sodium cyanate in the presence of pyridine and a polar aprotic solvent, such as acetonitrile.
  • the reaction is stirred, at room temperature, for a time period between about 2 hours to about 18 hours, preferably about 10 hours.
  • An amine of the formula, H 2 N-C(0)-NR 18 R 19 is then added and the reaction mixture so formed is stirred, at room temperature, for a time period between about 2 hours to about 24 hours, preferably about 8 hours.
  • reaction 4 of Preparation C the compound of formula XXXVIII is converted to the corresponding compound of formula XXXVII according to the procedure described above in reaction 2 of Preparation C.
  • reaction 1 of Scheme 1_ the compound of formula XXX is converted to the corresponding compound of formula X by reacting XXX with a compound of the formula, A- (X) o -(Y) d -A, wherein A is chloro or bromo, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride.
  • a base such as triethylamine
  • a polar aprotic solvent such as methylene chloride.
  • reaction 2 of Scheme 1_ the compound of formula X is converted to the corresponding compound of formula I by reacting X with a compound of the formula, H-(Z) e - R 4 wherein e is 1 and Z is oxygen, in the presence of potassium carbonate, potassium iodide and an aprotic solvent, such as butanone.
  • the reaction is heated to reflux for a time period between about 4 hours to about 8 hours, preferably about 6 hours.
  • reaction 1 of Scheme 2 the compound of formula XXX is converted to the corresponding compound of formula I by reacting XXX with a compound of the formula, A- (X)c-(Y) d -(Z) e -R 4 , wherein A is chloro or bromo, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride.
  • a base such as triethylamine
  • a polar aprotic solvent such as methylene chloride
  • reaction 1 of Scheme 3 the compound of formula X is converted to the corresponding compound of formula XII according to the procedure described above in reaction 2 of Scheme 1_.
  • reaction 2 of Scheme 3 the compound of formula XII is converted to the corresponding compound of formula XI by reacting XII with lithium hydroxide monohydrate in the presence of methanol, tetrahydrofuran and water. The reaction mixture is stirred overnight at room temperature.
  • reaction 3 of Scheme 3 the compound of formula XI is converted to the corresponding compound of formula II, by reacting XI with an amine, in the presence of 4- dimethylaminopyridine, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimine and a polar aprotic solvent, such as methylene chloride. The resulting reaction mixture is stirred overnight at room temperature.
  • reaction 1 of Scheme 4 the compound of formula X is converted to the corresponding compound of formula XV according to the procedure described above in reaction 2 of Scheme
  • reaction 2 of Scheme 4 the compound of formula XV is converted to the corresponding compound of formula XIV by hydrogenating XV in the presence of a catalyst, such as platinum on carbon, and a polar protic solvent, such as ethanol.
  • a catalyst such as platinum on carbon
  • a polar protic solvent such as ethanol.
  • the reaction is carried out under a pressure between about 30 psi to about 40 psi, preferably about 35 psi, for a time period between about 15 minutes to about 1 hour, preferably 30 minutes.
  • the compound of formula XIV is converted to the corresponding compound of formula V by first reacting XIV with 4-nitrophenyl chloroformate in the presence of a base, such as pyridine, and a polar aprotic solvent, such as methlyene chloride, followed by reacting the intermediate so formed with an amine.
  • a base such as pyridine
  • a polar aprotic solvent such as methlyene chloride
  • the reaction is stirred overnight at ambient temperature.
  • the compound of formula XIV is first treated with sodium hydride in an aprotic solvent, such as tetrahydrofuran, followed by reacting, the intermediate so formed with dimethyl-N-cyanodithio iminocarbonate.
  • the reaction mixture so formed is heated to reflux overnight.
  • the N-cyano-S-methyl-isothiourea intermediate is then reacted with an amine in the presence of a polar protic solvent, such as methanol.
  • the compound of formula XIV is reacted with an acid, such as 3-tert- butoxycarbonylaminopropionic acid in the presence of N-methylmorpholine, O-benzotriazole- 1-yl-N,N,N , N -tetramethyluronium hexafluorophosphate and a polar aprotic solvent, such as methylene chloride.
  • an acid such as 3-tert- butoxycarbonylaminopropionic acid in the presence of N-methylmorpholine, O-benzotriazole- 1-yl-N,N,N , N -tetramethyluronium hexafluorophosphate and a polar aprotic solvent, such as methylene chloride.
  • reaction 1 of Scheme 5 the compound of formula X is converted to the corresponding compound of formula XVI, wherein k is 0, 1 , 2, 3 or 4, according to the procedure described above in reaction 2 of Scheme 1_.
  • reaction 2 of Scheme 5 the compound of formula XVI is converted to the corresponding compound of formula VII by reacting XVI with an amine of the formula, R 16 R 17 N, wherein R 16 and R 17 are each indepenently hydrogen, a nitrogen containing (C 2 -C 9 )heterocycloalkyl or (C 2 - C 9 )heteroaryl group, or (C 1 -C 6 )alkyl optionally substituted by hydroxy, aminocarbonyl, (C C 8 )alkylaminocarbonyl, ((C r C 6 )alkyl) 2 carbonyl, carboxy, (C-rC.Jalkylsulfonylamino, (C C 6 )alkoxycarbonylamino, aminosulfonyl,
  • reaction mixture is stirred, at room temperature, for a time period between about 30 minutes to about 2 hours, preferably about 1 hour.
  • a reducing agent such as sodium cyanoborohydride is than added to the mixture and the reaction is allowed to stir overnight at room temperature.
  • R 16 and/or R 17 is/are hydrogen, the compound of formula VII may further be reacted according to the procedure described above in reaction 3 of Scheme 4, to provide ureas, sulfonamides, cyanoguanidinos, or amides.
  • reaction 1 of Scheme 6 the compound of formula X is converted to the corresponding compound of formula XXXIX according to the procedure described above in reaction 2 of Scheme 1_.
  • reaction 2 of Scheme 6 the compound of formua X is converted to the corresponding compound of formula XXXX according to the procedure described above in reaction 2 of Scheme 1_.
  • reaction 1 of Scheme 7 the acid compound of formula XXXVI is converted to the corresponding compound of formula XXXII by treating XXXVI with thionyl chloride neat or in an aprotic solvent, at room temperature, for a time period between about 1 hour to about 24 hours, preferably 1 hour.
  • the acid chloride so formed is dissolved in a polar aprotic solvent with a compound of the formula, (H 3 CO)(H 3 C)NH « HCI, in the presence of an amine base, such as triethylamine.
  • the reaction mixture is stirred, at room temperature, for a time period between about 1 hour to about 48 hours, preferably about 12 hours.
  • the amide compound of formula XXXII is converted to the corresponding compound of formula XXXI by reacting XXXII with a (C 2 -C 9 )heteroaryl lithium reagent in the presence of a polar aprotic solvent at a temperature between about -100°C to room temperature, preferably about -78°C.
  • the resulting reaction mixture is stirred for a time period between about 1 hour to about 24 hours, preferably about 12 hours, at a temperature between about -78°C to about 50°C, preferably about 20°C.
  • the pressure of each of the above reactions is not critical. Generally, the reactions will be conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).
  • the compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.
  • the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, Le., salts containing pharmacologically acceptable- anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1 ,1 '-methylene-bis-(2-hydroxy-3- naphthoate)] salts.
  • pharmacologically acceptable- anions such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate
  • Those compounds of the formula I which are also acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations.
  • such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques.
  • the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic compounds of formula I. These non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc.
  • salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
  • they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
  • stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields.
  • the active compounds are potent antagonists of the CCR1 receptors.
  • the active compounds are useful in the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), chronic bronchitis, xeno-transplantation, transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co
  • the activity of the compounds of the invention can be assessed according to procedures know to those of ordinary skill in the art. Examples of recognized methods for determining CCR1 induced migration can be found in Coligan, J. E., Kruisbeek, A.M.,
  • Chemotaxis Assay The ability of compounds to inhibit the chemotaxis to various chemokines can be evaluated using standard 48 or 96 well Boyden Chambers with a 5 micron polycarbonate filter. All reagents and cells can be prepared in standard RPMI (BioWhitikker Inc.) tissue culture medium supplemented with 1 mg/ml of bovine serum albumin. Briefly, MIP-1 ⁇
  • test agonists were placed into the lower chambers of the Boyden chamber. A polycarbonate filter was then applied and the upper chamber fastened.
  • the amount of agonist chosen is that determined to give the maximal amount of chemotaxis in this system (e.g., 1 nM for MIP-1 should be adequate).
  • THP-1 cells ATCC TIB-202
  • primary human monocytes or primary lymphocytes
  • Compound dilutions can be prepared using standard serological techniques and are mixed with cells prior to adding to the chamber.
  • the chamber is removed, the cells in the upper chamber aspirated, the upper part of the filter wiped and the number of cells migrating can be determined according to the following method.
  • the chamber (a 96 well variety manufactured by Neuroprobe) can be centrifuged to push cells off the lower chamber and the number of cells can be quantitated against a standard curve by a color change of the dye fluorocein diacetate.
  • the filter can be stained with Dif
  • the number of cells migrating in the presence of the compound are divided by the number of cells migrating in control wells (without the compound).
  • the quotant is the % inhibition for the compound which can then be plotted using standard graphics techniques against the concentration of compound used.
  • the 50% inhibition point is then determined using a line fit analysis for all concentrations tested.
  • the line fit for all data points must have an coefficient of correlation (R squared) of > 90% to be considered a valid assay.
  • compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers.
  • the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation.
  • the active compounds of the invention may also be formulated for sustained delivery.
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate).
  • binding agents e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g., lactose, microcrystalline cellulose or calcium phosphate
  • lubricants e.g., magnesium stearate, talc or silica
  • disintegrants e.g., potato starch or sodium
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).
  • the composition may take the form of tablets or lozenges formulated in conventional manner.
  • the active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion.
  • Formulations for injection may be presented in unit dosage form, in ampules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • the active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, ejj., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant ejj., dichlorodifluoromethane, trichlorofluo
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the pressurized container or nebulizer may contain a solution or suspension of the active compound.
  • Capsules and cartridges made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • a proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above is 0.1 to 1000 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
  • Aerosol formulations for treatment of the conditions referred to above are preferably arranged so that each metered dose or "puff of aerosol contains 20 ⁇ g to 1000 ⁇ g of the compound of the invention.
  • the overall daily dose with an aerosol will be within the range 0.1 mg to 1000 mg.
  • Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1 , 2 or 3 doses each time.
  • the active agents can be formulated for sustained delivery according to methods well known to those of ordinary skill in the art. Examples of such formulations can be found in United States Patents 3,538,214, 4,060,598, 4,173,626, 3,1 19,742, and 3,492,397.
  • the compounds of the invention can also be utilized in combination therapy with, but not limited to, other therapeutic agents such as with T-cell immunosuppressant agents such as rapamycin cyclosporin A and FK-506, with steroid sparing agents such as Cellcept®, or with classical anti-inflammatory agents (e.g. cyclooxygenase/lipoxygenase inhibitors) such as tenidap, aspirin, acetaminophen, naproxen and piroxicam.
  • T-cell immunosuppressant agents such as rapamycin cyclosporin A and FK-506, with steroid sparing agents such as Cellcept®
  • classical anti-inflammatory agents e.g. cyclooxygenase/lipoxy
  • NMR data are reported in parts per million ( ⁇ ) and are referenced to the deuterium lock signal from the sample solvent (deuteriochloroform unless otherwise specified). Commercial reagents were utilized without further purification.
  • THF refers to tetrahydrofuran.
  • DMF refers to N,N-dimethylformamide.
  • Chromatography refers to column chromatography performed using 32-63 mm silica gel and executed under nitrogen pressure (flash chromatography) conditions.
  • LRMS Low Resolution Mass Spectra
  • LRMS Low Resolution Mass Spectra
  • APCI Atmospheric Pressure Chemical lonization
  • Room or ambient temperature refers to 20-25 ⁇ C. All non-aqueous reactions were run under a nitrogen atmosphere for convenience and to maximize yields.
  • the names for the compounds of the invention were created by the Autonom 2.0 PC-batch version from Beilstein Informationssysteme GmbH (ISBN 3-89536-976-4).
  • (2R)-2-Amino-ethanesulfonic acid (5-chloro-2- ⁇ 2-[4-(4-fluoro-benzyl)-2-methyl- piperazin-1 -yl]-2-oxo-ethoxy ⁇ -phenyl)-amide
  • 2-(1 ,3-dioxo-1 ,3-dihydro-isoindol-2-yl)-ethanesulfonic acid (5-chloro-
  • Example 36 The title compounds for Examples 36 - 38 were prepared by a method analogous to that described in Example 35.
  • N-Acetylethylenediamine (0.019 mL, 0.188 mmol) was added and the reaction was stirred at room temperature over night. The reaction was concentrated in vacuo and chromatography on silica gel gave the title compound (0.019 g, 27 %).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)

Abstract

A compound of formula (I) or the pharmaceutically acceptable salt thereof; wherein a, b, c, d, e, j, R?1, R2, R3, and R4¿ ar e as defined above useful to treat inflammation and other immune disorders.

Description

NOVEL PIPERAZINE DERIVATIVES Background of the Invention The present invention relates to novel piperazine derivatives, methods of use and pharmaceutical compositions containing them. The compounds of the invention are potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). The CCR1 receptor is also sometimes referred to as the CC- CKR1 receptor. These compounds also inhibit MIP-1 (and the related chemokines shown to interact with CCR1 (ejj., RANTES and MCP-3)) induced chemotaxis of THP-1 cells and human leukocytes and are potentially useful for the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), chronic bronchitis, xeno-transplantation, transplantation tissue rejection (chronic and acute), organ transplant rejection (chronic and acute), atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis) and sequelae associated with certain cancers such as multiple myeloma. Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1 , as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1 , including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1 , HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex). They may also provide benefit for the sequelae associated with infection where such infection induces production of detrimental inflammatory cytokines such as TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria.
MIP-1 and RANTES are soluble chemotactic peptides (chemokines) which are produced by inflammatory cells, in particular CD8+ lymphocytes, polymorphonuclear leukocytes (PMNs) and macrophages, J.Biol. Chem,, 270 (30) 29671-29675 (1995). These chemokines act by inducing the migration and activation of key inflammatory and immunomodulatory cells. Elevated levels of chemokines have been found in the synovial fluid of rheumatoid arthritis patients, chronic and acute rejecting tissue from transplant patients and in the nasal secretions of allergic rhinitis patients following allergen exposure (Teran , et al,, L Immunol., 1806-1812 (1996), and Kuna et al., J. Allergy Clin. Immunol. 321 (1994)). Antibodies which interfere with the chemokine/receptor interaction by neutralizing MIP1α or gene disruption have provided direct evidence for the role of MIP-1α and RANTES in disease by limiting the recruitment of monocytes and CD8+ lymphocytes (Smith et al., J. Immunol, 153, 4704 (1994) and Cook et al., Science, 269, 1583 (1995)). Together this data demonstrates that CCR1 receptor antagonists would be an effective treatment of several immune based diseases. The compounds described within are potent and selective antagonists of the CCR1 receptor. Summary of the Invention
The present invention also relates to a compound of the 1 Formi
Figure imgf000003_0001
or the pharmaceutically acceptable salt thereof; wherein a is 1 , 2, 3, 4 or 5; b is O, 1 , 2, 3 or 4; c is 0 or 1 ; d is 1 , 2, 3, 4 or 5; e is 0 or 1 ; j is 1 , 2, 3, or 4;
X is C(O), C(S) or CH2;
Y is CH2, or if e is 0, Y is CHR8 wherein R8 is hydrogen, (C6-C10)aryl or NR9R 10.
Z is oxygen, NR9 or CR11R12; each R1 is independently selected from hydrogen, hydroxy, hydroxysulfonyl, halo, (C C6)alkyl, mercapto, mercapto(C1-C6)alkyl, (C1-C6)a)kylthiol (CrC6)alkylsulfinyl, (Cr C6)alkylsufonyl, (CrC6)alkylthio(C C6)alkyl, (C1-C6)alkylsulfinyl(C1-C6)alkyl, (Cr C6)alkylsulfonyl(CrC6)alkyl, (CrC6)alkoxy, (C6-C10)aryloxy, halo(CrC6)alkyl, trifluoromethyl, formyl, formyl(C C6)alkyl, nitro, nitroso, cyano, (C6-C10)aryl(CrC6)alkoxy, halo(C C6)alkoxy, trifluoromethoxy, (C3-C7)cycloalkyl,
Figure imgf000003_0002
hydroxy(C3-C7)cycloalkyl(C1- C6)alkyl, (C3-C7)cycloa)kylamino, (C3-C7)cycloalkylamino(C1-C6)alkyl, ((C3-C7)cycloalkyl)((Cr C6)alkyl)amino, ((C3-C7)cycloalkyl(C1-C6)alkyl)amino(C1-C6)alkyl, cyano(C1-C6)alkyl, (C2- C7)alkenyl, (C2-C7)alkynyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, (C6-Cιo)aryl(C2-C6)alkenyl, hydroxy(C1-C6)alkyl, hydroxy(C6-C10)aryl(C1-C6)alkyl, hydroxy(C1-C6)alkylthio(C1-C6)alkyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkynyl, (C1-C6)alkoxy(C1-C6)alkyl, (CrC6)alkoxy(C6- C10)aryl(C C6)alkyl, (C6-C10)aryloxy(C1-C6)alkyl, (C6-C1o)aryl(C1-C6)alkoxy(CrC6)alkyl, amino, (C1-C6)alkylamino, ((C1-Ce)alkyl)2amino, (C6-C10)arylamino, (C6-C10)aryl(Cι-C6)alkylamino, amino(CrC6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, hydroxy(C C6)alkylamino(C1-C6)alkyl, (C6-C10)arylamino(C1-C6)alkyl, (C6-C10)aryl (C C6)alkylamino(CrC6)alkyl, (C C6)alkylcarbonylamino, ((CrC6)alkylcarbonyl)((Cr C6)alkyl)amino, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, ((Cl-C6)alkylcarbonyl)((C -
C6)alkyl)amino(C1-C6)alkyl, (C C6)alkoxycarbonylamino, (C1-C6)alkoxycarbonyl)(C1-
C6)alkylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbnony)((C1- C6)alkyl)amino(C1-C6)alkyl,
, (CrC6)alkoxycarbonyl, (C6-C10)aryl(C C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C C6)alkylcarbonyl(C C6)alkyl, (C6-C10)arylcarbonyl, (C6-C10)arylcarbonyl(CrC6)alkyl, (C6- C10)aryl(C C6)alkylcarbonyl, (C6-C10)aryl(C1-C6)alkycarbonyl(C1-C6)alkyl, carboxy(CrC6)alkyl, (C-i-CeJalkoxycarbony C-i-CeJalkyl, (Ce-CK^ary C-rCβJalkoxycarbony C-i-Ce^lkyl, (Cr C6)alkoxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, aminocarbonyl, (CrC6)alkylaminocarbonyl, ((CrC6)alkyl)2aminocarbonyl, (C6-C10)arylaminocarbonyl, (Ce-C10)aryl(Cr C6)alkylaminocarbonyl, aminocarbonyl(Cι-C6)alkyl, (Cι-C6)alkylaminocarbonyl(C1-C6)alkyl, ((CrC6)alkyl)2aminocarbonyl(Cι-C6)alkyl, (C6-C10)arylaminocarbonyl(CrC6)alkyl, (C C6)alkylaminocarbonyl(C C6)alkyl, amidino, guanidino, ureido, (Cι-C6)alkylureido, ((C C6)alkyl)2ureido, ureido(C C5)alkyl, (C1-C6)alkylureido(C1-C6)alkyl, ((C C6)alkyl)2ureido(Cr C6)alkyl, (C2-C8)heterocycloalkyl, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl(CrC6)alkyl and (C2-C9)heteroaryl(C1-C6)alkyl; each R2 and R3 are independently selected from oxo, halo, (CrC6)alkyl, (C3- C8)cycloalkyl, (C3-C8)cycloalkyl(CrC6)alkyl, (C3-C8)cycloalkylamino(CrC6)alkyl, (C3-C- 8)cycloalkyl(C1-C6)alkylamino(C1-C6)alkyl, halo(C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C6-C10)aryl(C C6)alkyl, (C6-C10)aryl(C2-C6)alkenyl, H-C(O)-, H-C(0)-(C C6)alkyl, hydroxy(C C6)alkyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkynyl, hydroxy(C6- C10)aryl(C1-C6)alkyl, hydroxy(C3-C8)cycloalkyl(CrC6)alkyl, thio(C C6)alkyl, cyano(C C6)alkyl, halo(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C1-C6)alkoxy(C6-C1o)aryl(CrC6)alkyl, (C C6)alkoxy(C C6)alkyl, (C6-C10)aryloxy(C C6)alkyl, (C5-C1o)aryl(C1-C6)alkoxy(C1-C6)alkyl, (C C6)alkylthio(C1-C6)alkyl, (C C6)alkylsulfinyl(C1-C6)alkyl, (C1-C6)alkylsulfonyl(C1-C6)alkyl, hydroxy(C1-C6)alkylthio(C1-C6)alkyl, amino(CrC6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((C C6)alkyl)2amino(C C6)alkyl, (C6-C10)arylamino(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylamino(C1- C6)alkyl, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, azido(CrC6)alkyl, aminocarbonylamino(C C6)alkyl, (C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ((C C6)alkyl)2aminocarbonylamino(C1- C6)alkyl, (C1-C6)alkoxycarbonyl(C1-C6)alkylaminocarbonylamino(C1-C5)alkyl, (C C6)alkoxycarbonylamino(C1-C6)alkyl, hydroxy(C1-C6)alkylamino(C1-C6)alkyl, (C3-
Cιo)aryloxy(Cι-C6)alkylcarbonyloxy(CrC6)alkyl, (Cι-C6)alkoxy(C1-C6)alkylcarbonyloxy(C1- C6)alkyl, (C6-C1o)aryl(C1-C6)alkoxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylcarbonyl(C C6)alkyl, carboxy, (C C6)alkoxycarbonyl, (C6-C10)aryl(C C6)alkoxycarbonyl, (C6-C10)aryl(C1-C6)alkylcarbonyl, aminocarbonyl, (C
C6)alkylaminocarbonyl, ((Cι-C6)alkyl)2aminocarbonyl, (C6-C1o)arylaminocarbonyl, (C6- C10)aryl(C1-C6)alkylaminocarbonyl, carboxy(Cι-C6)alkyl, (C1-C6)alkoxycarbonyl(C1-Cβ)alkyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl(C1-C6)alkyl, aminocarbonyl(C C6)alkyI, (Cr
C6)alkylaminocarbonyl(Cι-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(Cι-C6)alkyl, (C6-
Cιo)arylaminocarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylaminocarbonyl(C1-C6)alkyl, (C6- C10)arylsulfonyl, (C2-C9)heterocycloalkyl, (C2-C8)heteroaryl, (C2-C8)heterocycloalkyl(C C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkyl or R14R15N(CrC6)alkyl wherein R14 and R15 are each independently (C C6)alkyl or (C1-C6)alkylcarbonyl;
R4 is (R5)f(R6)g(C6-C10)aryl, (R5)f(R6)g(C3-C10)cycloalkyl, (R5)f(R7)h(C2-C9)heteroaryl, or (R5)f(R7)h(C2-C9)heterocycloalkyl, wherein f is 1 , 2, 3 or 4; ,g and h are each independently 0, 1 , 2 or 3; R5 is one to three groups independently selected from (C2-
C9)heterocycloalkylcarbonyl, (C2-C9)heteroarylcarbonyl, (C2-C9)heteroaryl(C1-
C6)alkylaminocarbonyl, (C2-C9)heterocycloalkyl(C1-C6)alkylaminocarbonyl, (C
C6)alkylsulfonylamino(C1-C6)alkylaminocarbonyl, ureido(C C6)alkylaminocarbonyl, (C C6)alkylureido(C C6)alkylaminocarbonyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylaminocarbonyl, halo(C1-C6)alkylaminocarbonyl, aminosulfony C CβJalkylaminocarbonyl, (C
C6)alkylaminosulfonyl(Cι-C6)alkylaminocarbonyl, (Cι-C6)alkylsulfonylamino(C1-
C6)alkylcarbonylamino, cyanoguanidino(Cι-C6)alkylcarbonylamino, (C
C6)alkylcyanoguanidino(C C6)alkylcarbonylamino, ((Cι-C6)alkyl)2cyanoguanidino(Cι-
C6)alkylcarbonylamino, aminocarbony C CeJalkylcarbonylamino, (C2-C9)heteroaryl(Cr C6)alkylcarbonylamino, (C2-C9)heterocycloalkyl(C1-C6)alkylcarbonylamino, aminosulfonyl(Cr C6)alkylcarbonylamino, hydroxy(CrC6)alkylureido, amino(C1-C6)alkylureido, (C C6)alkylamino(C1-C6)alkylureido, ((CrC6)alkyl)2amino(C C6)alkylureido, (C2-
C9)heterocycloalkyl(C1-C6)alkylureido, (C2-C9)heteroaryl(C1-C6)alkylureido, aminosulfonyl(C C6)alkylureido, aminocarbonyl(CrC6)alkylureido, (CrC6)alkylaminocarbonyl(C1- C6)alkylureido, ((C1-Ce)alkyl)2aminocarbonyl(CrC6)alkylureido, acetylamino(Cι-C6)alkylureido, (acetylX CrCβJalkyOaminoO^-rCeJalkylureido, halo(C C6)alkylsulfonylamino, amino(Cr C6)alkylsulfonylamino, (C1-C6)alkylamino(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2amino(C1- C6)alkylsulfonylamino, acetylamino(C1-C6)alkylsulfonylamino, (acetyl)((C C6)alkyl)amino(Cι- C6)alkylsulfonylamino, ureido(C1-C6)alkylsulfonylamino, (C C6)alkylureido(Cr C6)alkylsulfonylamino, ((Cι-C6)alkyl)2ureido(CrC6)alkylsulfonylamino, (C
C6)alkylsulfonylamino(CrC6)alkylsulfonylamino, cyanoguanidino^rCβJalkylsulfonylamino, (C C6)alkylcyanoguanidino(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2cyanoguanidino(C1- C6)alkylsulfonylamino, aminocarbonyl(C C6)alkylsulfonylamino, (C
Cβ)alkoxycarbonylamino(C C6)alkylsulfonylamino, aminosulfonylamino, (C
C6)alkylaminosulfonylamino, ((C C6)alkyl)2aminosulfonylamino, aminocarbonyl(C
C6)alkylamino(C1-C6)alkylsulfonylaminol (C2-C8)heterocycloalkyloxycarbonylamino(Cι-
C6)alkylsulfonylamino, (C2-C9)hete|-oaryloxycarbonylamino(C1-C6)alkylsulfonylamino, cyanoguanidino, (CrC6)alkylcyanoguanidino, ((C C6)alkyl)2cyanoguanidino, (C2- Cg)heterocycloalkylcyanoguanidino, (C2-C8)heteroarylcyanoguanidino, (C2-
C9)heterocycloalkyl(C1-C6)alkylcyanoguanidino, (C2-C9)heteroaryl(C1-C6)alkylcyanoguanidino, amino(CrC6)alkylcyanoguanidino, (C1-C6)alkylamino(C1-C6)alkylcyanoguanidino, ((C Cs)alkyl)2amino(C C6)alkylcyanoguanidino, aminocarbonyl(C C6)alkylcyanoguanidino, (C C6)alkylaminocarbonyl(C1-C5)alkylcyanoguanidino, ((C1-C6)alkyl)2aminocarbonyl(C1-
C6)alkylcyanoguanidino, aminocarbonyl(CrC6)alkylamino, (C1-C6)alkylsulfonylamino(C1- C6)alkylamino, (Cι-C6)alkoxycarbonylamino(C1-C6)alkylamino, aminosulfonyl(C
C C^6)aallkkyyllaammiinnoo, (C2-C9)heteroaryl(C1-C6)alkylamino, acetylamino(CrC6)alkylamino, (a cceetyl)((C1-C6)alkyl)amino(C1-C6)alkylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylamino(C1- c6 i):alkyl, cyano(C1-C6)alkylaminoalkyl, aminocarbonyl(C1-C6)alkylamino(C1-C6)alkyl, ac :eetylamino(C1-C6)alkylamino(C1-C6)alkyl, (acetyl)((C C6)alkyl)amino(Cι-C6)alkylamino(Cr C6)aikyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylamino(Cι-C6)alkyl, (C2-
Cg)heterocycloalkyloxycarbonylamino(C1-C6)alkylamino(C1-C6)alkyl, (C2-
C9)heteroaryloxycarbonylamino(C1-C6)alkylamino(C1-C6)alkyl, cyanoguanidino(C
C6)alkylamino(Cι-C6)alkyl, (C1-C6)alkylcyanoguanidino(C1-C6)alkylamino(C1-C6)alkyl, ((C C6)alkyl)2cyanoguanidino(CrC6)alkylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-
C6)alkylamino(CrC6)alkyl, ureido(CrC6)alkylamino(CrC6)alkyl, (C1-Ce)alkylureido(Cι- C6)alkylamino(CrC6)alkyl, ((C1-C6)alkyl)2ureido(C C6)alkylamino(C1-Ce)alkyl, aminocarbonyloxy(CrC6)alkylamino(CrC6)alkyl, aminocarbonyl(Cr
C6)alkylcarbonylamino(C C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkylcarbonylamino(C1- C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, aminosulfonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C2-
C9)heterocycloalkyloxycarbonylamino(Cι-Ce)alkyl, cyanoguanidino(C
C6)alkylcarbonylamino(Cι-C6)alkyl, cyano(C1-C6)alkylcarbonylamino(C1-C6)alkyl, amino(C C6)alkylaminocarbonylamino(C1-C6)alkyl, (C1-C6)alkylamino(C1-
C6)alkylaminocarbonylamino(C C6)alkyl, ((C CeJalkyl^amino^
C6)alkylaminocarbonylamino(C C6)alkyl, hydroxy(C1-C6)alkylaminocarbonylamino(C1-
C6)alkyl, aminocarbonyl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (Cr Ce)alkylcarbonylamino(C1-C3)alkylaminocarbonylamino(C1-C6)alkyl, '^- -
C66)aalιkκyylιssuulMfounrιyylιa_imiιιiιnπoυ((ιCi- 1i--C66)acilιkκyylιa_im[πiιnιιooccaarrbDoonnyylιaammiιnπoo(^C11--C»-66)jaalιkκyylι,, ^ (CΓ C Cκ6 '))aallkkooxxvyccaarrbboonnvyllaammiinnoo(.CC11--CCR6 ,))aallkkvyllaammiinnooccaarrbboonnvyllaammiinnoo(.CCι1--CCc6 ')>aall^kyl, (C2 Cg)heterocycloalkyloxycarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-
Cg)heteroaryloxycarbonylamino(C1-C6)alkylaminocarbonylamino(Cι-C6)alkyl, (C2-
Cg)heterocycloalkyl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl,
Figure imgf000007_0001
C6)alkylaminocarbonylamino(C C6)alkyl, ureido(Cι-C6)alkylureido(Cι-C6)alkyl, (C
C6)alkylureido(CrC6)alkylureido(CrC6)alkyl, ((C1-C6)alkyl)2ureido(Cι-C6)alkylureido(C1-
C6)alkyl, cyanoguanidino(Cι-C6)alkylureido(Cι-C6)alkyl, halo(C1-C6)alkylsulfonyIamino(C1- C6)alkyl, amino(CrCβ)alkylsulfonylamino(C-ι-C6)alkyl, (Cι-C6)alkylamino(Cι-
C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, acetylamino(CrC6)alkylsulfonylamino(C1-C3)alkyl, (acety))((C1-C6)alkyI)amino(Cr
C6)alkylsulfonylamino(C1-C6)alkyl, ureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C
C6)alkylureido(CrC6)alkylsulfonylamino(CrC6)alkyl, ((C Cδ)alkyl)2ureido(Cι-
C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino(C1-C3)alkylsulfonylamino(C1- C6)alkyl, cyanoguanidino(C C6)alkylsulfonylamino(Cι-C6)alkyl, (Cr
C6)alkyl(cyanoguanidino)(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C
C6)alkyl)2(cyanoguanidino)(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminocarbonyl(C
C6)alkylsulfonylamino(Cι-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylsulfonylamino(C1- C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkyisulfonylamino(C1-C6)alkyl, (C2- Cg)heteroaryloxycarbonylamino(Cι-C6)alkylsulfonylamino(C C6)alkyl, aminosulfonylamino(C C6)alkyl, (C C6)alkylaminosulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminosulfonylamino(C1- C6)alkyl, cyanoguanidino^-Ce^lkyl, (C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, ((Cr C6)alkyl)2(cyanoguanidino)(Cι-C6)alkyl, (C2-C8)heterocycloalkyl(cyanoguanidino)(C1-C6)alkyl, (C2-C8)heterocycloalkyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, (C2-
C ι)heterocycloalkyl(cyanoguanidino)amino, (C2-C8)heteroaryl(cyanoguanidino)(C1-C6)alkyl,
(C2 ---CCgg)heteroaryl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, amino(C C6)a ιllkkyyll((ccyyaanno' guanidino)(C C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl(cyanoguanidino)(C1- C6)a illkkyyll,, ((C1-C6)alkyl)2amino(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, aminocarbonyl(C C -.D6/)ja|kyl(cyanoguanidino)(C C5)alkyl, (C CeJalkylaminocarbony Cr
C6)alkyl(cyanoguanidino)(C C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-
C6)alkyl(cyanoguanidino)(C C6)alkyl, aminosulfonyl, (Cι-C6)alkylaminosulfonyl, ((Cr C6)alkyl)2aminosulfonyl, (C2-C8)heterocycloalkylsulfonyl, amino(C1-C6)alkylaminosulfonyl, (C C6)alkylamino(CrC6)alkylaminosulfonyl, ((C1-C6)alkyl)2amino(CrC6)alkyIaminosulfony),
(C2.Cg)heteroarylaminosulfonyl, hydroxy(C1-C6)alkylaminosulfonyl, (C1-C6)alkoxy(C1- Cs)alkylaminosulfonyl, ureido(Cι-C6)alkylaminosulfonyl, (Cι-C6)alkylureido(C -
C6)alkylaminosulfonyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylaminosulfonyl, (Cr
C6)alkylsulfonylamino(C C6)alkylaminosulfonyl, (C1-C6)alkoxycarbonylamino(C1-
C6)alkylaminosulfonyl, (C2-Cg)heterocycloalkyloxycarbonylamino(CrC6)alkylaminosulfonyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylaminosulfonyl, aminocarbonyl(Cr C6)alkylaminosulfonyl, cyanoguanidino(C1-C6)alkylaminosulfonyl, (C2-C3)heteroaryl(C-\- C6)alkylaminosulfonyl, (C2-C8)heterocycloalkylaminosulfonyl, R6 is one to three groups independently selected from hydrogen, hydroxy, hydroxysulfonyl, halo, (Cι-C6)alkyl, mercapto, mercapto(C1-C6)alkyl, (CrC6)alkylthio, (C C6)alkylsulfinyl, (C C6)alkylsulfonyl, (C6-C10)arylsulfonyl, (Cι-C6)alkylthio(Cι-C6)alkyl, (C1-C6)alkylsulfinyl(CrC6)alkyl, (C C6)alkylsulfonyl(C C6)alkyl, (CrC6)alkoxy, hydroxy(C C6)alkoxy, (C6-C10)aryloxy, halo(C C6)alkyl, trifluoro(Cι-C6)aIkyl, formyl, formyl(C1-C6)alkyl, nitro, nitroso, cyano, (C6-Cl0)aryl(C1- C6)alkoxy, halo(C C6)alkoxy, trifluoro(CrC6)alkoxy, amino(CrC6)alkoxy, (C3-C10)cycloalkyl, (C3-C 0)cycloalkyl(C1-C6)alkyl, hydroxy(C3-C10)cycloalkyl(Cι-C6)alkyl, (C3-C10)cycloalkylamino, (C3-C10)cycloalkylamino(C C6)alkyl, cyano(CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6- Cιo)aryl, (C6-C1o)aryl(C1-C6)alkyl, (C6-C10)aryl(C2-C6)alkenyl, hydroxy(CrCe)alkyl, (hydroxy) (Ce-C10)aryl(C1-C6)alkyl, ((C1-C6)alkylamino)(C6-C10)aryl(C1-C6)alkyl, hydroxy(C
Cs)alkylthio(C1-C6)alkyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkynyl, (C C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy(C6-C10)aryl(C1-C6)alkyl, aryloxy(CrC6)alkyl, (C6- C10)aryl(C1-C6)alkoxy(C1-C6)alkyl, amino, (C C6)alkylamino, ((C1-C6)alkyl)2amino, (C6- C10)arylamino, (C6-C10)aryl(CrC6)alkylamino, amino(C1-C6)alkylamino, (C2-
C9)heterocycloalkylamino, (C2-C9)heteroarylamino, (C3-C10)cycloalkyl(C1-C6)alkyl)amino, (C CB)alkylcarbonylamino, (C C6)alkoxycarbonylamino, (C2-C6)alkenylcarbonylamino, (C3- C10)cycloalkylcarbonylamino, (C6-C10)arylcarbonylamino, (C2- C9)heterocycloalkylcarbonylamino, halo(C C6)alkylcarbonylamino, (C1-C6)alkoxy(C1- C6)alkylcarbonylamino, (C C6)alkoxycarbonyl(Cι-C6)alkylcarbonylamino, ((C
C6)alkylcarbonyl)((CrC6)alkyl)amino, ((C1-C6)alkoxycarbonyl)((C1-C6)alkyl)amino, (C C6)alkylsulfonylamino, amino(CrC6)alkyl, (CrC6)alkylamino(C1-C6)alkyl, ((Cr
C6)alkyl)2amino(C C6)alkyl, hydroxy(C1-C6)alkylamino(C1-C6)alkyl, (C6-C10)arylamino(C C6)alkyl, (C6-C1o)aryl(C1-C6)alkylamino(C1-C6)alkyl, (C C6)alkylcarbonylamino(C C6)alkyl, (C6-C10)arylcarbonylamino(C1-C6)alkyl, ((CrC6)alkylcarbonyl)( (C1-C6)alkyl)amino(C1-C6)alkyl, C3-Cιo)cycloalkyl(C1-C8)alkyl)amino(C1-C6)alky], (C C6)alkoxycarbonylamino(Cι-C6)alkyl, (C C6)alkoxycarbonyl(C1-C6)alkylcarbonylamino(Cl-C6)alkyl, ((C1-C6)alkoxycarbonyl)((C1-
C6)alkyl)amino(C C6)alkyl, (CrC6)alkylsulfonylamino(CrC6)alkyl, ((CrC6)alkylsulfonyl)((C1- C6)alkyl)amino(CrC5)alkyl, (C6-C10)arylsulfonylamino(C1-C6)alkyl, ((C6-C10)arylsulfonyl)((C C6)alkyl)amino(CrC6)alkyl, (C2-C8)heterocycloalkylamino(C1-C6)alkyl, (C2-
C9)heteroarylamino(C C6)alkyl, (C CeJalkoxycarbonyl, (C6-C10)aryl(C1-C5)alkoxycarbonyl, (Cι-C6)alkylcarbonyl, (C6-C10)arylcarbonyl, (C6-C o)aryl(C1-C6)alkylcarbonyl, hydroxy(Cr C6)alkoxycarbonyl, (C C6)alkoxycarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxycarbonyl(C1- C6)alkyl, (C1-C6)alkoxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, ((C
C6)alkyl)2aminocarbonyloxy(C C6)alkyl, (C1-C6)alkylcarbonyl(C1-C6)alkyl, (C6-
C10)arylcarbonyl(C1-C6)alkyl, (C6-C1o)aryl(C1-C6)alkylcarbonyl(C1-C6)alkyl, aminocarbonyl, (Cr C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl, (C6-C10)arylaminocarbonyl, (C6- C10)aryl(C1-C6)alkylaminocarbonyl, (aminocarbonyl(C C6)alkylaminocarbonyl, ((C
C6)alkylaminocarbonyl(C1-C6)alkylaminocarbonyl, ((C1-C6)alkoxycarbonyl(C1-
C6)alkylaminocarbonyl, (amino(CrCs)alkyl)aminocarbonyl, (hydroxy(C C6)alkylaminocarbonyl, aminocarbonyl(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl, ((CrC6)alkyl)2aminocarbonyl(C1-C6)alkyl, (C6-C1o)arylaminocarbonyl(C1-C3)alkyl, (C6- Cιo)aryl(C1-C6)alkylaminocarbonyl(C1-C6)alkyl, amidino, hydroxyamidino, guanidino, ureido, (C C6)alkylureido, (C6-C10)arylureido, ((C6-C1Q)aryl)2ureido, (C6-C10)aryl(C1-C6)alkylureido, halo(CrC6)alkylureido, ((CrC6)alkyl)((C6-C10)aryl)ureido, ((CrC6)alkyl)2ureido, halo(Cr C6)alkylcarbonylureido, ureido(C1-C6)alkyl, (C1-C6)alkylureido(C1-C6)alkyl, ((Cr
C6)alkyl)2ureido(C1-C6)alkyl, (C6-C10)arylureido(CrC6)alkyl, (C6-C10)aryl)2ureido(C1-C6)alkyl, (C6-C1o)aryl(C C6)alkylureido(C1-C6)alkyl, halo(CrC6)alkylureido(CrC6)alkyl, (halo(C C6)alkyl)((CrC6)alkyl)ureido(Cι-C6)alkyl, ((C1-C6)alkoxycarbonyl(C1-C6)alkyl)ureido(C1-
C6)alkyl, glycinamido, (C C6)alkylglycinamido, aminocarbonylglycinamido, (C1-C6)alkoxy(C1- C6)alkylcarbonylglycinamido, (aminocarbonyl)((CrC6)alkyl)glycinamido, ((C
C6)alkoxycarbonyl(C1-C6)alkylcarbonyl)((C1-C6)alkyl)glycinamido, ((Cr
C6)alkoxycarbonylamιno(C C6)alkylcarbonyl)glycinamido, (C6-Cι0)arylcarbonyiglycinamido, ((C6-C10)arylcarbonyl)((C1-C6)alkyl)glycinamido, ((C6-C10)aryl(C1-
C6)alkylaminocarbonyl)glycinamido, (C6-C10)aryl(C C6)alkylaminocarbonyl)((C1- C6)alkyl)glycinamido, (Cβ-C10)arylaminocarbonylglycinamido, ((C6-C10)arylaminocarbonyl)((C1- C6)alkyl)glycinamido, glycinamido(C1-C6)alkyl, alaninamido, (C1-C6)alkylalaninamido, alaninamido(CrC6)alkyl, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl, (C2-C9)heteroaryl(C C6)alkyl and (C2-C9)heterocycloalkyl(C C6)alkyl;
R7 is one to three groups independently selected from hydrogen, hydroxy, halo, (C C6)alkyl, (C1-C6)alkylsulfonyl, (C6-C10)arylsulfonyl, (C C6)alkoxy, hydroxy(CrC6)alkoxy, halo(C1-C3)alkyl, fomyl, nitro, cyano, halo(C1-C6)alkoxy, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6- C10)aryl, (C6-C10)aryl(CrC6)alkyl, amino, (CrC6)alkylamino, ((C1-C6)alkyl)2amino, (C6- C10)arylamino, (C6-C1o)aryl(C1-C6)alkylamino, (C1-C6)alkylcarbonylamino, (C
C6)alkoxycarbonylamino, (C2-C6)alkenylcarbonylamino, cycloalkylcarbonylamino, (C6- C10)arylcarbonylamino, halo(C1-C6)alkylcarbonylamino, (Cι-C6)alkoxy(Cr
C6)alkylcarbonylamino, (C C6)alkoxycarbonyl(CrC6)alkylcarbonylamino, ((C
C6)alkylcarbonyl)( (C C6)alkyl)amino, ((C C6)alkoxycarbonyl)( (C C6)alkyl)amino, (C C6)alkylsulfonylamino, amino(Cι-C6)alkyl, (C -C6)alkylamino(C1-C6)alkyl, ((C
C6)alkyl)2amino(C C6)alkyl, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C6- C10)arylcarbonylamino(Cι-C6)alkyl, ((C C6)alkylcarbonyl)( (C C6)alkyl)amino(C1-C6)alkyl, (C C6)alkoxycarbonylamino(C1-C6)alkyl, (Cι-Ce)alkoxycarbonyl, (Ce-C^Jary^d-
C6)alkoxycarbonyl, (CrC6)alkylcarbonyl, (C6-C10)arylcarbonyl, C6)alkylcarbonyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl,
Figure imgf000010_0001
(C3-C10)arylaminocarbonyl, aminocarbonyl(C C6)alkyl, (C1-C6)alkylaminocarbonyl(Cι-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl, (Ce-C^Jarylaminocarbonyl^ CeJalkyl, guanidino, ureido, (C C6)alkylureido, ureido(C C6)alkyl, (C1-C6)alkylureido(Cι-C6)alkyl, and glycinamido; R9 and R10 are each independently selected from the group consisting of hydrogen, (C
C6)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylcarbonyl(C1- C6)alkyl, (C6-C10)aryl(C C6)alkylcarbonyl, (C6-C10)aryl(CrC6)alkylcarbonyl(C1-C6)alkyl, aminocarbonyl, (CrC6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl and (C C6)alkoxycarbonyl; and R11 and R12 are each independently selected from the group consisting of hydrogen,
(CrC6)alkyl, (C6-Cι0)aryl, (C6-C10)aryl(C1-C6)alkyl, hydroxy, (C C6)alkoxy, hydroxy(C C6)alkyl, (Cι-C6)alkoxy(C -C6)alkyl, amino, (CrC6)alkylamino, ((C1-C6)alkyl)2amino, (Cr C6)alkylcarbonylamino, (C3-C8)cycloalkylcarbonylamino, (C3-C8)cycloalkyl(Cr
C6)alkylcarbonylamino, (C C6)alkoxycarbonylamino,- (CrC6)alkylsulfonylamino, (C6- C10)arylcarbonylamino, (C1-C6)alkoxycarbonyl(Cι-C6)alkylcarbonylamino, (C6-C10)aryl(C1- C6)alkylcarbonylamino, ((C6-C1o)aryl(C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, (Cr
C6)alkylcarbonylamino(C1-C6)alkyl, (C3-C8)cycloalkylcarbonylamino(C C6)alkyl, (Cr
C6)alkoxycarbonylamino(Cι-C6)alkyl, (C2-C9)heterocycloalkylcarbonylamino(C C6)alkyl, (C6- C1o)aryl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C2-C9)heteroarylcarbonylamino(C1-C6)alkyl, (C6- C10)arylsulfonylamino, (Cι-C6)alkylsulfonylamino(C1-C6)alkyl, aminocarbonylamino, (Cr C6)alkylaminocarbonylamino, halo(C C6)alkylaminocarbonylamino, ((C
C6)alkyl)2aminocarbonylamino, aminocarbonylamino(Cι-C6)alkyl, (Cr
C6)alkylaminocarbonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonylamino(C1-C6)alkyl,
Figure imgf000010_0002
C6)alkyl, ((C1-C6)alkyl)2amino(C C6)alkyl, carboxy(CrC6)alkyl, (C1-C6)alkoxycarbonyl(C1- C6)alkyl, aminocarbonyl(C C6)alkyl and (C C6)alkylaminocarbonyl(CrC6)alkyl.
Preferred compounds of formula I include those wherein R1 is hydrogen, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, (Cι-C6)alkyl, hydroxy or (C C6)alkylcarbonyloxy.
Other preferred compounds of formula I include those wherein R2 and R3 are each independently selected from (CrC6)alkyl, (C3-C8)cycloalkyl, amino(CrC6)alkyl, amino(C3- C8)cycloalkyl, (C1-C6)alkylamino(C1-C6)alkyl, (Cι-C3)alkylamino(C3-C8)cycloalkyl, hydroxy(C C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkyl, ureido(CrC6)alkyl, (C1-C6)alkyureido(C1- C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkyl or (C2-C9)heterocycloalkyl(C1-C6)alkyl.
Other preferred compounds of formula I include those wherein c is 1; X is C(O); d is 1 ; Y is CH2; e is 1 ; and Z is oxygen.
Other preferred compounds of formula I include those wherein c is 1 ; X is C(O); d is 2; Y is ethylene; and e is 0. Other preferred compounds of formula I include those wherein c is 1 ; X is C(O); d is 1 ; Y is CH2; e is 1 ; and Z is NR9 wherein R9 is hydrogen or (C1-C6)alkyl.
Other preferred compounds of formula 1 include those wherein c is 1 ; X is CH2; d is 1 ;
Y is CH2; e is 1 ; and Z is oxygen. Other preferred compounds of formula I include those wherein c is 1 ; X is CH2; d is 2;
Y is ethylene; and e is 0.
Other preferred compounds of formula I include those wherein c is 1 ; X is CH2; d is 1 ;
Y is CH2; e is 1 ; and Z is NR9 wherein R9 is hydrogen or (CrC6)alkyl.
Other preferred compounds of formula I include those wherein c is 1 ; X is C(O); d is 1 ; Y is CHR8 wherein R8 is NR9R10; R9 and R10 are each independently hydrogen, (CrC6)alkyl or (C-|-C6)alkylcarbonyl; e is 1 ; and Z is oxygen.
Other preferred compounds of formula I include those wherein c is 1 ; X is C(O); d is 1 ; Y is CHR8 wherein R8 is NR9R10; R9 and R10 are each independently hydrogen, (C C6)alkyl or (CrCe^lkylcarbonyl; e is 1 ; and Z is CR11R12 wherein R11 and R12 are hydrogen. Other preferred compounds of formula I include those wherein c is 1 ; X is C(O); d is
1 ; Y is CHR8 wherein R8 is NR9R10; R9 and R10 are each independently hydrogen, (C C6)alkyl or (CrC6)alkylcarbonyl; e is 1 ; and Z is NR9 wherein R9 is hydrogen or (C C6)alkyl.
Other preferred'compounds of formula I include those wherein c is 1 ; X is CH2; d is 1 ;
Y is CHR8 wherein R8 is NR9R10; R9 and R10 are each independently hydrogen, (CrC6)alkyl or (C C6)alkylcarbonyl; e is 1 ; and Z is oxygen.
Other preferred compounds of formula I include those wherein c is 1 ; X is CH2; d is 1 ;
Y is CHR8 wherein R8 is NR9R10; R9 and R10 are each independently hydrogen, (CrC6)alkyl or (CrC6)alkylcarbonyl; e is 1 ; and Z is CR11R12 wherein R11 and R12 are hydrogen.
Other preferred compounds of formula I include those wherein c is 1 ; X is CH2; d is 1 ; Y is CHR8 wherein R8 is NR9R10; R9 and R10 are each independently hydrogen, (CrC6)alkyl or (C C6)alkylcarbonyl; e is 1 ; and Z is NR9 wherein R9 is hydrogen or (C1-C6)alkyl.
Other preferred compounds of formula I include those wherein R4 is (R5)f(R6)g(C6- C10)aryl or (R5)f(R7)h(C2-C9)heteroaryl wherein f, g and h are independently 1 or 2.
Other preferred compounds of formula I include those wherein R5 is (C2- C9)heterocycloalkylcarbonyl, (C2-C8)heteroarylcarbonyl, (C2-C8)heteroaryl(C
C6)alkylaminocarbonyl, (C2-C8)heterocycloalkyl(C1-C6)alkylaminocarbonyl, (Cr
C6)alkylsulfonylamino(C Ce)alkylaminocarbonyl, ureido(CrC6)alkylaminocarbonyl, (cr C^alkylureido C-i-C^alkylaminocarbonyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylaminocarbonyl, aminosulfonyl(C1-C6)alkylaminocarbonyl or (C1-C6)alkylaminosulfonyl(C1- C6)alkylaminocarbonyl.
Other preferred compounds of formula I include those wherein R5 is (C C6)alkylsulfonylamino(C1-C6)alkylcarbonylamino, cyanoguanidino(C1-C6)alkylcarbonylamino, (C1-C6)alkylcyanoguanidino(C1-C6)alkylcarbonylamino, ((Cι-C6)alkyl)2cyanoguanidino(C
C6)alkylcarbonylamino, aminocarbonyl(CrC6)alkylcarbonylamino, (C2-C9)heteroaryl(C C6)alkylcarbonylamino, (C2-C9)heterocycloalkyl(C1-C6)alkylcarbonylamino, or aminosulfony C CeJalkylcarbonylamino. Other preferred compounds of formula I include those wherein R5 is amino(C
C6)alkylureido, (C1-C6)alkylamino(C1-C6)alkylureido, ((C1-C6)alkyl)2amino(C1-C6)alkylureido, (C2-C8)heterocycloalkyl(CrC6)alkylureido, (C2-C9)heteroaryl(Cι-C6)alkylureido, aminosulfonyl(C C6)alkylureido, aminocarbonyl(CrC6)alkylureido, (C
C6)alkylaminocarbonyl(C C6)alkylureido, ((C C6)alkyl)2aminocarbonyl(C1-Ce)alkylureido, acetylamino(C C6)alkylureido, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylureido.
Other preferred compounds of formula I include those wherein R5 is amino(Cι- C6)alkylsulfonylamino, (Cι-C3)alkylamino(C1-C6)alkylsulfonylamino, ((C -C6)alkyl)2amino(C1- C6)alkylsulfonylamino, acetylamino(Cι-C6)alkylsulfonylamino, (acetyl)((Cι-C6)alkyl)amino(C C6)alkylsulfonylamino, ureido(C1-C6)alkylsulfonylamino, (C1-C6)alkylureido(C1- C6)alkylsulfonylamino, ((Cι-C6)alkyl)2ureido(C1-C6)alkylsulfonylamino, (C
C6)alkylsulfonylamino(C1-C6)alkylsulfonylamino, cyanoguanidino(C1-C6)alkylsulfonylamino, (C C6)alkylcyanoguanidino(Cι-C6)alkylsulfonylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-
C6)alkylsulfonylamino, aminocarbonyl(CτC5)alkylsulfonylamino, (C
C6)alkoxycarbonylamino(C C6)alkylsulfonylamino, aminosulfonylamino, (C C6)alkylaminosulfonylamino, ((C1-C6)alkyl)2aminosulfonylamino, aminocarbonyl(C
C6)alkylamino(Cι-C6)alkylsulfonylamino, (C2-C9)heterocycloalkyloxycarbonylamino(C
C6)alkylsulfonylamino or (C2-Cg)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino.
Other preferred compounds of formula I include those wherein R5 is cyanoguanidino, (C C6)alkylcyanoguanidino, ((CrCe)alkyl)2cyanoguanidino, (C2- C9)heterocycloalkylcyanoguanidino, (C2-C9)heteroarylcyanoguanidino, (C2-
C9)heterocycloalkyl(CrC6)alkylcyanoguanidino, (C2-C9)heteroaryl(CrC6)alkylcyanoguanidino, amino(C C6)alkylcyanoguanidino, (C1-C3)alkylamino(C1-C6)alkylcyanoguanidino, ((Cr C6)alkyl)2amino(C1-C6)alkylcyanoguanidino, aminocarbonyl(C1-C6)alkylcyanoguanidino, (Cr C6)alkylaminocarbonyl(C1-C6)alkylcyanoguanidino or ((CrC^alky ∑aminocarbony C-,- C6)alkylcyanoguanidino.
Other preferred compounds of formula I include those wherein R5 is aminocarbonyl(Cι-Ce)alkylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylamino, (Cr
Cs)alkoxycarbonylamino(C C6)alkylamino, aminosuifony C CβJalkylamino, (C2-
C9)heteroaryl(C1-C6)alkylamino, acetylamino(C1-C6)alkylamino or (acetyl)((C-,- C6)alkyl)amino(C1-C6)alkylamino.
Other preferred compounds of formula I include those wherein R5 is cyano(C C6)alkylaminoalkyl or aminocarbonyl(Cι-C6)alkylamino(C1-C6)alkyl. Other preferred compounds of formula I include those wherein R5 is acetylamino(Cι- C6)alkylamino(C Ce)alkyl, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylamino(C1-C6)alkyl, (C C6)alkoxycarbonylamino(CrC6)alkylamino(C1-C6)alkyl, (C2-
C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylamino(C1-Ce)alkyl, (C2- C9)heteroaryloxycarbonylamino(C1-C6)alkylamino(C1-C6)alkyl, cyanoguanidino(C1-
C6)aIkylamino(C1-C6)alkyl, (C C6)alkylcyanoguanidino(C1-C6)alkylamino(C -C6)alkyl, ((C C6)alkyl)2cyanoguanidino(Cι-C6)alkylamino(C C6)alkyl, (Cι-C6)alkylsulfonylamino(Cr
C6)alkylamino(CrC6)alkyl, ureido(C C6)alkylamino(C1-C3)alkyl, (CrC6)alkylureido(C C6)alkylamino(CrC6)alkyl, ((C1-C6)alkyl)2ureido(Cι-C6)alkylamino(C1-C6)alkyl or aminocarbonyloxy(CrC6)alkylamino(CrC6)alkyl.
Other preferred compounds of formula I include those wherein R5 is acetylamino(C1- C6)aIkylcarbonylamino(C1-C6)alkyl, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylcarbonylamino(C1- C6)alkyl, aminocarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1- C6)alkylcarbonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1- C6)alkylcarbonylamino(Cι-C6)alkyl, aminosulfonyl(C1-C6)alkylcarbonylamino(C -C6)alkyl, (C2- Cg)heterocycloalkyloxycarbonylamino(C C6)alkyl, cyanoguanidino(C
Ce)alkylcarbonylamino(C C6)alkyl or cyano(C C6)alkylcarbonylamino(Cι-C6)alkyl.
Other preferred compounds of formula I include those wherein R5 is amino(C C5)alkylaminocarbonylamino(C C6)alkyl, (Cι-C6)alkylamino(CrC6)alkylaminocarbonyl amino^rCsJalkyl, ((C1-C6)alkyl)2amino(C1-C6)alkylaminocarbonylamino(CrC6)alkyl, aminocarbonyl(C1-C6)alkylaminocarbonylamino(CrC6)alkyl, (CrC6) alkylcarbonylamino(C1- C6)alkylaminocarbonylamino(C C6)alkyl, (C1-C6)alkylsulfonylamino(C1-
C6)alkylaminocarbonylamino(C1-C6)alkyl, (CrC5)alkoxycarbonyl amino(C
C6)alkylaminocarbonylamino(C C6)alkyl, (C2-C9)heterocycloalkyloxycarbonyl amino(C C6)alkylaminocarbonylamino(CrC6)alkyl, (C2-C9)heteroaryloxycarbonylamino(Cr
C6)alkylaminocarbonylamino(Cι-C6)alkyl, (C2-C9)heterocycloalkyl(CrC6)alkylaminocarbony lamino(CrC6)alkyl, (C2-C9)heteroaryl(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ureido(C-|- C6)alkylureido(C C6)alkyl, (C1-C6)alkylureido(C C6)alkylureido(C1-C6)alkyl, ((C
C6)alkyl)2ureido(C1-C6)alkylureido(C1-C6)alkyl or cyanoguanidino(C1-C6)alkylureido(C1- C6)alkyl.
Other preferred compounds of formula I include those wherein R5 is amino(C C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(Cι-C6)alkylsulfonylamino(C1-C6)alkyl, acetylamino(Cr
C6)alkylsulfonylamino(C1-C6)alkyl, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylsulfonylamino(C1- C6)alkyl, ureido(C C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylureido(C1-
C6)alkylsulfonylamino(C C6)alkyl, ((Cι-C6)alkyl)2ureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C3)alkylsulfonylamino(C1-C6)alkylsulfonylamino(Cι-C6)alkyl, cyanoguanidino(C1- C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkyl(cyanoguanidino)(Cι-C6)alkylsulfonylamino(C1- C6)alkyl, ((C1-C6)alkyl)2(cyanoguanidino)(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminocarbonyl(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-
C6)alkylsulfonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1- C6)alkylsulfonylamino(C C6)alkyl, (C2-C9)heteroaryloxycarbonylamino(C1-
C6)alkylsulfonylamino(CrC6)alkyl, aminosulfonylamino(Cι-C6)alkyl, (Cr
C6)alkylaminosulfonylamino(C1-C6)alkyl or ((C1-C6)alkyl)2aminosulfonylamino(C1-C6)alkyl.
Other preferred compounds of formula I include those wherein R5 is cyanoguanidino(CrC6)alkyl, (C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, ((Cr C6)alkyl)2(cyanoguanidino)(CrC6)alkyl, (C2-C9)heterocycloalkyl(cyanoguanidino)(C C6)alkyl, (C CgJheteroary cyanoguanidinoJ^ CβJalkyl, (C2-C9)heterocycloalkyl(Cr
C6)alkyl(cyanoguanidino)(Cι-C6)alkyl, (C2-C9)heteroaryl(CrC6)alkyl(cyanoguanidino)(Cι-
C6)alkyl, amino(C C6)alkyl(cyanoguanidino)(CrC6)alkyl, (CrC6)alkylamino(Cr
C6)alkyl(cyanoguanidino)(C C6)alkyl, ((C1-C6)alkyl)2amino(C1-C3)alkyl(cyanoguanidino)(C1- C6)alkyl, aminocarbonyl(C1-C6)alkyl(cyanoguanidino)(CrC6)alkyl, (Cr
CeJalkylaminocarbony C CeJalky cyanoguanidinoJ^i-CeJalkyl or ((Cr
C6)alkyl)2aminocarbonyl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl.
Other preferred compounds of formula I include those wherein R5 is (C2- Cg)heterocycloalkylsulfonyl, amino^ CeJalkylaminosulfonyl, (CrC6)alkylamino(Cr C6)alkylaminosulfonyl, ((C1-C6)alkyl)2amino(C1-C6)alkylaminosulfonyl, (C2-
C9)heteroarylaminosulfonyl, ureido(Cι-C6)alkylaminosulfonyl, (CrC6)alkylureido(Cι-
C6)alkylaminosulfonyl, ((C1-C6)alkyl)2ureido(CrC6)alkylaminosulfonyl, (C
C6)alkylsulfonylamino(CrC6)alkylaminosulfonyl, (CrC6)alkoxycarbonylamino(Cr
C6)alkylaminosulfonyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylaminosulfonyl, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylaminosulfonyl, aminocarbonyl(C1-
C6)alkylaminosulfonyl, cyanoguanidino(C1-C3)alkylaminosulfonyl, (C2-C9)heteroaryl(Cr C6)alkylaminosulfonyl, (C2-C9)heterocycloalkylaminosulfonyl, Other preferred compounds of formula I include those wherein R5 is halo(C1-C6)alkylaminocarbonyl,
Figure imgf000014_0001
C8)alkylureido, halo(CrC6)alkylsulfonylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylamino(C1- C6)alkyl, hydroxy(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, halo(Cr
C6)alkylsulfonylamino(C C6)alkyl, aminosulfonyl, (CrC6)alkylaminosulfonyl, ((C C6)alkyl)2aminosulfonyl, hydroxy(C C6)alkylaminosulfonyl, and (C1-C6)alkoxy(C1- C6)alkylaminosulfonyl.
Other preferred compounds of formula I include those wherein R6 and R7 are each independently halo, halo(C C6)alkyl, (CrC6)alkyl, (C C6)alkoxy, trifluoromethyl, trifluoromethoxy, hydroxy, aminocarbonyl, cyano, ureido, (C C6)alkylsulfonylamino, (C C6)alkoxycarbonylamino or glycinamino. The present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, L , salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1 ,1 '-methylene-bis-(2-hydroxy-3- naphthoate)]salts. The invention also relates to base addition salts of formula I. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations ( g^, potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water- soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
The compounds of this invention may contain olefin-like double bonds. When such bonds are present, the compounds of the invention exist as cis and trans configurations and as mixtures thereof.
The present invention also relates to compounds of formula I wherein any of the hydrogens may optionally be replaced by deuterium.
Unless otherwise indicated, the alkyl, alkenyl and alkynyl groups referred to herein, as well as the alkyl moieties of other groups referred to herein (e j., alkoxy), may be linear or branched, and they may also be cyclic (e^j., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl) or be linear or branched and contain cyclic moieties. Unless otherwise indicated, halogen includes fluorine, chlorine, bromine, and iodine.
(C3-C10)Cycloalkyl when used herein refers to cycloalkyl groups containing zero to two levels of unsaturation such as cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, 1 ,3-cyclohexadiene, cycloheptyl, cycloheptenyl, bicyclo[3.2.1]octane, norbornanyl etc.
(C2-C9)HeterocycloaIkyl when used herein refers to pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, oxiranyl, methylenedioxyl, chromenyl, barbituryl, isoxazolidinyl, 1 ,3-oxazolidin-3-yl, isothiazolidinyl, 1 ,3-thiazolidin-3-yl, 1 ,2-pyrazolidin-2-yl, 1 ,3-pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1 ,2-tetrahydrothiazin-2-yl, 1 ,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1 ,2-tetrahydrodiazin-2-yl, 1 ,3- tetrahydrodiazin-1-yl, tetrahydroazepinyl, piperazinyl, chromanyl, etc. (C2-C8)Heteroaryl when used herein refers to furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1 ,3,5-oxadiazolyl, 1 ,2,4- oxadiazolyl, 1 ,2,3-oxadiazolyl, 1 ,3,5-thiadiazolyl, 1 ,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1 ,2,3-triazinyl, 1 ,3,5-triazinyl, pyrazolo[3,4- bjpyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzo[b]thiophenyl, 5, 6, 7, 8-tetrahydro-quinolin-3-yl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthenyl, isothianaphthenyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indolizinyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzoxazinyl; etc. Aryl when used herein refers to phenyl or naphthyl.
The term "ureido", as used herein, refers to an "amino-carbonyl-amino" moiety.
The term "acetyl", as used herein, refers to an "alkyl-carbonyl" moiety wherein alkyl is defined as above.
The term "cyanoguanidino", as used herein, refers to a functional group having the following formula
Figure imgf000016_0001
The term "(C2-Cg)heterocycloalkyl(C=N-CN)amino", as used herein refers to a functional group having the following formula
Figure imgf000016_0002
wherein "HET" refers to a (C2-C9)heterocyloalkyl or (C2-C9)heteroaryl group and the nigrogen of said group is the place of attachment.
The term "mercapto", as used herein, refers to a "HS-" moeity. The compounds of this invention include all conformation al isomers ( g., cis and trans isomers) and all optical isomers of compounds of the formula I
Figure imgf000016_0003
enantiomers and diastereomers), as well as racemic, diastereomeric and other mixtures of such isomers.
The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and sequelae associated with certain cancers such as multiple myeloma. Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1 , as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1 , including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1 , HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex). They may also provide benefit for the sequelae associated with infection where such infection induces production of detrimental inflammatory cytokines such as TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria in a mammal, preferably a human, comprising an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting chemokine binding to the receptor CCR1 in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier. Examples of such disorders and conditions are those enumerated in the preceding paragraph. The present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and sequelae associated with certain cancers such as multiple myeloma. Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1 , as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1 , including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1 , HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex). They may also provide benefit for the sequelae associated with infection where such infection induces production of detrimental inflammatory cytokines such as TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
The present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and sequelae associated with certain cancers such as multiple myeloma. Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1 , as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1 , including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1 , HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex). They may also provide benefit for the sequelae associated with infection where such infection induces production of detrimental inflammatory cytokines such as TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial meningitis, Kawasaki syndrome, myocardial infarction, acute liver failure, lyme disease, septic shock, cancer, trauma, and malaria in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases, rheumatoid arthritis, recent onset type I diabetes, lupus, inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, vasculitis, acute and chronic inflammatory conditions, osteoar'thritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, glomerulonephritis, allergic conditions, asthma, atopic dermatitis, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre, chronic bronchitis, xeno-transplantation, chronic and acute transplantation tissue rejection, chronic and acute organ transplant rejection, atherosclerosis, restenosis, HIV infectivity, granulomatous diseases, sarcoidosis, leprosy and tuberculosis and sequelae associated with certain cancers such as multiple myeloma. Compounds in this series may also limit the production of cytokines at inflammatory sites, including but not limited to TNF and IL-1 , as a consequence of decreasing cell infiltration, providing benefit for diseases linked to TNF and IL-1 , including congestive heart failure, pulmonary emphysema or dyspnea associated therewith, emphysema; HIV-1 , HIV-2, HIV-3; cytomegalovirus (CMV), adenoviruses, Herpes viruses (Herpes zoster and Herpes simplex). They may also provide benefit for the sequelae associated with infection where such infection induces production of detrimental inflammatory cytokines such as TNF e.g, fungal meningitis, joint tissue damage, hyperplasia, pannus formation and bone resorption, psoriatic arthritis, hepatic failure, bacterial me-ninπitiQ K'a /P ak'i cvnrlmmo
Figure imgf000019_0001
infαrH-irtn DPI ito
Figure imgf000019_0002
fαi tro K/m_ Hicα-c_
Figure imgf000019_0003
C6)alkylcarbonylamino, ((C1-C6)alkyl)2amino(C C6)alkylcarbonylamino, acetylamino(Cr C6)alkylcarbonylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylcarbonyIamino, (Cr
C6)alkylsulfonylamino(Cι-C6)alkylcarbonylamino, cyanoguanidino(C1-C6)alkylcarbonylamino, (C1-C6)alkylcyanoguanidino(Cι-C6)alkylcarbonylamino, ((CrC6)alkyl)2cyanoguanidino(Cr C6)alkylcarbonylamino, aminocarbony C CδJalkylcarbonylamino, aminocarbonylamino^r C6)alkylcarbonylamino, (Cι-Ce)alkylaminocarbonylamino(C1-C6)alkylcarbonylamino, ((C C6)alkyl)2aminocarbonylamino(C1-C6)alkylcarbonylamino, (C2-Cg)heteroaryl(Cι-
C6)alkylcarbonylamino, (C^CgJheterocycloalky^C CθJalkylcarbonylamino, aminosulfonyl(Cr C6)alkylcarbonylamino, hydroxy(C1-C5)alkylureido, (amino(CrC6)alkylureido, (C C6)alkylamino(Cι-Ce)alkylureido, ((CrC5)alkyl)2amino(C1-C6)alkylureido, (C2-
Cg)heterocycloalkyl(Cι-C6)alkylureido, (C2-C8)heteroaryl(Cι-C6)alkylureido, aminosulfonyl(C C6)alkylureido, aminocarbonyl(C C6)alkylureido, (CrC6)alkylaminocarbonyl(Cr
C6)alkylureido, ((C1-C6)alkyl)2aminocarbonyl(Cι-C6)alkylureido, acetylamino(C1-C6)alkylureido, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylureido, carboxy(C C6)alkylureido, halo(C Cs)alkylsulfonylamino, amino(C C6)alkylsulfonylamino, (Cι-C6)alkylamino(C
C6)alkylsulfonylamino, ((C1-C6)alkyl)2amino(C1-C6)alkylsulfonylamino, acetylamino(Cι- C6)alkylsulfonylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylsulfonylamino, ureido(C C6)alkylsulfonylamino, (C1-C6)alkylureido(C1-C6)alkylsulfonylamino, ((C1-C6)alkyl)2ureido(C1- C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C3)alkylsulfonyIamino, cyanoguanidino(C1-C6)alkylsulfonylamino, (C1-C6)alkylcyanoguanidino(C1-
C6)alkylsulfonylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkylsulfonylamino, aminocarbonyl(C1-C6)alkylsulfonylamino, (C1-C6)alkoxycarbonylamino(C1-
C6)alkylsulfonylamino, aminosulfonylamino, (C C6)alkylaminosulfonylamino, ((Cr C6)alkyl)2aminosulfonylamino, aminocarbonyl(C1-Ce)alkylamino(C1-C6)alkylsulfonylamino, (C2- C9)heterocycloalkyloxycarbonylamino(C C6)alkylsulfonylamino (C2-
Cg)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino, cyanoguanidino, (C
C6)alkylcyanoguanidino, ((C C6)alkyl)2cyanoguanidino, (C2-
Cg)heterocycloalkylcyanoguanidino, (C2-C9)heteroarylcyanoguanidino, (C2-
Cg)heterocycloalkyl(C-ι-C6)alkylcyanoguanidino, (C2-Cg)heteroaryl(CrC6)alkylcyanoguanidino, amino(C C6)alkylcyanoguanidino, (Cι-C6)alkylamino(C1-C6)alkylcyanoguanidino, ((Cr C6)alkyl)2amino(C1-C6)alkylcyanoguanidino, aminocarbony C CθJalkylcyanoguanidino, (C C6)alkylaminocarbonyl(C1-C6)alkylcyanoguanidino, ((C C6)alkyl)2aminocarbonyl(C1-
C6)alkylcyanoguanidino, hydroxy^ CeJalkylamino, aminocarbonyl(CrC6)aIkylamino, carboxy(CrC6)alkylamino, (CrC6)alkylsulfonylamino(C1-C6)alkylamino, (C C6)alkoxycarbonylamino(C1-C6)alkylamino, aminosulfonyl(C1-C6)alkylamino, (C2-
C9)heteroaryl(C-|-C6)alkylamino, acetylamino(Cι-C6)alkylamino, (acetyl)((C
C6)alkyl)amino(C C6)alkylamino, (C C6)alkylamino, ((CrC6)alkyl)2amino, (C6-C10)arylamino, (C6-C10)aryl(CrC6)alkylamino, amino(C C6)alkylamino, (C2-C9)heterocycloalkylamino, (C2- C9)heteroarylamino, (C3-C10)cycloalkyl(C1-C6)alkyl)amino, (C1-C6)alkylcarbonylamino, (C C6)alkoxycarbonylamino, (C2-C6)alkenylcarbonylamino, (C3-C10)cycloalkylcarbonylamino, (C6- Cιo)arylcarbonylamino, (C2-C9)heterocycloalkylcarbonylamino, halo(C C6)alkylcarbonylamino, (C1-C6)alkoxy(Cι-C6)alkylcarbonylamino, (C1-C6)alkoxycarbonyl(C1- C6)alkylcarbonylamino, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, ((C
C6)alkoxycarbonyl)((C C6)alkyl)amino, (C1-C6)alkylsulfonylamino, (C3-C 0)cycloalkylamino, ureido, (C1-C6)alkylureido, (C6-C 0)arylureido, ((C6-C10)aryl)2ureido, (C6-Cι0)aryl(C C6)alkylureido, halo(C1-C6)alkylureido, ((C1-C6)alkyl)((C6-Cι0)aryl)ureido, ((CrC6)alkyl)2ureido, halo(CrC6)alkylcarbonylureido, glycinamido, (C1-C6)alkylglycinamido, aminocarbonylglycinamido, (C1-C6)alkoxy(C1-C6)alkylcarbonylglycinamido,
(aminocarbonyl)((C C8)alkyl)glycinamido, ((C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonyl)((C1- C6)alkyl)glycinamido, ((C C6)alkoxycarbonylamino(C C6)alkylcarbonyl)glycinarnido, (C6- C10)arylcarbonylglycinamido, ((C5-C10)arylcarbonyl)((C1-C6)alkyl)glycinamido, ((C6-Cι0)aryl(Cr C6)alkylaminocarbonyl)glycinamido, (C6-C10)aryl(C1-C6)alkylaminocarbonyl)((C1-
C6)alkyl)glycinamido, (C6-C10)arylaminocarbonylglycinamido and ((C6-
C10)arylaminocarbonyl)((C1-C6)alkyl)gIycinamido.
R18 and R19 together with the nitrogen to which they are attached is selected from the group consisting of (C2-C9)heteroaryl(C1-C6)alkylamino, (C2-C9)heterocycloalkyl(C1- C6)alkylamino, (CrC6)alkylsulfonylamino, (Cι-C6)alkylsulfonylamino(C1-C6)alkylamino, ureido(C1-C6)alkylamino, (C Ce)alkylureido(C1-C6)alkylamino, ((CrC6)alkyl)2ureido(C C6)alkylamino, halo(C C6)alkylamino, aminosulfonyl(C1-C6)alkylamino, (C
C6)alkylamιnosulfonyl(C C6)alkylamino, carboxy(C C6)alkylamino, (C CθJalkoxycarbony Cr C6)alkylamino, cyano(C C6)alkylamino, aminocarbonyl(C1-C6)alkylamino, acetylamino(C C6)alkylamino, (acetyl)((C1-C6)alkyl)amino(C1-C6)alkylamino, (Cι-C6)alkoxycarbonylamino(Cr C6)alkylamino, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylamino, (C2-
C9)heteroaryloxycarbonylamino(C1-C6)alkylamino, cyanoguanidino(C1-C6)alkylamino, (C CeJalkylcyanoguanidino^rCβJalkylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-C6)alkyIamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylamino, ureido(C C6)alkylamino, (C1-C6)alkylureido(C1- C6)alkylamino, ((CrC6)alkyl)2ureido(C C6)alkylamino, aminocarbonyloxy(CrC6)alkylamino, acetylamino(C1-C6)alkylcarbonylamino, (acetyl)((C1-C6)alkyl)amino(C C6)alkylcarbonylamino, aminocarbonyl(C1-C6)alkylcarbonylamino, (Cι-C6)alkylaminocarbonyl(Cι-
C6)alkylcarbonylamino, ((C1-C6)alkyl)2aminocarbonyl(Cι-C6)alkylcarbonylamino, ureido(C C6)alkylcarbonylamino, (C1-C6)alkylureido(C1-C6)alkylcarbonylamino, ((C1-C6)alkyl)2ureido(C1- C6)alkylcarbonylamino, (C1-C6)alkoxycarbonylamino(Cι-C6)alkylcarbonylamino, aminosulfonyl(C1-C6)alkylcarbonylamino, hydroxy(C1-C6)alkylamino(C1-
C5)alkylcarbonylamino, (CrC6)alkoxy(CrC6)alkylamino(C C6)alky[carbonylamino, (C2- C9)heterocycloalkyloxycarbonylamino, (C2-C9)heteroarylcarbonylamino(C
C6)alkylcarbonylamino, (C2-C9)heterocycloalkylcarbonylamino(Cι-C6)alkylcarbonylamino, cyanoguanidino(C1-C6)alkylcarbonylamino, cyano(C1-C6)alkylcarbonylamino, (C
C6)alkylcarbonylamino(C1C6)alkylamino-carbonylamino, amino(C1- C6)alkylaminocarbonylamino, (Cι-C6)alkylamino(C1-C6)alkylaminocarbonyl amino, ((C C6)alkyl)2amino(Cι-C6)alkylaminocarbonylamino, carboxy^ CβJalkylaminocarbonyl amino, aminocarbonyl(C C6)alkylaminocarbonylamino, (C C6) alkylcarbonylamino(Cι-
C6)alkylaminocarbonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylaminocarbonylamino, (C C6)alkoxycarbonyl amino(CrC6)a)kylaminocarbonylamino, (C2- C9)heterocycloalkyloxycarbonyl amino(CrC6)alkylaminocarbonylamino, (C2-
C9)heteroaryIoxycarbonylamino(C1-C6)alkylaminocarbonylamino, (C2-C9)heterocycloalkyl(Cr C6)alkylaminocarbonylamino, (C2-C9)heteroaryl(Cι-C6)alkylaminocarbonylamino, ureido(C C6)alkylureido, (C1-C6)alkylureido(C1-C6)alkylureido, ((C1-C6)alkyl)2ureido(C1-C6)alkylureido, cyanoguanidino^-i-CeJalkylureido, amino(C1-C6)alkylsulfonylamino, (Cι-C6)a)kylamino(Cι- C6)alkylsulfonylamino, ((C -C6)alkyl)2amino(C1-C6)alkylsulfonylamino, acetylamino(Cr C6)alkylsulfonylamino, (acetyl)((C1-C6)alkyl)amino(C1-Cβ)alkylsulfonylamino, ureido(Cr C6)alkylsulfonylamino, (C1-C6)alkylureido(C1-C6)alkylsulfonylamino, ((Cι-C5)alkyl)2ureido(C C6)alkylsulfonylamino, (CrC6)alkylsulfonylamino(CrC6)alkylsulfonylamino, cyanoguanidino(CrC6)alkylsulfonylamino, (C1-C6)alkyl(cyanoguanidino)(C Cs)alkylsulfonylamino, ((C1-C6)alkyl)2(cyanoguanidino)(C1-C6)alkylsulfonylamino, aminocarbonyl(C C8)alkylsulfonylamino, (C CeJalkoxycarbonylamino^r
C6)alkylsulfonylamino, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylsulfonylamino, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino, aminosulfonylamino(C-|-
C6)alkyl, (C1-C6)alkylaminosulfonylamino, ((CrC8)alkyl)2aminosulfonyIamino(C1-Ce)alkyl, cyanoguanidino, (CrC6)alkyl(cyanoguanidino), ((C C6)alkyl)2(cyanoguanidino), (C2- C9)heterocycloalkyl(cyanoguanidino), (C2-C9)heterocycloalkyl(cyanoguanidino), (C2- C9)heteroaryl(cyanoguanidino), (C2-Cg)heterocycloalkyl(C1-C6)alkyl(cyanoguanidino), (C2- C9)heteroaryl(C C6)alkyl(cyanoguanidino), amino(CrC6)alkyl(cyanoguanidino), (C
C6)alkylamino(C C6)alkyl(cyanoguanidino), ((C C6)alkyl)2amino(C - C6)alkyl(cyanoguanidino), aminocarbonyl(C1-C3)alkyl(cyanoguanidino), (C
C6)alkylaminocarbonyl(Cι-C6)alkyl(cyanoguanidino), ((CrC6)alkyl)2aminocarbonyl(Cr
C6)alkyl(cyanoguanidino), (C2-C9)heterocycloalkyl, amino(C1-C6)alkylamino, (C ■r C6)alkylamino(C C6)alkylamino, ((C1-C6)alkyl)2amino(C -C6)alkylamino, (C
C9)heteroarylamino, ureido(C1-C6)alkylamino, (C C8)alkylureido(CrCe)alkylamino, ((C C6)alkyl)2ureido(C Cβ)alkylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkylamino, (C
C6)alkoxycarbonylamino(CrC6)alkylamino, (CrCgJheterocycloalkyloxycarbonylamino^-i
C6)alkylamino, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylamino, aminocarbony Ci C6)alkylamino, cyanoguanidino(C1-C8)alkylamino, (C2-C9)heteroaryl(C1-C6)alkylamino, (C2- C9)heterocycloalkylamino, (C C6)alkylcarbonylamino, halo(C1-C6)alkylcarbonylamino, (Cr C6)alkoxycarbonylamino, ureido, (C C6)alkylureido, ((Cι-C6)alkyl)2ureido, amino, (C C6)alkylamino, (C3-C10)cycloalkylamino, ((C C6)alkyl)2amino, hydroxy(Cι-C6)alkylamino, (C6- C10)arylamino, (C8-Cι0)aryl(C1-C8)alkylamino, (C C6)alkylcarbonylamino, (C6-
Cιo)arylcarbonylamino, ((C1-C8)alkylcarbonyl)((Cι-C6)alkyl)amino, (C3-C10)cycloalkyl(C1- C6)alkyl)amino, (C1-C6)alkoxycarbonylamino, (C1-C6)alkoxycarbonyl(C1-
C6)alkylcarbonylamino, ((C1-C6)alkoxycarbonyl)((CrC6)alkyl)amino, (C
C8)alkylsulfonylamino, ((CrCe alkylsulfony^C-i-CeJalky amino, (C6-Cι0)arylsulfonylamino, ((C6-C10)arylsulfonyl)((C C6)alkyl)amino, (C2-C9)heterocycloalkylamino, (C2-
Cg)heteroarylamino, halo(CrC8)alkylamino, (C6-C10)arylamino, (C6-Ci0)aryl(CrC6)alkylamino, (aminocarbonyl(C C6)alkylamino, ((C1-C6)alkylaminocarbonyl(C1-C8)alkylamino, (carboxy(C C6)alkyl)amino, ((C1-C6)alkoxycarbonyl(C1-C8)alkylamino, (amino(CrC6)alkyl)amino, (hydroxy^rCeJalkylamino, ureido, (C C8)alkylureido, ((C1-C6)alkyl)2ureido, (C8- C10)arylureido, (C6-C10)aryl)2ureido, (C8-Cι0)aryl(Cι-C6)alkylureido, halo(CrC6)alkylureido, (halo(C1-C8)alkyl)((C C6)alkyl)ureido, ((CrCeJalkoxycarbony C-rC^alky ureido, and glycinamido.
PREPARATION A
Figure imgf000024_0001
XXXIV
Figure imgf000024_0002
H
(R2)_ -f (R )ι xxxiii
H
H
Figure imgf000024_0003
PREPARATION B
Figure imgf000025_0001
Figure imgf000025_0002
Figure imgf000025_0003
XIX PREPARATION B (Con't)
Figure imgf000026_0001
XVIII
Figure imgf000026_0002
PREPARATION C
H3CO-R" ■SO2-CI
XXV
Figure imgf000027_0001
H3CO-R -SO2- ■N NR18R1£ H3CO-R -SO2-NR18R19 H
XXIV
XXVIII
Figure imgf000027_0002
XXXVII XXIII SCHEME 1
H
Figure imgf000028_0001
Figure imgf000028_0002
Figure imgf000028_0003
SCHEME 2
H
Figure imgf000029_0001
Figure imgf000029_0002
SCHEME3
X
Figure imgf000030_0001
Figure imgf000030_0002
Figure imgf000030_0003
SCHEME4
X
Figure imgf000031_0001
Figure imgf000031_0002
Figure imgf000031_0003
SCHEME 5
X
Figure imgf000032_0001
XVI
Figure imgf000032_0002
VII SCHEME6
X
Figure imgf000033_0001
Figure imgf000033_0002
XXXIX
Figure imgf000033_0003
xxxx SCHEME 7
XXXVI
Figure imgf000034_0001
VIII
XXXII
Figure imgf000034_0002
Figure imgf000034_0003
ln reaction 1 of Preparation A, the compound of formula XXXV, wherein b is 0, 1 or 2, is converted to the corresponding compound of formula XXXIV by reacting XXXV with an ethyldiamine compound of the formula, (R3)j-ethyldiamin'e, in the presence of an aprotic solvent, such as diethylether. The reaction mixture is heated to reflux for a time period between about 1 hour to about 12 hours.
In reaction 2 of Preparation A, the compound of formula XXXIV is converted to the corresponding compound of formula XXXIII by reducing XXXIV with a reducing agent, such as sodium borohydride, in a refluxing protic solvent, such as ethanol.
In reaction 3 of Preparation A, the compound of formula XXXIII is converted to the corresponding compound of formula XXX by reacting XXXIII with a benzaldehyde compound of the formula
Figure imgf000035_0001
in the presence of a base, such as triethylamine, and a reducing agent, such as sodium triacetoxyborohydride, in an aprotic solvent, such as 1 ,2-dichloroethane. The reaction mixture is stirred at room temperature for a time period between about 1 hour to about 4 hours, preferably about 2 hours.
In reaction 1 of Preparation B, the compound of formula XXII, wherein b is 0, 1 or 2, is converted to the corresponding compound of formula XXI by reacting XXIII with a benzaldehyde compound of the formula
Figure imgf000035_0002
in the presence of a base, such as triethylamine, a reducing agent, such as sodium borohydride and an aprotic solvent, such as 1 ,2-dichloroethane. The reaction is stirred, at room temperature, for a time period between about 1 hour to about 4 hours, preferably about 2 hours. In reaction 2 of Preparation B, the compound of formula XXI is converted to the corresponding compound of formula XX by first reacting a compound of the formula
Figure imgf000035_0003
wherein j is 0, 1 or 2, with 4-methyl morpholine and isobutylchloroformate in the presence of a polar aprotic solvent, such as tetrahydrofuran, followed by reacting the intermediate so formed with the compound of formula XXI. The reaction mixture, so formed, is stirred overnight at room temperature. In reaction 3 of Preparation B, the compound of formula XX is converted to the corresponding piperizine-2,5-dione compound of formula XIX by treating XX with trifluoroacetic acid in the presence of a polar aprotic solvent, such as methylene chloride. The reaction is stirred, at room temperature, for a time period between about 1 hour to about 4 hours, preferably about 2 hours. In reaction 4 of Preparation B, the compound of formula XIX is converted to the corresponding compound of formula XVIII by reducing XIX with a reducing agent, such as lithium aluminum hydride. The reaction is conducted at a temperature between about -10°C to about 10°C, preferably about 0°C, for a time period between about 10 minutes to about 90 minutes, preferably about 40 minutes. In reaction 1 of the Preparation C, the compound of formula XXV is converted to the corresponding compound of formula XXIV by reacting XXV with an amine of the formula, NHR18R19, wherein R18 and R19 are each independently selected from hydrogen, a nitrogen containing (C2-C9)heterocycloalkyl or (C2-C9)heteroaryl group, or (C C6)alkyl optionally substituted by hydroxy, aminocarbonyl, (CrC6)alkylaminocarbonyl, ((C C6)alkyl)2carbonyl, carboxy, (CrC6)alkylsulfonylamino, (Cι-C6)alkoxycarbonylamino, aminosulfonyl, (C C8)alkylaminosulfonyl, ((C C8)alkyl)2aminosulfonyl, (C8-C10)alkoxy, (C2-C9)heteroaryl, (C2- C9)heterocycloalkyl, (C C6)alkylcarbonylamino, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, cyano, ureido, (C C6)alkylureido, ((Cι-C6)alkyl)2ureido, cyanoguanidino, (C C6)alkylcyanoguanidino and ((C C6)alkyl)2cyanoguanidino, or R18 and R19 are taken together with the nitrogen to which they are attached to form a (C2-C9)heteroaryl or (C2- C9)heterocycloalkyl group, in the presence of a polar aprotic solvent, such as methylene chloride. The reaction mixture is stirred, at room temperature, for a time period between about 1 hour to about 24 hours, preferably about 2 hours.
In reaction 2 of Preparation C, the compound of formula XXIV is converted to the corresponding compound of formula XXIII by reacting XXIV with thiophenol in the presence of a base, such as sodium hydride, and a polar aprotic solvent, such as dimethylformamide. The reaction is heated to reflux for a time period between about 1 hour to about 10 hours, preferably about 4 hours.
In reaction 3 of Preparation C, the compound of formula XXV is converted to the corresponding compound of formula XXXVIII by reacting XXV with sodium cyanate in the presence of pyridine and a polar aprotic solvent, such as acetonitrile. The reaction is stirred, at room temperature, for a time period between about 2 hours to about 18 hours, preferably about 10 hours. An amine of the formula, H2N-C(0)-NR18R19, is then added and the reaction mixture so formed is stirred, at room temperature, for a time period between about 2 hours to about 24 hours, preferably about 8 hours.
In reaction 4 of Preparation C, the compound of formula XXXVIII is converted to the corresponding compound of formula XXXVII according to the procedure described above in reaction 2 of Preparation C.
In reaction 1 of Scheme 1_, the compound of formula XXX is converted to the corresponding compound of formula X by reacting XXX with a compound of the formula, A- (X)o-(Y)d-A, wherein A is chloro or bromo, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride. The reaction is stirred at a temperature between about -10°C to about 10°C, for a time period between about 15 minutes to about 90 minutes, preferably about 30 minutes.
In reaction 2 of Scheme 1_, the compound of formula X is converted to the corresponding compound of formula I by reacting X with a compound of the formula, H-(Z)e- R4 wherein e is 1 and Z is oxygen, in the presence of potassium carbonate, potassium iodide and an aprotic solvent, such as butanone. The reaction is heated to reflux for a time period between about 4 hours to about 8 hours, preferably about 6 hours.
In reaction 1 of Scheme 2, the compound of formula XXX is converted to the corresponding compound of formula I by reacting XXX with a compound of the formula, A- (X)c-(Y)d-(Z)e-R4, wherein A is chloro or bromo, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride. The reaction is stirred at a temperature between about -10°C to about 10°C, for a time period between about 15 minutes to about 90 minutes, preferably about 30 minutes.
In reaction 1 of Scheme 3, the compound of formula X is converted to the corresponding compound of formula XII according to the procedure described above in reaction 2 of Scheme 1_.
In reaction 2 of Scheme 3, the compound of formula XII is converted to the corresponding compound of formula XI by reacting XII with lithium hydroxide monohydrate in the presence of methanol, tetrahydrofuran and water. The reaction mixture is stirred overnight at room temperature.
In reaction 3 of Scheme 3, the compound of formula XI is converted to the corresponding compound of formula II, by reacting XI with an amine, in the presence of 4- dimethylaminopyridine, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimine and a polar aprotic solvent, such as methylene chloride. The resulting reaction mixture is stirred overnight at room temperature. In reaction 1 of Scheme 4, the compound of formula X is converted to the corresponding compound of formula XV according to the procedure described above in reaction 2 of Scheme
In reaction 2 of Scheme 4, the compound of formula XV is converted to the corresponding compound of formula XIV by hydrogenating XV in the presence of a catalyst, such as platinum on carbon, and a polar protic solvent, such as ethanol. The reaction is carried out under a pressure between about 30 psi to about 40 psi, preferably about 35 psi, for a time period between about 15 minutes to about 1 hour, preferably 30 minutes.
In reaction 3 of Scheme 4, for urea formation, the compound of formula XIV is converted to the corresponding compound of formula V by first reacting XIV with 4-nitrophenyl chloroformate in the presence of a base, such as pyridine, and a polar aprotic solvent, such as methlyene chloride, followed by reacting the intermediate so formed with an amine. The reaction mixture, so formed, is allowed to stir overnight at room temperature. For sulfonamide formation, the compound of formula XIV is reacted with a sulfonyl chloride compound of the formula, R16-CI, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride. The reaction is stirred overnight at ambient temperature. For cyanoguanidine formation, the compound of formula XIV is first treated with sodium hydride in an aprotic solvent, such as tetrahydrofuran, followed by reacting, the intermediate so formed with dimethyl-N-cyanodithio iminocarbonate. The reaction mixture so formed is heated to reflux overnight. The N-cyano-S-methyl-isothiourea intermediate is then reacted with an amine in the presence of a polar protic solvent, such as methanol. For amide formation, the compound of formula XIV is reacted with an acid, such as 3-tert- butoxycarbonylaminopropionic acid in the presence of N-methylmorpholine, O-benzotriazole- 1-yl-N,N,N , N -tetramethyluronium hexafluorophosphate and a polar aprotic solvent, such as methylene chloride.
In reaction 1 of Scheme 5, the compound of formula X is converted to the corresponding compound of formula XVI, wherein k is 0, 1 , 2, 3 or 4, according to the procedure described above in reaction 2 of Scheme 1_. In reaction 2 of Scheme 5, the compound of formula XVI is converted to the corresponding compound of formula VII by reacting XVI with an amine of the formula, R16 R17N, wherein R16 and R17 are each indepenently hydrogen, a nitrogen containing (C2-C9)heterocycloalkyl or (C2- C9)heteroaryl group, or (C1-C6)alkyl optionally substituted by hydroxy, aminocarbonyl, (C C8)alkylaminocarbonyl, ((CrC6)alkyl)2carbonyl, carboxy, (C-rC.Jalkylsulfonylamino, (C C6)alkoxycarbonylamino, aminosulfonyl, (C C6)alkylaminosulfonyl, ((C C8)alkyl)2aminosulfonyl, (C8-C10)alkoxy, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl, (C,- C6)alkylcarbonylamino, ((C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, cyano, ureido, (Cr C6)alkylureido, ((C C^alkyl^ureido, cyanoguanidino, (C C6)alkylcyanoguanidino and ((C C8)alkyl)2cyanoguanidino, in the presence of a 10:1 ratio solution of dichloroethane/acetic acid. The reaction mixture is stirred, at room temperature, for a time period between about 30 minutes to about 2 hours, preferably about 1 hour. A reducing agent, such as sodium cyanoborohydride is than added to the mixture and the reaction is allowed to stir overnight at room temperature. When R16 and/or R17 is/are hydrogen, the compound of formula VII may further be reacted according to the procedure described above in reaction 3 of Scheme 4, to provide ureas, sulfonamides, cyanoguanidinos, or amides.
In reaction 1 of Scheme 6, the compound of formula X is converted to the corresponding compound of formula XXXIX according to the procedure described above in reaction 2 of Scheme 1_.
In reaction 2 of Scheme 6, the compound of formua X is converted to the corresponding compound of formula XXXX according to the procedure described above in reaction 2 of Scheme 1_.
In reaction 1 of Scheme 7, the acid compound of formula XXXVI is converted to the corresponding compound of formula XXXII by treating XXXVI with thionyl chloride neat or in an aprotic solvent, at room temperature, for a time period between about 1 hour to about 24 hours, preferably 1 hour. The acid chloride so formed is dissolved in a polar aprotic solvent with a compound of the formula, (H3CO)(H3C)NH«HCI, in the presence of an amine base, such as triethylamine. The reaction mixture is stirred, at room temperature, for a time period between about 1 hour to about 48 hours, preferably about 12 hours.
In reaction 2 of Scheme 7, the amide compound of formula XXXII is converted to the corresponding compound of formula XXXI by reacting XXXII with a (C2-C9)heteroaryl lithium reagent in the presence of a polar aprotic solvent at a temperature between about -100°C to room temperature, preferably about -78°C. The resulting reaction mixture is stirred for a time period between about 1 hour to about 24 hours, preferably about 12 hours, at a temperature between about -78°C to about 50°C, preferably about 20°C.
Unless indicated otherwise, the pressure of each of the above reactions is not critical. Generally, the reactions will be conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere). The compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.
The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, Le., salts containing pharmacologically acceptable- anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1 ,1 '-methylene-bis-(2-hydroxy-3- naphthoate)] salts.
Those compounds of the formula I which are also acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic compounds of formula I. These non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields.
Compounds of the formula I and their pharmaceutically acceptable salts (hereinafter also referred to, collectively, as "the active compounds") are potent antagonists of the CCR1 receptors. The active compounds are useful in the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), chronic bronchitis, xeno-transplantation, transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases
(including sarcoidosis, leprosy and tuberculosis).
The activity of the compounds of the invention can be assessed according to procedures know to those of ordinary skill in the art. Examples of recognized methods for determining CCR1 induced migration can be found in Coligan, J. E., Kruisbeek, A.M.,
Margulies, D.H., Shevach, E.M., Strober, W. editors: Current Protocols In Immunology,
6.12.1- 6.12.3. (John Wiley and Sons, NY, 1991 ). One specific example of how to determine the activity of a compound for inhibiting migration is described in detail below.
Chemotaxis Assay: The ability of compounds to inhibit the chemotaxis to various chemokines can be evaluated using standard 48 or 96 well Boyden Chambers with a 5 micron polycarbonate filter. All reagents and cells can be prepared in standard RPMI (BioWhitikker Inc.) tissue culture medium supplemented with 1 mg/ml of bovine serum albumin. Briefly, MIP-1α
(Peprotech, Inc., P.O. Box 275, Rocky Hill NJ) or other test agonists, were placed into the lower chambers of the Boyden chamber. A polycarbonate filter was then applied and the upper chamber fastened. The amount of agonist chosen is that determined to give the maximal amount of chemotaxis in this system (e.g., 1 nM for MIP-1 should be adequate).
THP-1 cells (ATCC TIB-202), primary human monocytes, or primary lymphocytes, isolated by standard techniques can then be added to the upper chambers in triplicate together with various concentrations of the test compound. Compound dilutions can be prepared using standard serological techniques and are mixed with cells prior to adding to the chamber.
After a suitable incubation period at 37 degrees centigrade (e.g. 3.5 hours for THP-1 cells, 90 minutes for primary monocytes), the chamber is removed, the cells in the upper chamber aspirated, the upper part of the filter wiped and the number of cells migrating can be determined according to the following method.
For THP-1 cells, the chamber (a 96 well variety manufactured by Neuroprobe) can be centrifuged to push cells off the lower chamber and the number of cells can be quantitated against a standard curve by a color change of the dye fluorocein diacetate. For primary human monocytes, or lymphocytes, the filter can be stained with Dif
Quik® dye (American Scientific Products) and the number of cells migrating can be determined microscopically.
The number of cells migrating in the presence of the compound are divided by the number of cells migrating in control wells (without the compound). The quotant is the % inhibition for the compound which can then be plotted using standard graphics techniques against the concentration of compound used. The 50% inhibition point is then determined using a line fit analysis for all concentrations tested. The line fit for all data points must have an coefficient of correlation (R squared) of > 90% to be considered a valid assay.
All of the compounds of the invention that were tested had IC 50 of less than 25μM, in the Chemotaxis assay. The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation. The active compounds of the invention may also be formulated for sustained delivery.
For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid). For buccal administration, the composition may take the form of tablets or lozenges formulated in conventional manner.
The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form,
Figure imgf000042_0001
in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, ejj., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
A proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above (e.g., rheumatoid arthritis) is 0.1 to 1000 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
Aerosol formulations for treatment of the conditions referred to above (e.g., rheumatoid arthritis) in the average adult human are preferably arranged so that each metered dose or "puff of aerosol contains 20 μg to 1000 μg of the compound of the invention. The overall daily dose with an aerosol will be within the range 0.1 mg to 1000 mg. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1 , 2 or 3 doses each time.
The active agents can be formulated for sustained delivery according to methods well known to those of ordinary skill in the art. Examples of such formulations can be found in United States Patents 3,538,214, 4,060,598, 4,173,626, 3,1 19,742, and 3,492,397. The compounds of the invention can also be utilized in combination therapy with, but not limited to, other therapeutic agents such as with T-cell immunosuppressant agents such as rapamycin cyclosporin A and FK-506, with steroid sparing agents such as Cellcept®, or with classical anti-inflammatory agents (e.g. cyclooxygenase/lipoxygenase inhibitors) such as tenidap, aspirin, acetaminophen, naproxen and piroxicam. The following Examples illustrate the preparation of the compounds of the present invention. NMR data are reported in parts per million (δ) and are referenced to the deuterium lock signal from the sample solvent (deuteriochloroform unless otherwise specified). Commercial reagents were utilized without further purification. THF refers to tetrahydrofuran. DMF refers to N,N-dimethylformamide. Chromatography refers to column chromatography performed using 32-63 mm silica gel and executed under nitrogen pressure (flash chromatography) conditions. Low Resolution Mass Spectra (LRMS) were recorded on either a Hewlett Packard 5989®, utilizing chemical ionization (ammonium), or a Fisons (or Micro Mass) Atmospheric Pressure Chemical lonization (APCI) platform which uses a 50/50 mixture of acetonitrile/water with 0.1% formic acid as the ionizing agent. Room or ambient temperature refers to 20-25όC. All non-aqueous reactions were run under a nitrogen atmosphere for convenience and to maximize yields. The names for the compounds of the invention were created by the Autonom 2.0 PC-batch version from Beilstein Informationssysteme GmbH (ISBN 3-89536-976-4).
Example 1
(2R,5S)-2-[4-C loro-2-(piperazine-1-carbonyl)-p enoxy]-1-[4-(4-fluoro-benzyl)- 2,5-dimethyl-piperazin-1 -yl]-ethanone
(R)-2-(4-Fluoro-benzylamino)-propionic acid methyl ester
To a solution of (R)-2-amino-propionic acid methyl ester hydrochloride (25 g, 179 mmol) and 4-fluorobenzaldehyde (23 ml, 215 mmol) in 1 ,2-dichloroethane (200 ml) was added triethylamine (25 ml, 179 mmol). The resulting mixture was stirred for two hours at ambient temperature followed by addition of sodium acetoxyborohydride (57 g, 268 mmol) in four portions. The resulting mixture was stirred overnight at ambient temperature. The reaction was neutralized with dilute aqueous sodium hydroxide solution and extracted with dichloromethane (2X). The organic layers were combined, dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (34.4 g, 91 % yield).
(2R,5S)-2-[(2-tert-Butoxycarbony[amino-propionyl)-(4-fluoro-benzyl)-amino]-propionic acid methyl ester
To a solution of (R)-2-te'rt-butoxycarbonylamino-propionic acid (37 g, 195 mmol) in dry tetrahydrofuran (250 ml) at 0 °C was added 4-methyl morpholine (21.5 ml, 195 mmol) followed by isobutylchloroformate (25.3 ml, 195 mmol). The reaction was allowed to warm to ambient temperature and stirred for two hours. This was followed by the addition of (S)-2-(4- fluoro-benzylamino)-propionic acid methyl ester (34.4 g, 162 mmol). The resulting mixture was stirred overnight at ambient temperature. The reaction mixture was filtered through a pad of celite and the filter cake was washed with ethyl acetate. The filtrate was concentrated in vacuo, diluted with ethyl acetate and washed with water and brine. The organics were dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (43.2 g, 70% yield).
(2R,5S)-1-(4-Fluoro-benzyl)-3,6-dimethyl-piperazine-2,5-dione To a solution of (2R,5S)-2-[(2-tert-butoxycarbonylamino-propionyl)-(4-fluoro-benzyl)- aminoj-propionic acid methyl ester (43 g, 382 mmol) in dichloromethane (120 ml) at 0 °C was added trifluoroacetic acid (60 ml). The reaction was allowed to warm to ambient temperature and stirred for 2 hours. The reaction was cooled to 0 °C and slowly quenched by addition of 3N aqueous sodium hydroxide until basic. The resulting mixture was extracted with dichloromethane (2X). The combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo to give the title compound (22 g, 78% yield). (2R, 5S)-1 -(4-Fluoro-benzy!)-2,5-dimethyl-piperazine
To a solution of (2R, 5S)-1-(4-fluoro-benzyl)-3,6-dimethyl-piperazine-2,5-dione (22 g, 87.9 mmol) in dry tetrahydrofuran (160 ml) at 0 °C was added a solution of lithium aluminum hydride (1 M in tetrahydrofuran, 373 ml, 373 mmol) dropwise over 40 minutes. The reaction mixture was then refluxed for 4 hours, cooled to ambient temperature and slowly quenched with water. The resulting mixture was filtered through a pad of celite and the filter cake was washed with ethyl acetate. The filtrate was then concentrated, diluted with ethyl acetate and washed with saturated aqueous sodium hydrogen carbonate. The organic layer was separated, dried over magnesium sulfate, filtered and concentrated in vacuo to give the title compound (17.7 g, 91 % yield).
(2R, 5S)-2-Chloro-1 - [4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1 -yl]-ethanone To a solution of (2R, 5S)-1-(4-fluoro-benzyl)-2,5-dimethyl-piperazine (2.5 g, 11.25mmmol) in dry dichloromethane (11 ml) at 0 °C was added triethylamine (1.57 ml, 11.2 mmol) followed by chloroacetyl chloride (0.858 ml, 11.2 mmol). The resulting reaction mixture was stirred for 30 minutes. The reaction was then filtered through a pad of celite, washed with dichloromethane and the resulting filtrate was concentrated to give a yellow oil. Chromatography on silica get gave the title compound (2.84 g, 86% yield).
(2R, 5S)-5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo- ethoxyj-benzoic acid methyl ester To a solution of (2R, 5S)-2-chloro-1- [4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]- ethanone (2.75 g, 9.2 mmol) in butanone (50 ml) was added methyl 5-chloro-2- hydroxybenzoate (1.55 g, 9.2 mmol), potassium carbonate (2.54 g, 18.4 mmol) and potassium iodide (1.52 g, 9.2 mmol). The resulting mixture was stirred at reflux for 6 hours. The reaction was then cooled, diluted with ethyl acetate, and washed with brine. The organics were dried over magnesium sulfate, filtered and concentrated in vacuo to give an orange oil. Chromatography on silica gel gave the title compound (4.1 g, 100% yield). ( R, 5S)-5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo- ethoxy}-benzoic acid
To a solution of (2R, 5S)-5-chioro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1- yl]-2-oxo-ethoxy}-benzoic acid methyl ester (4.12 g, 9.18 mmol) in tetrahydrofuran (10 ml), methanol (10 ml) and water (4 ml) was added lithium hydroxide monohydrate (1.93 g, 45.9 mmol). The resulting mixture was stirred overnight at ambient temperature. The reaction was then concentrated, diluted with 1 N hydrochloric acid and extracted with dichloromethane (2X). The organic layers were combined, dried over magnesium sulfate, filtered and concentrated to give a white foam. Triteration in dichloromethane and diethyl ether gave the title compound (1.38 g, 35% yield).
(2R, 5S)-4-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo- ethoxy}-benzoyl)-piperazine-1 -carboxylic acid tert-butyl ester
To a solution of (2R, 5S)-5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1- yl]-2-oxo-ethoxy}-benzoic acid (0.10 g, 0.212 mmol) in dichloromethane (4 ml) was added 4- dimethylaminopyridine (0.039 g, 0.318 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.061 g, 0.318 mmol) and tert-butyl 1-piperazinecarboxylate (0.041 g, 0.222 mmol). The resulting mixture was stirred overnight at ambient temperature. It was then diluted with dichloromethane and washed with brine. The organics were dried over magnesium sulfate, filtered and concentrated to give a clear oil. Chromatography on silica gel gave the title compound (0.110 g, 85% yield).
(2R, 5S)-2-[4-Chloro-2-(piperazine-1 -carbonyl)-phenoxy]-1 -[4-(4-fluoro-benzyl)-2,5- dimethyl-piperazin-1-yrj-ethanone
To a solution of (2R, 5S)-4-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin- 1-yl]-2-oxo-ethoxy}-benzoyl)-piperazine-1 -carboxylic acid tert-butyl ester (0.110 g, 0.182 mmol) in dichloroethane (10 ml) wass added trifluoroacetic acid (5 ml). The reaction was stirred for two hours at ambient temperature. The reaction was then diluted with dichloromethane and washed with 1 N aqueous sodium hydroxide. The organics were dried over magnesium sulfate, filtered and concentrated to give the title compound (0.080 g, 87% yield). The title compounds for Examples 2 - 12 were prepared by a method analogous to that described in Example 1.
Figure imgf000047_0001
Example 13
Figure imgf000048_0001
(2R)-3-Amino-N-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2- oxo-ethoxy}-phenyl)-propionamide [2-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}- phenylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester
To a solution of 2-(2-amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2-methyl- piperazin-1-yl]-ethanone (0.066 g, 0.17 mmol) in methylene chloride (2 mL) at ambient temperature was added N-methylmorpholine (0.025 mL, 0.23 mmol), 3-tert- butoxycarbonylamino-propionic acid (0.044 g, 0.23 mmol) and 0-benzotriazole-1-yl-N,N,N',N'- tetramethyluronium hexafluorophosphate (0.076 g, 0.20 mmol). The resulting solution was stirred at ambient temperature for 60 hours, then concentrated. Radial chromatography (2 mm plate) gave the title compound (0.114 g)
(2R)-3-Amino-N-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo- ethoxy}-phenyl)-propionamide
To a solution of [2-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo- ethoxy}-phenylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester (0.110 g, 0.2 mmol) in methylene chloride (3 mL) was added trifluoroacetic acid (0.50 mL). The reaction was stirred for 2 hours at ambient temperature then diluted with saturated aqueous sodium hydrogen carbonate. The mixture was extracted with methylene chloride and the combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo to give the title compound (0.069 g)
The title compounds for Examples 14 - 19 were prepared by a method analogous to that described in Example 13.
Figure imgf000049_0001
Figure imgf000049_0003
Example 20
Figure imgf000049_0002
(2R,5S)-1-(2-Amino-ethyl)-3-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1 - yl]-2-oxo-ethoxy}-phenyl)-urea (2R, 5S)-2-(4-Chloro-2-nitro-phenoxy)-1 -[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1 - yl]-ethanone
To a solution of (2R, 5S)-5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1- yl]-2-oxo-ethoxy}-benzoic acid methyl ester (1.0 g, 3.35 mmol) in butanone (35 ml) was added 2-nitro-4-chlorophenol (0.639 g, 3.69 mmol), potassium carbonate (0.925 g, 6.7mmol) and potassium iodide (0.556 g, 3.35 mmol). The reaction mixture was heated at reflux overnight. The reaction mixture was then cooled, diluted with water and extracted with ethyl acetate. The combined organics were dried over magnesium sulfate, filtered and concentrated to give an orange oil. Chromatography on silica gel gave the title compound (1.35 g, 93% yield). (2R, 5S)-2-(2-Amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-
1-yl]-ethanone
To a solution of (2R, 5S)-2-(4-chloro-2-nitro-phenoxy)-1-[4-(4-fluoro-benzyl)-2,5- dimethyl-piperazin-1-yrj-ethanone (2.2 g, 5.05 mmol) in ethanol (50 ml) in a par bottle was added 5% platinum on carbon (2.2 g). The reaction mixture was subjected to hydrogen gas (35 psi) for thirty minutes. The reaction mixture was filtered through celite and washed with ethanol. The filtrate was concentrated to give a tan foam. Chromatography on silica gel gave the title compound (1.42 g, 70% yield).
(2R, 5S)-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo- ethoxy}-phenyl)-carbamic acid 4-nitro-phenyl ester To a solution of (2R, 5S)-2-(2-amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2,5- dimethyl-piperazin-1-yl]-ethanone (0.150 g, 0.37 mmol) in dichloromethane (7 ml) was added pyridine (0.066 ml, 0.82 mmol) followed by 4-nitrophenyl chloroformate (0.075 g, 0.41 mmol). The reaction was stirred at ambient temperature for 3 1/2 hours. The reaction mixture was concentrated followed by chromatography on silica gel to give the title compound (0.153 g, 74%yield).
(2R,5S)-1-(2-Amino-ethyl)-3-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl- piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-urea
To a solution of (2R, 5S)-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1- yl]-2-oxo-ethoxy}-phenyl)-carbamic acid 4-nitro-phenyl ester (0.206 g, 0.37 mmol) in dry methanol (6 ml) was added ethyldiamine (0.05 ml, 0.814 mmol). The reaction was stirred at ambient temperature overnight. The reaction was concentrated and chromatagraphed on silica gel to give the title compound (0.115 g, 63% yield).
The title compounds for Examples 21 - 27 were prepared by a method analogous to that described in Example 20.
Figure imgf000051_0001
Figure imgf000051_0003
Example 28
Figure imgf000051_0002
(2R)-2-Amino-ethanesulfonic acid (5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl- piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-amide
2-(1 ,3-Dioxo-1 ,3-dihydro-isoindol-2-yl)-ethanesulfonic acid (5-chloro-2-{2-[4-(4-fluoro- benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-amide To a solution of of 2-(2-amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2-methyl- piperazin-1-yl]-ethanone (0.050 g, 0.13 mmol) in methylene chloride (1 mL) at ambient temperature was added triethylamine (0.027 mL, 0.19 mmol) and 2-(1 ,3-dioxo-1 ,3-dihydro- isoindol-2-yl)-ethanesulfonyl chloride (0.045 g, 0.17 mmol). The reaction was stirred overnight at ambient temperature. Additional triethylamine ((0.027 mL, 0.19 mmol) and 2- (1 ,3-dioxo-1 ,3-dihydro-isoindol-2-yl)-ethanesulfonyl chloride (0.045 g, 0.17 mmol) was added. The reaction was stirred one hour, then additional triethylamine (0.055 mL, 0.34 mmol) was added. The reaction was stirred and hour, then additional 2-(1 ,3-dioxo-1 ,3-dihydro-isoindol-2- yl)-ethanesulfonyl chloride (0.090 g, 0.34 mmol) was added. After stirring an additional 1 hour, the reaction was treated with saturated aqueous sodium hydrogen carbonate and extracted with methylene chloride (3X). The combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo. Purification via radial chromatography (2 mm plate) gave the title compound (0.030 g).
(2R)-2-Amino-ethanesulfonic acid (5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl- piperazin-1 -yl]-2-oxo-ethoxy}-phenyl)-amide To a solution of 2-(1 ,3-dioxo-1 ,3-dihydro-isoindol-2-yl)-ethanesulfonic acid (5-chloro-
2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-amide (0.030 g, 0.048 mmol) in EtOH (1 mL) at ambient temperature was added hydrazine hydrate (0.025 mL). The reaction was stirred overnight at ambient temperature then diluted with water and extracted with methylene chloride (2X). The combined organics were washed with saturated aqueous brine and dried over sodium sulfate, filtered and concentrated in vacuo. Purification via radial chromatography (2 mm plate) gave the title compound (0.014 g).
The title compounds for Examples 29 - 34 were prepared by a method analogous to that described in Example 28.
Figure imgf000052_0001
Figure imgf000053_0002
Example 35
Figure imgf000053_0001
(2R)-N-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo- ethoxy}-phenyl)-cyanoguanidine
1-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)- N-cyano-S-methyl-isothiourea
To a solution of of 2-(2-amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2-methyl- piperazin-1-yl]-ethanone (0.30 g, 0.77 mmol) in tetrahydrofuran (5 mL) at ambient temperature was added sodium hydride (0.029 g, 1.22 mmol) and the reaction was stirred for 30 minutes. To this was added S,S1 -dimethyl N-cyanodithio iminocarbonate (0.168, 1.15 mmol) and the mixture was heated at reflux overnight. The reaction was cooled and quenched with saturated aqueous ammonium chloride. The mixture was extracted with EtOAc and the combined organics were dried over Na2S0 , filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (0.350 g) (2R)-N-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1 -yl]-2-oxo-ethoxy}- phenyl)-cyanoguanidine
To a solution of 1-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo- ethoxy}-phenyl)-N-cyano-S-methyl-isothiourea (0.045 g, 0.092 mmol) in EtOH (1 L) was added ammonium hydroxide (0.100 mL) and the resulting solution was shaken at 60 °C overnight. The crude reaction mixture was purified directly via radial chromatography (2 mm plate) to give the title compound (0.027 g).
The title compounds for Examples 36 - 38 were prepared by a method analogous to that described in Example 35.
Figure imgf000054_0001
Figure imgf000054_0002
Example 39
Figure imgf000055_0001
(2R,5S)-2-{4-Chloro-2-[(2-diethylamino-ethylamino)-methyl]-phenoxy}-1-[4-(4- fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone (2R,5S)-5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}- benzaldehyde
To a solution of 2-chloro-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone (2.87 g, 9.6 mmol) in DMF (20 mL) was added 5-chlorosalicylaldehyde (1.65 g, 10.5 mmol), potassium carbonate (2.64 g, 19.2 mmol) and potassium iodide (1.59 g, 9.6 mmol). The resulting mixture was heated to 100 °C for 12 hours. The reaction was cooled, diluted with saturated aqueous brine and extracted with ethyl acetate (3X). The combined organics were dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo to give crude product. Purification via chromatography on silica gel (15% EtOAc/Hexanes) gave the title compound 3.40 g, 85% yield.) (2R,5S)-2-{4-Chloro-2-[(2-diethylamino-ethylamino)-methyl]-phenoxy}-1-[4-(4-fiuoro- benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone
To a solution of (2R,5S)-5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1- yl]-2-oxo-ethoxy}-benzaldehyde (0.100 g, 0.25 mmol) in 10:1 dichloroethane acetic acid (2.2 mL) was added (diethylamino)ethylamine (0.088 mL, 0.625 mmol) and the resulting solution was stirred for 1 hour at ambient temperature. To this was added sodium cyanoborohydride ( 0.0094 g, 0.15 mmol) and the reaction was stirred overnight at ambient temperature. Upon completion water was added and the mixture was basified with solid sodium bicarbonate (pH > 10). The product was extracted with dichloromethane (2X) and diethyl ether (2X). The combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (0.039 g, x 30% yield)
The title compounds for Examples 40 - 62 were prepared by a method analogous to that described in Example 39.
Figure imgf000056_0001
Figure imgf000057_0001
Example 63
Figure imgf000057_0002
N-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}- berιzyl)-2-diethylamino-acetamide
(2R,5S)-2-(2-Aminomethyl-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2,5-dimethyl- piperazin-1 -yl]-ethanone
To a solution of (2R,5S)-5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1- yl]-2-oxo-ethoxy}-benzaldehyde (1.86 g, 4.44 mmol) in MeOH (20 mL) was added ammonium acetate (3.42 g, 44 mmol) and sodium cyanoborohydride (0.195 g, 3.1 mmol). The resulting mixture was stirred overnight at ambient temperature. The reaction was quenched with concentrated hydrochloric acid and concentrated in vacuo. The residue was dissolved in water and basified with aqueous 3N NaOH (pH > 10). The product was extracted with dichloromethane (2X) and ethyl acetate (2X). The combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (1.29 g, 69 % yield)
N-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}- benzyl)-2-diethylamino-acetamide
To a solution of N,N-dimethylglycine (0.014 g, 0.13 mmol) and (2R,5S)-2-(2- aminomethyl-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-ethanone (0.063 g, 0.15 mmol) in dichloromethane (2 mL) was added 1-(3-dimethylaminopropyl)-3- ethylcarbodiimide (0.034 g, 0.18 mmol), 1 -hydroxybenzotriazole (0.021g, 0.15 mmol), and triethylamine (0.036 mL, 0.36 mmol). After the reaction was stirred for 48 hours, the solution was diluted with saturated aqueous sodium bicarbonate and extracted with dichloromethane (3X). The combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (0.063 g, 80 %).
The title compounds for Examples 64. - 85 were prepared by a method analogous to that described in Example 63.
Figure imgf000058_0001
Figure imgf000058_0002
Figure imgf000059_0001
Figure imgf000060_0002
Example 86
Figure imgf000060_0001
(2R,5S)-(N-{2-[3-(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]- 2-oxo-ethoxy}-benzyl)-ureido]-ethyl}-acetamide
To a solution of (2R,5S)-5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1- ylJ-2-oxo-ethoxy}-benzylamine (0.200 g, 0.477 mmol) in methylene chloride (10 mL) was added pyridine (0.077 mL, 0.954 mmol) and 4-nitro phenyl chloroformate (0.097 g, 0.525 mmol). The resulting mixture was stirred for one hour at ambient temperature and then concentrated in vacuo. The residue (0.055g, 0.094 mmol) was dissolved in methanol (1 mL). N-Acetylethylenediamine (0.019 mL, 0.188 mmol) was added and the reaction was stirred at room temperature over night. The reaction was concentrated in vacuo and chromatography on silica gel gave the title compound (0.019 g, 27 %).
The title compounds for Examples 87 - 90 were prepared by a method analogous to that described in Example 86.
Figure imgf000061_0001
Figure imgf000061_0003
Example 91
Figure imgf000061_0002
(2R.5S)- 2-Amino-ethanesulfonic acid 5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5- dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzylamide
(2R,5S)-2-(1 ,3-Dioxo-1 ,3-dihydro-isoindol-2-yl)-ethanesulfonic acid 5-chloro-2-{2-[4- (4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzylamide
To a solution of (2R,5S)-5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1- yl]-2-oxo-ethoxy}-benzyl amine (0.060 g, 0.143 mmol) in methylene chloride (3 mL) was added 2-(1 ,3-dioxo-1 ,3-dihydro-isoindol-2-yl)-ethanesulfonyl chloride (0.043 g, 0.150 mmol) and triethylamine (0.060 mL, 0.43 mmol) and the solution was stirred 1 hr at ambient temperature. The reaction was diluted with saturated aqueous sodium hydrogen carbonate and extracted with methylene chloride. The combined organics were dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the title compound (0.073 g, 77%).
(2R.5S)- 2-Amino-ethanesulfonic acid 5-chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl- piperazin-1-yl]-2-oxo-ethoxy}-benzylamide
To a solution of (2R,5S)-2-(1 ,3-Dioxo-1 ,3-dihydro-isoindol-2-yl)-ethanesulfonic acid 5- chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-benzylamide (0.073 g, 0.111 mmol) in EtOH (1 mL) was added hydrazine (35% aq. 0.25 mL, 2.73 mmol) and the solution was stirred overnight at ambient temperature. The reaction was filtered through a glass frit and washed with EtOH. The filtrate was concentrated in vacuo to give the title compound (0.056 g, 96%)
The title compounds for Examples 92 - 93 were prepared by a method analogous to that described in Example 91.
Figure imgf000062_0001
Figure imgf000062_0002
Example 94
Figure imgf000063_0001
(2R)-N-(2-Amino-ethyl)-N,-(5-chloro-2-{2-[4-(4-fluoro-benzyl)-2-methyl-piperazin- 1-yl]-2-oxo-ethoxy}-benzyl)-cyanoguanidine
A solution of 2-(2-aminomethyl-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-2-methyI- piperazin-1-yl]-ethanone (0.025 g, 0.062 mmol) and diphenyl cyanocarbonimidate (0.016 g,
0.068 mmol) in ethanol (1 mL) was heated on a shaker plate at 60°C. After 22 h, ethylenediamine (0.008 mL, 0.123 mmol) was added and the resulting solution was heated on a shaker plate at 60°C for an additional 21 h. The solution was cooled to ambient temperature, concentrated and purified using radial chromatography to yield the title compound (0.021 g, 67%). The title compounds for Examples 95 - 96 were prepared by a method analogous to that described in Example 94.
Figure imgf000063_0002
Figure imgf000063_0003
Example 97
Figure imgf000064_0001
(2R, 5S)-5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-N- methyl-benzenesulfonamide 5-Chloro-2-methoxy-N-methyl-benzenesulfonamide
To a solution of 5-Chloro-2-methoxy-benzenesulfonyl chloride (1.0g, 4.15 mmol) in tetrahydrofuran(δml) was bubbled methylamine gas until saturated. The reaction mixture was sealed with a septa and stirred overnight at ambient temperature. The reaction mixture was then concentrated, triterated in dichloromethane and ether, filtered and dried yielding the above titled compound 1.05 g (>100%) white solid.
5-Chloro-2-hydroxy-N-methyl-benzenesulfonamide
To a solution of sodium hydride (60% in mineral oil, 90.24 mg, 2.25mmol) in dry dimethyl formamide was added thiophenol (0.225 ml, 2.25mmol) dropwise. To this was then added 5-Chloro-2-methoxy-N-methyl-benzenesulfonamide (531 mg, 2.25mmol) followed by refluxing for 4 hours. The reaction mixture was cooled, diluted with ethyl acetate and washed with a 1 N sulfuric acid solution. The organic layer was separated, dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel yielded the above titled compound (320mg, 53% yield).
(2R, 5S)-5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo- ethoxy}-N-methyl-benzenesulfonamide
To a solution of (2R, 5S)-2-Chloro-1- [4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yrj- ethanone (375mg, 1.26 mmol) in butanone (12ml) was added 5-Chloro-2-hydroxy-N-methyl- benzenesulfonamide (280mg,1.26mmol), potassium carbonate (348mg, 2.52mmol) and potassium iodide (209mg, 1.26mmol). The resulting reaction mixture was refluxed for 4 hours. It was allowed to cool, diluted with ethyl acetate and washed with brine. The organic layer was separated, dried over magnesium sulfate, filtered and concentrated in vacuo. Chromatography on silica gel gave the above titled compound (320mg, 53% yield). The title compounds for Examples 98 - 100 were prepared by a method analogous to that described in Example 97.
Figure imgf000065_0001
Figure imgf000065_0002

Claims

CLAIMS FOR FOREIGN FILING
A method of preparing a compound of the formula
Figure imgf000066_0001
or the pharmaceutically acceptable salt thereof; wherein a is 1 , 2, 3, 4 or 5; b is O, 1 , 2, 3 or 4; c is O or 1 ; d is 1 , 2, 3, 4 or 5; e is 0 or 1 ; j is 1 , 2, 3, or 4;
X is C(O), C(S) or CH2;
Y is CH2, or if e is 0, Y is CHR8 wherein R8 is hydrogen, (C6-C10)aryl or NR9R10; Z is oxygen, NR9 or CR11R12; each R1 is independently selected from hydrogen, hydroxy, hydroxysulfonyl, halo, (C Cβ)a\ky\, mercapto, mercapto^TC^alkyl, (CrC6)alkylthio, (C-i-CeJalkylsurfinyl, (C C6)alkylsufonyl, (C1-C6)alkylthio(C1-C6)alkyl, (C1-C6)alkylsulfinyl(C C6)alkyl, (C C6)alkylsulfonyl(Cι-C6)alkyl, (CrC6)alkoxy, (C6-C 0)aryloxy, halo(Cι-C6)alkyl, trifluoromethyl, formyl, formyl(C C6)alkyl, nitro, nitroso, cyano, (C6-C1o)aryl(C1-C6)alkoxy, halo(C C6)alkoxy, trifluoromethoxy, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(CrC6)alkyl, hydroxy(C3-C7)cycloalkyl(Cr C6)alkyl, (C3-C7)cycloalkylamino, (C3-C7)cycloalkylamino(CrC6)alkyl, ((C3-C7)cycloalkyl)((C C6)alkyl)amino, ((C3-C7)cycloalkyl(Cι-C6)alkyl)amino(C C6)alkyl, cyano(C C6)alkyl, (C2- C7)alkenyl, (C2-C7)alkynyl, (C6-C10)aryl, (Ce-C^Jary d-CeJalkyl, (C6-C10)aryl(C2-C6)alkenyl, hydroxy(CrC6)alkyl, hydroxy(C6-C10)aryl(C C6)alkyl, hydroxy(C1-C6)alkylthio(C1-C6)alkyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkynyl, (C1-C6)alkoxy(C1-C6)alkyl, (CrCe)alkoxy(C6- Cιo)aryl(C C6)alkyl, (C6-C1o)aryloxy(C1-C6)alkyl, (Ce-C^Jary C CeJal oxy^ CeJalkyl, amino, (Cι-C6)alkylamino, ((C C6)alkyl)2amino, (C6-C10)arylamino, (C6-C10)aryl(C1-C6)alkylamino, amino(C C6)alkyl, (C -C6)alkylamino(C1-C6)alkyl, ((C -C6)alkyl)2amino(C1-C6)alkyl, hydroxy(C1-C6)alkylamino(C1-C6)alkyl, (C3-Cι0)arylamino(C1-C6)alkyl, (C6-C10)aryl (C C6)alkylamino(C1-C6)alkyl, (Cι-C6)alkylcarbonylamino, ((Cι-C6)alkylcarbonyl)((Cr C6)alkyl)amino, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, ((C1-C5)alkylcarbonyl)((C1-
C6)alkyl)amino(CrC6)alkyl, (C C6)alkoxycarbonylamino, (C C6)alkoxycarbonyl)(C -
C6)alkylamino, (Cι-C6)alkoxycarbonylamino(C1-C6)alkyl, (CrC6)alkoxycarbnony)((C1- C6)alkyl)amino(C1-C6)alkyl, carboxy, (C1-C6)alkoxycarbonyl, (C6-C10)aryl(Cr
C6)alkoxycarbonyl, (C CeJalkylcarbonyl, (CrC6)alkylcarbonyl(C1-C6)alkyl, (C6- Cιo)arylcarbonyl, (Cβ-CioJarylcarbony C CδJalkyl, (C6-C10)aryl(C1-C6)alkylcarbonyl, (C6- C1o)aryl(C1-C6)alkycarbonyl(Cι-C6)alkyl, carboxy(Cι-C6)alkyl, (C1-C6)alkoxycarbonyl(C1- C6)alkyl, (C6-C1o)aryl(C1-C6)alkoxycarbonyl(C1-Cβ)alkyl, (C1-C6)alkoxy(C1-
C6)alkylcarbonyloxy(Cι-C6)alkyl, aminocarbonyl, (CrC6)alkylaminocarbonyl, ((C C6)alkyl)2aminocarbonyl, (C6-Cιo)arylaminocarbonyl, (C6-C10)aryl(C1-C6)alkylaminocarbonyl, aminocarbonyl(C C6)alkyl, (C1-C5)alkylaminocarbonyl(C-|-C6)alkyl, ((C
C6)alkyl)2aminocarbonyl(Cι-C6)alkyl, (C6-C10)arylaminocarbonyl(CrC6)alkyl, (C
C6)alkylaminocarbonyl(C -C6)alkyl, amidino, guanidino, ureido, (C C6)alkylureido, ((C C6)alkyl)2ureido, ureido(C C6)alkyl, (C1-C6)alkylureido(C1-C6)alkyl, ((C1-C3)alkyl)2ureido(C1- C6)alkyl, (C2-C9)heterocycloalkyl, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl(C1-C6)alkyl and (C2-C9)heteroaryl(CrC6)alkyl; each R2 and R3 are independently selected from oxo, halo, (CrC6)alkyl, (C3- C8)cycloalkyl, (C3-C8)cycloalkyl(C C5)alkyl, (C3-C8)cycloalkylamino(C1-C6)alkyl, (C3-C- 8)cycloalkyl(C1-C6)alkylamino(C1-C6)alkyl, halo(C C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C6-C10)aryl(C C6)alkyl, (C6-C10)aryl(C2-C6)alkenyl, H-C(O)-, H-C(0)-(C C6)alkyl, hydroxy(C C5)alkyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkynyl, hydroxy(C6- C10)aryl(CrC6)alkyl, hydroxy(C3-C8)cycloalkyl(C C6)alkyl, thio(CrC6)alkyl, cyano(C C6)alkyl, halo(C1-C6)alkylcarbonylamino(Cι-C6)alkyl, (C1-C6)alkoxy(C6-C10)aryl(C1-C6)alkyl, (C C6)alkoxy(CrC6)alkyl, (C6-Cι0)aryloxy(CrC6)alkyl, (C6-C1o)aryl(C1-C6)alkoxy(CrC6)alkyl, (C C6)alkylthio(C1-C6)alkyl, (C1-C6)alkylsulfinyl(C1-C6)alkyl, (C1-C6)alkylsulfonyl(C1-C6)alkyi, hydroxy(C1-C6)alkylthio(CrC6)alkyl, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((C Cs)alkyl)2amino(C1-Cβ)alkyl, (C6-C10)arylamino(CrC6)alkyl, (C6-Cι0)aryl(C1-C6)alkylamino(C - C6)alkyl, (CrC6)alkylcarbonylamino(Cι-C6)alkyl, azido(C C6)alkyl, aminocarbonylamino(C C6)alkyl, (C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ((CrC6)alkyl)2aminocarbonylamino(Cr C6)alkyl, (C C6)alkoxycarbonyl(C Ce)alkylaminocarbonylamino(CrC6)alkyl, (C
C6)alkoxycarbonylamino(C1-C6)alkyl, hydroxy(C1-C6)alkylamino(C1-C6)alkyl, (C6-
C10)aryloxy(C1-C6)alkylcarbonyloxy(C1-Cβ)alkyl, (C1-C6)alkoxy(C C6)alkylcarbonyloxy(C1- C6)alkyl, (C6-C1o)aryl(C1-C6)alkoxy(C1-C6)alkylcarbonyloxy(C1-C6)alkyl, (CrC6)alkylcarbonyl, (C1-C6)alkylcarbonyl(C1-C6)alkyl, carboxy, (C C6)alkoxycarbonyl, (C6-C10)aryl(C C6)alkoxycarbonyl, (C5-C 0)aryl(Cι-C6)alkylcarbonyl, aminocarbonyl, (Cr
C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl, (C6-C10)arylaminocarbonyl, (C6- C10)aryl(C1-C6)alkylaminocarbonyl, carboxy(CrC6)alkyl, (CrC6)alkoxycarbonyl(CrC6)alkyl, (C6-C1o)aryl(C1-C6)alkoxycarbonyl(C1-C6)alkyl, aminocarbonyl(Cι-C6)alkyl, (Cr
C6)alkylaminocarbonyl(Cι-C6)alkyl, ((C C6)alkyl)2aminocarbonyl(C C6)alkyl, (C6- C10)arylaminocarbonyl(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkylaminocarbonyl(Cι-C6)alkyl, (C6- C10)arylsulfonyl, (C2-C9)heterocycloalkyl, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl(Cr C6)alkyl, (C2-C9)heteroaryl(C C6)alkyl or R14R15N(C C6)alkyl wherein R14 and R15 are each independently (d-C^alkyl or (C C6)alkylcarbonyl;
R4 is (R5)f(R6)g(C6-C10)aryl, (R5)f(R6)g(C3-C10)cycloalkyl, (R5)f(R7)h(C2-C9)heteroaryl, or (R5)f(R7) (C2-C9)heterocycloalkyl, wherein f is 1 , 2, 3 or 4; g and h are each independently 0, 1 , 2 or 3;
R5 is one to three groups independently selected from (C2- C9)heterocycloalkylcarbonyl, (C2-C9)heteroarylcarbonyl, (C2-C9)heteroaryl(C
C6)alkylaminocarbonyl, (C2-C9)heterocycloalkyl(C1-C6)alkylaminocarbonyl, (d- C6)alkylsulfonylamino(C1-C6)alkylaminocarbonyl, ureido(C1-C6)alkylaminocarbonyl, (C CeJalkylureido^ CeJalkylaminocarbonyl, ((Ct-C6)alkyl)2ureido(Cι-C6)alkylanninocarbonyl, halo(C1-C6)alkylaminocarbonyl, aminosulfonyl(C1-C6)alkylaminocarbonyl, (C
C5)alkylaminosulfonyl(C1-C6)alkylaminocarbonyl, (C1-C6)alkylsulfonylamino(C1-
C6)alkylcarbonylamino, cyanoguanidino^ CeJalkylcarbonylamino, (C C6)alkylcyanoguanidino(C1-C6)alkylcarbonylamino, ((C1-C6)alkyl)2cyanoguanidino(C1-
C6)alkylcarbonylamino, aminocarbony C-i-CeJalkylcarbonylamino, (C2-C9)heteroaryl(C1- C6)alkylcarbonylamino, (C2-C9)heterocycloalkyl(C1-C6)alkylcarbonylamino, aminosulfony C C6)alkylcarbonylamino, hydroxy(CrC6)alkylureido, amino(C1-C6)alkylureido, (C C6)alkylamino(CrC6)alkylureido, ((C1-C6)alkyl)2amino(C1-C6)alkylureido, (C2- C9)heterocycloalkyl(C1-C6)alkylureido, (C2-C9)heteroaryl(CrC6)alkylureido, aminosulfonyl(Cι- C6)alkylureido, aminocarbonyl(CrC6)alkylureido, (C1-C6)alkylaminocarbonyl(C1-
C6)alkylureido, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkylureido, acetylamino(Cι-C6)alkylureido, (acetyl)((Cι-C6)alkyl)amino(Cι-C6)alkylureido, halo(CrC6)alkylsulfonylamino, amino(C C6)alkylsulfonylamino, (C1-C6)alkylamino(C1-C6)alkylsulfonylamino, ((C1-Cβ)alkyl)2amino(Cι- C6)alkylsulfonylamino, acetylamino(Cι-C6)alkylsulfonylamino, (acetyl)((C1-C6)alkyl)amino(C1- C6)alkylsulfonylamino, ureido(C C6)alkylsulfonylamino, (C CeJalkylureido^
C6)alkylsulfonylamino, ((C Ce)alkyl)2ureido(C1-C6)alkylsulfonylamino, (C
C6)alkylsulfonylamino(C1-C6)alkylsulfonylamino, cyanoguanidino(C C6)alkylsulfonylamino, (C1-C6)alkylcyanoguanidino(C1-C3)alkylsulfonylamino, ((CrC6)alkyl)2cyanoguanidino(C1- C6)alkylsulfonylamino, aminocarbony C CeJalkylsulfonylamino, (C
C6)alkoxycarbonylamino(C1-C6)alkylsulfonylamino, aminosulfonylamino, (C
C6)alkylaminosulfonylamino, ((CrC6)alkyl)2aminosulfonylamino, aminocarbonyl(C
C6)alkylamino(CrC6)alkylsulfonylamino, (C2-C9)heterocycloalkyloxycarbonylamino(Cr
C6)alkylsulfonylamino, (C2-C9)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino', cyanoguanidino, (CrC6)alkylcyanoguanidino, ((C C6)alkyl)2cyanoguanidino, (C2- C9)heterocycloalkylcyanoguanidino, (C2-C9)heteroarylcyanoguanidino, (C2-
C9)heterocycloalkyl(C C6)alkylcyanoguanidino, (d-CgJheteroary CrCeJalkylcyanoguanidino, amino(C1-C6)alkylcyanoguanidino, (C-rC^alkylamino d-Cg/alkylcyanoguanidino, ((C C6)alkyl)2amino(C1-C6)alkylcyanoguanidino, aminocarbonyl(C C6)alkylcyanoguanidino, (C C6)alkylaminocarbonyl(Cι-C6)alkylcyanoguanidino, ((C1-C6)alkyl)2aminocarbonyl(C1-
C6)alkylcyanoguanidino, aminocarbonyl(C1-C6)alkylamino, (C1-C6)alkylsulfonylamino(C1- C6)alkylamino, (C1-C6)alkoxycarbonylamino(C1-C6)alkylamino, aminosulfonylfXr
C6)alkylamino, (C2-C9)heteroaryl(Cι-C6)alkylamino, acetylamino(Cι-C6)alkylamino,
(acetyl)((C1-C6)alkyl)amino(C1-C6)alkylamino, (C1-C6)alkoxycarbonyl(C -C6)alkylamino(C1- C6)alkyl, cyano(CrC6)alkylaminoalkyl, aminocarbonyl(C1-C6)alkylamino(C1-C6)alkyl, acetylamino(C1-C6)alkylamino(C1-C6)alkyl, (acetyl)((CrC6)alkyl)amino(C1-C6)alkylamino(C1- C6)alkyl, (CrC5)alkoxycarbonylamino(C1-C6)alkylamino(C C6)alkyl, (C2-
C9)heterocycloalkyloxycarbonylamino(C C6)alkylamino(C1-C6)alkyl, (C2-
Cg)heteroaryloxycarbonylamino(C1-C6)alkylamino(C1-C6)alkyl, cyanoguanidino(C
C6)alkylamino(C C6)alkyl, (C1-C6)alkylcyanoguanidino(C -C6)alkylamino(C1-C6)alkyl, ((C C6)alkyl)2cyanoguanidino(C1-C6)alkylamino(C1-C6)alkyl, (Cι-C6)alkylsulfonylamino(C C6)alkylamino(Cι-C6)alkyl, ureido^ CeJalkylamino^ CeJalkyl, (Ci-C6)alkylureido(C C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylamino(C1-C6)alkyl, aminocarbonyloxy(C1-C6)alkylamino(C1-C6)alkyl, aminocarbonyl(Cr
C6)alkylcarbonylamino(C C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkylcarbonylamino(C1- C6)alkyl, ((C1-Ce)alkyl)2aminocarbonyl(C1-Ce)alkylcarbonylamino(C1-C6)alkyl, aminosulfonyl(C1-C3)alkylcarbonyIamino(C1-C6)alkyl, (C2-
C )heterocycloalkyloxycarbonylamino(C C6)alkyl, (C2-C9)heterocycloalkylcarbonylamino(Cr C6)alkylcarbonylamino(CrC6)alkyl, cyanoguanidino(C1-C6)alkylcarbonylamino(C1-C6)alkyl, cyano(C1-C6)alkylcarbonylamino(Cι-C6)alkyl, amino(C1-C6)alkylaminocarbonylamino(C1-
C6)alkyl, (C1-C6)alkylamino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, ((C C6)alkyl)2amino(C1-C6)alkylaminocarbonylamino(C1-C6)alkyl, hydroxy(C
Cs)alkylaminocarbonylamino(C1-C6)alkyl, aminocarbonyl(CrC6)alkylaminocarbonylamino(C C6)alkyl, (Cι-C6)alkylcarbonylamino(C1-C6)alkylaminocarbonylamino(C1-C3)alkyl, (C CeJalkylsulfonylamino^i-CeJalkylaminocarbonylamino^rCeJalkyl, (C
C l)alkoxycarbonylamino(C -C6)alkylaminocarbonylamino(C1-C6)alkyl, (C2-
C9 ι)heterocycloalkyloxycarbonylamino(C1-C6)alkylaminocarbonylamino(C-|-C6)alkyl, (C2- c9 ι)heteroaryloxycarbonylamino(C1-C6)alkylaminocarbonylamino(Cι-C6)alkyl, (C2-
C _;9))heterocycloalkyl(C1-C6)alkylaminocarbony . lamino( .C C6). alky. l, (C2-C9)heteroaryl(C
C6)a "l"k•y'llaammiinnooccaarrbboonnyyllaammiinnoo((CC11--CC66))aallkkyyll,, uurreeiiddoo((CC11--CC66))aallkkyylluurreeiiddoo((CC11--CCss))aallkkyyll,, ((CCr
C6)alky lluurreeiiddoo(^C1-CC6e)Jaallkkyylluurreeiiddoo(^C1-CC6e)Jaallkkyyll,, ((((CC11--CC66))aallkkyyll))22uurreeiiddoo((CC11--CC66))aallkkyylluurreeiiddoo((CC1- C6)alky 'lI, cyanoguanidino(C1-C6)alkylureido(Cι-C6)alkyl, halo(C C6)alkylsulfonylamino(C C6)alkyl, amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C C6)alkylamino(C
C6)alkylsulfonylamino(C C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, acetylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (acetyl)((C1-C6)alkyl)amino(C1-
C6)alkylsulfonylamino(C1-C6)alkyl, ureido(C1-C6)alkylsulfonylamino(Cι-C6)alkyl, (C
C6)alkylureido(C1-C6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2ureido(C1-
C6)alkylsulfonylamino(C1-C6)alkyl, (Cι-C6)alkylsuIfonylamino(C1-C6)alkyIsulfonylamino(C C6)alkyl, cyanoguanidino(C1-Ce)alkylsulfonylamino(C1-C6)alkyl, (Cr
C6)alkyl(cyanoguanidino)(C1-C6)alkylsulfonylamino(C1-Ce)alkyl, ((C
C6)alkyl)2(cyanoguanidino)(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminocarbonyl(Cr
C6)alkylsulfonylamino(C1-C5)alkyl, (C1-C6)alkoxycarbonylamino(C1-C6)alkylsulfonylamino(C1- C6)alkyl, (C2-C9)heterocycloalkyloxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C2- C9)heteroaryloxycarbonylamino(C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminosulfonylamino(Cr C6)alkyl, (CrC6)alkylaminosulfonylamino(C1-C6)alkyl, ((C1-C6)alkyl)2aminosulfonylamino(C1- Ce)alkyl, cyanoguanidino(CrC6)alkyl, (Cι-C6)alkyl(cyanoguanidino)(CrC6)alkyl, ((C C6)alkyl)2(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heterocycloalkyl(cyanoguanidino)(Cι-C6)alkyl, (C2-C9)heterocycloalkyl(Cι-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, (C2- C9)heterocycloalkyl(cyanoguanidino)amino, (C2-C9)heteroaryl(cyanoguanidino)(C1-C6)alkyl, (C2-C9)heteroaryl(C1-C6)alkyl(cyanoguanidino)(C1-C6)alkyl, amino(C
C6)alkyl(cyanoguanidino)(C1-C3)alkyl, (C1-C6)alkylamino(C1-C6)alkyl(cyanoguanidino)(C1-
C6)alkyl, ((C CeJalkyl^amino^ CeJalky cyanoguanidinoJ^ CeJalkyl, aminocarbonyl(C C6)alkyl(cyanoguanidino)(C1-C6)alkyl, (Ci-CeJalkylaminocarbonyKC.,- C6)alkyl(cyanoguanidino)(C C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-
C6)alkyl(cyanoguanidino)(C1-C6)alkyl, aminosulfonyl, (CrCeJalkylaminosulfonyl, ((Cr C6)alkyl)2aminosulfonyl, (C2-C9)heterocycloalkylsulfonyl, amino(CrC6)alkylaminosulfonyl, (C C6)alkylamino(C1-C6)alkylaminosulfonyl, ((C1-C6)alkyl)2amino(CrC6)alkylaminosulfonyl,
(C2.Cg)heteroarylaminosulfonyl, hydroxy(CrC6)alkylaminosulfonyl, (CrC6)alkoxy(Cr C6)alkylaminosulfonyl, ureido(C C6)alkylaminosulfonyl, (C CeJalkylureido^
C6)alkylaminosulfonyl, ((C1-C6)alkyl)2ureido(C1-C6)alkylaminosuIfonyl, (C
C6)alkylsulfonylamino(C C6)alkylaminosulfonyl, (C1-C6)alkoxycarbonylamino(C1-
C6)alkylaminosulfonyl, (C2-Cg)heterocycloalkyloxycarbonylamino(C-|-C6)alkylaminosulfonyl, (C2-Cg)heteroaryloxycarbonylamino(CrC6)alkylaminosulfonyl, aminocarbonyl(Cι- C6)alkylaminosulfonyl, cyanoguanidino(Cι-C6)alkylaminosulfonyl, (C2-C9)heteroaryl(C C6)alkylaminosulfonyl, (C2-C9)heterocycloalkylaminosulfonyl, R6 is one to three groups independently selected from hydrogen, hydroxy, hydroxysulfonyl, halo, (C-|-C6)alkyl, mercapto, mercapto(C C6)alkyl, (C1-C6)alkylthio, (C C6)alkylsulfinyl, (C C6)alkylsulfonyl, (C6-C10)arylsulfonyl, (C C6)alkylthio(C1-C6)alkyl, (C1-C6)alkylsulfinyl(C1-C6)alkyl, (C CeJalkylsulfony C CeJalkyl, (C C6)alkoxy, hydroxy(CrC6)alkoxy, (C6-C10)aryloxy, halo(C C6)alkyl, trifluoro(Cι-C6)alkyl, formyl, formyl(C C6)alkyl, nitro, nitroso, cyano, (C6-C10)aryl(C C6)alkoxy, halo(C C6)alkoxy, trifluoro(C1-C6)alkoxy, amino(C C6)alkoxy, (C3-C10)cycloalkyl, (Cs-C^Jcycloalky^C CeJalkyl, hydroxy(C3-C10)cycloalkyl(CrC6)alkyl, (C3-C10)cycloalkylamino, (C3-C10)cycloalkylamino(C1-C6)alkyl, cyano(C C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6- C10)aryl, (C6-Cι0)aryl(C1-C6)alkyl, (C6-C10)aryl(C2-C6)alkenyl, hydroxy(C C6)alkyl, (hydroxy) (C6-C10)aryl(C C6)alkyl, ((C1-C6)alkylamino)(C3-C1o)aryl(C1-C6)alkyl, hydroxy(C C6)alkylthio(C1-C6)alkyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkenyl, hydroxy(C2-C6)alkynyl, (C C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxy(C6-C10)aryl(C1-C6)alkyl, aryloxy(C C6)alkyl, (C6- C10)aryl(C1-C6)alkoxy(C1-C6)alkyl, amino, (C1-C6)alkylamino, ((C C6)alkyl)2amino, (C6- C10)arylamino, (C6-C10)aryl(C1-C6)alkylamino, amino(Cι-C6)alkylamino, (C2-
C9)heterocycloalkylamino, (C2-C8)heteroarylamino, (C3-C o)cycloalkyl(C -C6)alkyl)amino, (Cr C6)alkylcarbonylamino, (C1-C6)alkoxycarbonylamino, (C2-C6)alkenylcarbonylamino, (C3- C10)cycloalkylcarbonylamino, (C6-C10)arylcarbonylamino, (C2-
Cg)heterocycloalkylcarbonylamino, halo(C C6)alkylcarbonylamino, (CrC6)alkoxy(Cr C6)alkylcarbonylamino, (Cι-C6)alkoxycarbonyl(C C6)alkylcarbonylamino, ((Cr
CeJalkylcar ony ^C CeJalkylJamino, ((C1-C6)alkoxycarbonyl)((C1-C6)alkyl)amino, (Cr Cβ)alkylsulfonylamιno, amino(C C6)alkyl, (C C6)alkylamino(Cι-C6)alkyl, ((Cr
C6)alkyl)2amino(C C6)alkyl, hydroxy(C1-C6)alkylamino(C1-C6)alkyl, (C6-C 0)arylamino(C1- C6)alkyl, (C6-C10)aryl(CrC6)alkylamino(CrC6)alkyl, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C6-Cιo)arylcarbonylamino(C1-C6)alkyl, ((CrCe)alkylcarbonyl)( (C1-C6)alkyl)amino(C1-C6)alkyl, C3-C10)cycloalkyl(C1-C6)alkyl)amino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino(C1-Ce)alkyl, (Cr C6)alkoxycarbonyl(C1-C6)alkylcarbonylamino(C1-C6)alkyl, ((C C6)alkoxycarbonyl)((Cr
C6)alkyl)amino(CrC6)alkyl, (CrC6)alkylsulfonylamino(C1-C6)alkyl, ((C1-C6)alkylsulfonyl)((C1- C6)alkyl)amino(C1-C6)alkyl, (C6-C10)arylsulfonylamino(C1-C6)alkyl, ((C6-C10)arylsulfonyl)((Cr C6)alkyl)amino(C1-C6)alkyl, (C2-C9)heterocycloalkylamino(CrC6)alkyl, (C2-
Cg)heteroarylamino(C C6)alkyl, (C C6)alkoxycarbonyl, (C6-C 0)aryl(C1-C6)alkoxycarbonyl, (C C6)alkylcarbonyl, (C6-Cιo)arylcarbonyl, (Ce-CioJary C CδJalkylcarbonyl, hydroxy(C1- Cs)alkoxycarbonyl, (C-rCeJalkox carbony CrCeJalkyl, (C6-C1o)aryl(C1-C6)alkoxycarbonyl(Cr C6)a\kyl, (CrCβ)alkoxy(C C6}alkylcarbonyloxy(CrCβ)a\kyl, ((C
C6)alkyl)2aminocarbonyloxy(CrC6)alkyl, (C C6)alkylcarbonyl(Cι-C6)alkyl, (Cβ-
C10)arylcarbonyl(CrC6)alkyl, (Ce-C1o)aryl(C1-C6)alkylcarbonyl(C1-C6)alkyl, aminocarbonyl, (C C6)alkylaminocarbonyl, ((Cι-C6)alkyl)2aminocarbonyl, (C6-C10)arylaminocarbonyl, (C6- Cιo)aryl(CrC6)alkylaminocarbonyl, (aminocarbonyl(C1-C6)alkylaminocarbonyl, ((C
C6)alkylaminocarbonyl(C1-C6)alkylaminocarbonyl, ((C1-C6)alkoxycarbonyl(C1-
C6)alkylaminocarbonyl, (amino(Cι-C6)alkyl)aminocarbonyl, (hydroxy(C
C6)alkylaminocarbonyl, aminocarbonyl(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl, ((C1-C6)alkyl)2aminocarbonyl(C1-C6)alkyl, (C6-C10)arylaminocarbonyl(C C6)alkyl, (C6- CioJary C CeJalkylaminocarbonyl^ CeJalkyl, amidino, hydroxyamidino, guanidino, ureido, (C C6)alkylureido, (C6-C10)arylureido, ((C6-C10)aryl)2ureido, (C6-C10)aryl(C1-C6)alkylureido, halo(C C6)alkylureido, ((C C^alky ^Ce-C^ary ureido, ((CrC6)alkyl)2ureido, halo(C C6)alkylcarbonylureido, ureido(C.,-C6)alkyl,
Figure imgf000072_0001
((C
C6)alkyl)2ureido(C C6)alkyl, (C6-C10)arylureido(C1-C6)alkyl, (C6-C1o)aryl)2ureido(C1-C6)alkyi, (C6-C10)aryl(C1-C6)alkylureido(C1-C6)alkyl, halo(C1-C6)alkylureido(C1-C6)alkyl, (halo(C C6)alkyl)((C1-C6)alkyl)ureido(C1-C6)alkyl, ((C1-C6)alkoxycarbonyl(C C6)alkyl)ureido(C1-
C6)alkyl, glycinamido, (C C6)alkylglycinamido, aminocarbonylglycinamido, (C1-C6)alkoxy(C1- C6)alkylcarbonylglycinamido, (aminocarbonyl)((C C6)alkyl)glycinamido, ((C
C6)alkoxycarbonyl(C1-C6)alkylcarbonyl)((C1-C6)alkyl)glycinamido, ((C
C6)alkoxycarbonylamino(C1-C6)alkylcarbonyl)glycinamido, (C6-C10)arylcarbonylglycinamido, ((C6-C1o)arylcarbonyl)((C1-C6)alkyl)glycinamido, ((C6-C10)aryl(C1-
C6)alkylaminocarbonyl)glycinamido, (C6-C1o)aryl(C1-C6)alkylaminocarbonyl)((C1-
C6)alkyl)glycinamido, (C6-C10)arylaminocarbonylglycinamido, ((C6-C10)arylaminocarbonyl)((C1- C6)alkyl)glycinamido, glycinamido(C C6)alkyl, alaninamido, (C1-C6)alkylalaninamido, alaninamido(C1-C6)alkyl, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl, (C2-C9)heteroaryl(Cr C6)a)ky} and (C2-C8)he.erocycloa)kyl(Cι-C6)alkyl;
R7 is one to three groups independently selected from hydrogen, hydroxy, halo, (C C6)alkyl, (C C6)alkylsulfonyl, (C6-C10)arylsulfonyl, (C C6)alkoxy, hydroxy(C Ce)a]koxy, halo(C C6)alkyl, fomyl, nitro, cyano, halo(C C6)alkoxy, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6- C10)aryl, (C6-C10)aryl(C C6)alkyl, amino, (CrCβ)alkylamino, ((C1-C6)alkyl)2amino, (C6- C10)arylamino, (C6-C10)aryl(Cι-C6)alkylamino, (C C6)alkylcarbonylamino, (Cr
C6)alkoxycarbonylamino, (C2-C6)alkenylcarbonylamino, cycloalkylcarbonylamino, (C6- C10)arylcarbonylamino, halo(CrC6)alkylcarbonylamino, (C1-C6)alkoxy(C -
Cs)alkylcarbonylamino, (C1-C6)alkoxycarbonyl(C1-C6)alkylcarbonylamino, ((C
C6)alkylcarbonyl)( (CrC6)alkyl)amino, ((CrC6)alkoxycarbonyl)( (C C6)alkyl)amino, (C C6)alkylsulfonylamino, amino(CrC6)alkyl, (C C6)alkylamino(C Ce)alkyl, ((Cr
C6)alkyl)2amino(C C6)alkyl, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C6-
C10)ary}carbonyiamino(C Cs)alky\, ((C C6)alkylcarbonyl)( (C1-C6)alkyl)amino(C1-C6)alkyl, (C C6)alkoxycarbonylamino(CrC6)alkyl, (CrC6)alkoxycarbonyI, (C6-C10)aryl(C1-
C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C6-C10)arylcarbonyl, (C6-C10)aryl(Cr C6)alkylcarbonyl, aminocarbonyl, (Cι-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl,
(C6-C10)arylaminocarbonyl, aminocarbonyl(C C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl,
((C1-C6)alkyl)2aminocarbonyl(CrC6)alkyl, (C6-C10)arylaminocarbonyl(C1-C6)alkyl, guanidino, ureido, (C C6)alkylureido, ureido(C C6)alkyl, (C1-Cβ)alkylureido(CrC6)alkyl, and glycinamido;
R9 and R10 are each independently selected from the group consisting of hydrogen, (C C6)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, (C C6)alkylcarbonyl, (C1-C6)alkylcarbonyl(C1- C6)alkyl, (C6-C1o)aryl(C1-C6)alkylcarbonyl, (C6-C1o)aryl(C1-C6)alkylcarbonyl(C1-C6)alkyl, aminocarbonyl, (Cι-C6)alkylaminocarbonyl, ((C1-C6)alkyl)2aminocarbonyl and (C C6)alkoxycarbonyl; and
R11 and R12 are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, hydroxy, (C C6)alkoxy, hydroxy(CrC6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, amino, (C1-C6)alkylamino, ((C C6)alkyl)2amino, (C C6)alkylcarbonylamino, (C3-C8)cycloalkylcarbonylamino, (C3-C8)cycloalkyl(C1-
C6)alkylcarbonylamino, (CrC6)alkoxycarbonylamino, (C -C6)alkylsulfonylamino, (C6- C10)arylcarbonylamino, (C1-C6)alkoxycarbonyl(C C6)alkylcarbonylamino, (C6-C10)aryl(C C6)alkylcarbonylamino, ((C6-C10)aryl(C1-C6)alkylcarbonyl)((C1-C6)alkyl)amino, (C C6)alkylcarbonylamino(C1-C6)alkyl, (C3-C8)cycloalkylcarbonylamino(CrC6)alkyl, (Cr
C6)alkoxycarbonylamino(C1-C6)alkyl, (C2-C9)heterocycloalkylcarbonylamino(C1-C6)alkyl, (C6- C1o)aryl(C1-C6)alkylcarbonylamino(C1-C5)alkyl, (C2-C9)heteroarylcarbonylamino(C C6)alkyl, (C6- C 0)arylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkyl, aminocarbonylamino, (C C6)alkylaminocarbonylamino, halo(CrC6)alkylaminocarbonylamino, ((C C6)alkyl)2aminocarbonylamino, aminocarbonylamino(CrC5)alkyl, (C
C6)alkylaminocarbonylamino(C1-C6)alkyl, ((C C6)alkyl)2aminocarbonylamino(CrC6)alkyl, halo(C1-C6)alkylaminocarbonylamino(Cι-C6)alkyl, amino(C C6)alkyl, (C1-C6)alkylamino(C1- C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, carboxy(C C6)alkyl, (C1-C6)alkoxycarbonyl(C1- C6)alkyl, aminocarbonyl(C C6)alkyl and (C1-C6)alkylaminocarbonyl(C1-C6)alkyl; wherein:
Figure imgf000074_0001
Figure imgf000074_0002
wherein the compound of formula X is converted to the corresponding compound of formula I by reacting X with a compound of the formula, H-(Z)e-R4 wherein e is 1 and Z is oxygen, in the presence of potassium carbonate, potassium iodide and an aprotic solvent, such as butanone and the reaction is heated to reflux for a time period between about 4 hours to about 8 hours. 2. the method of preparation of claim 1 , wherein:
Figure imgf000075_0001
Figure imgf000075_0002
wherein the compound of formula XXX is converted to the corresponding compound of formula I by reacting XXX with a compound of the formula, A-(X)c-(Y)d-(Z)e-R4, wherein A is chloro or bromo, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride and the reaction is stirred at a temperature between about -10°C to about 10°C, for a time period between about 15 minutes to about 90 minutes. 3. The method of preparation of claim 1 , wherein:
Figure imgf000076_0001
Figure imgf000076_0002
wherein the compound of formula XI is converted to the corresponding compound of formula II, by reacting XI with an amine, in the presence of 4-dimethylaminopyridine, 1-(3- dimethylaminopropyl)-3-ethylcarbodiimine and a polar aprotic solvent, such as methylene chloride and the resulting reaction mixture is stirred overnight at room temperature. 4. The method of preparation of claim 1 , wherein:
Figure imgf000077_0001
Figure imgf000077_0002
wherein, for urea formation, the compound of formula XIV is converted to the corresponding compound of formula V by first reacting XIV with 4-nitrophenyl chloroformate in the presence of a base, such as pyridine, and a polar aprotic solvent, such as methlyene chloride, followed by reacting the intermediate so formed with an amine and the reaction mixture, so formed, is allowed to stir overnight at room temperature; for sulfonamide formation, the compound of formula XIV is reacted with a sulfonyl chloride compound of the formula, R16-C1, in the presence of a base, such as triethylamine, and a polar aprotic solvent, such as methylene chloride and the reaction is stirred overnight at ambient temperature; for cyanoguanidine formation, the compound of formula XIV is first treated with sodium hydride in an aprotic solvent, such as tetrahydrofuran, followed by reacting, the intermediate so formed with dimethyl-N-cyanodithio iminocarbonate and the reaction mixture so formed is heated to reflux overnight and the N-cyano-S-methyl-isothiourea intermediate is then reacted with an amine in the presence of a polar protic solvent, such as methanol; for amide formation, the compound of formula XIV is reacted with an acid, such as 3-tert-butoxycarbonylaminopropionic acid in the presence of N-methylmorpholine, 0-benzotriazole-1-yl-N,N,N , -tetramethyluronium hexafluorophosphate and a polar aprotic solvent, such as methylene chloride. 5. The method of preparation of claim 1 , wherein:
Figure imgf000078_0001
XVI
Figure imgf000078_0002
VII wherein the compound of formula XVI is converted to the corresponding compound of formula VII by reacting XVI with an amine of the formula, R16 R17N, wherein R16 and R17 are each indepenently hydrogen, a nitrogen containing (C2-C9)heterocycloalkyl or (C2-C8)heteroary) group, or (Cι-C6)alkyl optionally substituted by hydroxy, aminocarbonyl, (C C6)alkyIaminocarbonyl, ((C C6)aikyl)2carbony|, carboxy, (C C6)alkylsulfonylamino, (Cr C6)alkoxycarbonylamino, aminosulfonyl, (C1-C6)alkylaminosulfonyl, ((Cr
C6)alkyl)2aminosulfonyl, (C6-C10)alkoxy, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl, (Cr C6)alkylcarbonylamino, ((C C6)alkylcarbonyl)((CrC6)alkyl)amino, cyano, ureido, (Cr C6)alkylureido, ((C C6)alkyl)2ureido, cyanoguanidino, (CrC6)alkylcyanoguanidino and ((C C6)alkyl)2cyanoguanidino, in the presence of a 10:1 ratio solution of dichloroethane/acetic acid and the reaction mixture is stirred, at room temperature, for a time period between about 30 minutes to about 2 hours and a reducing agent, such as sodium cyanoborohydride is than added to the mixture and the reaction is allowed to stir overnight at room temperature; when R16 and/or R17 is/are hydrogen, the compound of formula VII may further be reacted according to the procedure in claim, to provide ureas, sulfonamides, cyanoguanidinos, or amides. 6. The method of preparation of claim 1 , wherein: X
Figure imgf000079_0001
Figure imgf000079_0002
XXXIX
Figure imgf000079_0003
XXXX wherein the compound of formula X is converted to the corresponding compound of formula XXXX according to the procedure in claim 1or the compound of formula X is converted to the corresponding compound of formula XXXIX according to the procedure in claim 1. 7. The method of preparation of claim 1 , wherein: XXXII
Figure imgf000080_0001
Figure imgf000080_0002
wherein the amide compound of formula XXXII is converted to the corresponding compound of formula XXXI by reacting XXXII with a (C2-C9)heteroaryl lithium reagent in the presence of a polar aprotic solvent at a temperature between about -100°C to room temperature and the resulting reaction mixture is stirred for a time period between about 1 hour to about 24 hoursat a temperature between about -78°C to about 50"C.
PCT/IB2001/000375 2000-03-31 2001-03-14 Novel piperazine derivatives WO2001072728A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
PL01358618A PL358618A1 (en) 2000-03-31 2001-03-14 Novel piperazine derivatives
HU0300567A HUP0300567A3 (en) 2000-03-31 2001-03-14 Process for preparation of novel piperazine derivatives
UA2002097590A UA73553C2 (en) 2000-03-31 2001-03-14 Piperazine derivatives
SK1365-2002A SK13652002A3 (en) 2000-03-31 2001-03-14 Novel piperazine derivatives
EEP200200567A EE200200567A (en) 2000-03-31 2001-03-14 New piperazine derivatives
KR1020027012974A KR20020084273A (en) 2000-03-31 2001-03-14 Novel piperazine derivatives
APAP/P/2002/002637A AP2002002637A0 (en) 2000-03-31 2001-03-14 Novel piperazine
AU2001239469A AU2001239469A1 (en) 2000-03-31 2001-03-14 Novel piperazine derivatives
JP2001570640A JP2003528867A (en) 2000-03-31 2001-03-14 New piperazine derivatives
BR0109703-2A BR0109703A (en) 2000-03-31 2001-03-14 Piperazine Derivatives
MXPA02009645A MXPA02009645A (en) 2000-03-31 2001-03-14 Novel piperazine derivatives.
EP01914083A EP1268455A2 (en) 2000-03-31 2001-03-14 Piperazine derivatives
CA002404626A CA2404626A1 (en) 2000-03-31 2001-03-14 Novel piperazine derivatives
IL15192301A IL151923A0 (en) 2000-03-31 2001-03-14 Novel piperazine derivatives
NZ521290A NZ521290A (en) 2000-03-31 2001-03-14 Novel piperazine derivatives
EA200200873A EA006079B1 (en) 2000-03-31 2001-03-14 Novel piperazine derivatives
DZ013306A DZ3306A1 (en) 2000-03-31 2001-10-04 Piperazine derivatives
IS6546A IS6546A (en) 2000-03-31 2002-09-10 New piperazine derivatives
BG107091A BG107091A (en) 2000-03-31 2002-09-12 Novel piperazine derivatives
NO20024649A NO20024649D0 (en) 2000-03-31 2002-09-27 New piperazine derivatives
HRP20020785 HRP20020785A2 (en) 2000-03-31 2002-09-30 Novel piperazine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19378900P 2000-03-31 2000-03-31
US60/193,789 2000-03-31

Publications (4)

Publication Number Publication Date
WO2001072728A2 true WO2001072728A2 (en) 2001-10-04
WO2001072728A3 WO2001072728A3 (en) 2002-07-18
WO2001072728A9 WO2001072728A9 (en) 2002-10-10
WO2001072728B1 WO2001072728B1 (en) 2003-01-09

Family

ID=22715010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000375 WO2001072728A2 (en) 2000-03-31 2001-03-14 Novel piperazine derivatives

Country Status (34)

Country Link
US (2) US6649611B2 (en)
EP (1) EP1268455A2 (en)
JP (1) JP2003528867A (en)
KR (1) KR20020084273A (en)
CN (1) CN1450999A (en)
AP (1) AP2002002637A0 (en)
AR (1) AR033813A1 (en)
AU (1) AU2001239469A1 (en)
BG (1) BG107091A (en)
BR (1) BR0109703A (en)
CA (1) CA2404626A1 (en)
CZ (1) CZ20023154A3 (en)
DZ (1) DZ3306A1 (en)
EA (1) EA006079B1 (en)
EE (1) EE200200567A (en)
HR (1) HRP20020785A2 (en)
HU (1) HUP0300567A3 (en)
IL (1) IL151923A0 (en)
IS (1) IS6546A (en)
MA (1) MA26887A1 (en)
MX (1) MXPA02009645A (en)
NO (1) NO20024649D0 (en)
NZ (1) NZ521290A (en)
OA (1) OA12239A (en)
PA (1) PA8514401A1 (en)
PE (1) PE20011309A1 (en)
PL (1) PL358618A1 (en)
SK (1) SK13652002A3 (en)
SV (1) SV2002000356A (en)
TN (1) TNSN01047A1 (en)
UA (1) UA73553C2 (en)
WO (1) WO2001072728A2 (en)
YU (1) YU69902A (en)
ZA (1) ZA200207827B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068381A2 (en) * 2001-02-27 2002-09-06 Mitokor Aryl-n-cyanoguanidines and methods related thereto
WO2002102787A2 (en) * 2001-06-20 2002-12-27 Pfizer Products Inc. Novel sulfonic acid derivatives
WO2003035627A1 (en) * 2001-10-22 2003-05-01 Pfizer Products Inc. Piperazine derivatives with ccr1 receptor antagonist activity
WO2004039376A1 (en) * 2002-10-30 2004-05-13 Pfizer Products Inc. Use of piperazine derivatives as ccr1 antagonists
WO2004039377A1 (en) * 2002-10-30 2004-05-13 Pfizer Products Inc. Use of piperazine sulfonic acid derivatives as ccr1 antagonists for the treatment of fibrosis, alzheimer disease and other disorders
WO2004055031A1 (en) * 2002-12-13 2004-07-01 Pfizer Products Inc. Phosphorus-containing piperazine derivatives as ccr1 antagonists
WO2005016344A1 (en) * 2003-08-14 2005-02-24 Pfizer Limited Piperazine derivatives for the treatment of hiv infections
FR2864080A1 (en) * 2003-12-23 2005-06-24 Sanofi Synthelabo New 1-carboxy-piperazine or -homopiperazine derivatives, useful for treatment and prevention of e.g. pain and cancer, are inhibitors of fatty acid amide hydrolase
WO2005077372A1 (en) * 2004-02-06 2005-08-25 Schering Aktiengesellschaft Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma
FR2866888A1 (en) * 2004-02-26 2005-09-02 Sanofi Synthelabo New 1-alkyl-(homo)piperazine-4-carboxylate ester derivatives, are fatty acid amidohydrolase inhibitors useful e.g. for treating pain, cancer or neurodegenerative, cardiovascular, inflammatory or allergic disease
US7339059B2 (en) 2004-02-25 2008-03-04 Active Biotech Ab Benzofurans and indols
US7671215B2 (en) 2003-05-16 2010-03-02 Lek Pharmaceuticals, D.D. Process for the preparation of compounds having an ace inhibitory action
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
US11667613B2 (en) 2019-09-26 2023-06-06 Novartis Ag Antiviral pyrazolopyridinone compounds

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812230B2 (en) * 2001-08-07 2004-11-02 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists for the treatment of progressive renal fibrosis
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
EP1425029A4 (en) * 2001-08-10 2006-06-07 Palatin Technologies Inc Peptidomimetics of biologically active metallopeptides
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
DK1471054T3 (en) * 2002-01-11 2009-11-09 Daiichi Sankyo Co Ltd Amino alcohol derivative or phosphonic acid derivative and medical composition containing them
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
WO2003105853A1 (en) * 2002-06-12 2003-12-24 Chemocentryx, Inc. 1-aryl-4-substituted piperazines derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
RU2332212C2 (en) 2004-02-24 2008-08-27 Санкио Компани, Лимитед Aminoalcohol
AU2005219438B2 (en) * 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
MX2007015617A (en) * 2005-06-10 2008-03-06 Elixir Pharmaceuticals Inc Sulfonamide compounds and uses thereof.
US7829589B2 (en) * 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
AU2007254179B2 (en) * 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
US20080102505A1 (en) * 2006-09-18 2008-05-01 Petrie Thomas R Jr Method of treating viral infections with ultraviolet light
MX2012007172A (en) * 2010-01-05 2012-07-03 Actelion Pharmaceuticals Ltd Piperazines as antimalarial agents.
US9439884B2 (en) * 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
CA2875798A1 (en) 2012-06-07 2013-12-12 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
WO2016145186A1 (en) 2015-03-12 2016-09-15 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
CN113754566B (en) * 2021-10-14 2023-03-21 山东新华制药股份有限公司 OAB-14 synthesis process

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056771A2 (en) * 1997-06-12 1998-12-17 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (en) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4060596A (en) * 1972-09-30 1977-11-29 Sony Corporation Method of making goethite powder
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
JP2651043B2 (en) * 1990-07-10 1997-09-10 麒麟麦酒株式会社 Diphenylmethylpiperazine derivative
FR2724656B1 (en) * 1994-09-15 1996-12-13 Adir NOVEL BENZOPYRAN DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056771A2 (en) * 1997-06-12 1998-12-17 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927218B2 (en) 2001-02-27 2005-08-09 Migenix Corp. Aryl N-cyanoguanidines and methods related thereto
WO2002068381A3 (en) * 2001-02-27 2002-10-31 Mitokor Aryl-n-cyanoguanidines and methods related thereto
US6562821B2 (en) 2001-02-27 2003-05-13 Mitokor Aryl-N-cyanoguanidines and methods related thereto
US7230132B2 (en) 2001-02-27 2007-06-12 Migenix Corp. Aryl N-cyanoguanidines and methods related thereto
WO2002068381A2 (en) * 2001-02-27 2002-09-06 Mitokor Aryl-n-cyanoguanidines and methods related thereto
WO2002102787A2 (en) * 2001-06-20 2002-12-27 Pfizer Products Inc. Novel sulfonic acid derivatives
WO2002102787A3 (en) * 2001-06-20 2004-04-29 Pfizer Prod Inc Novel sulfonic acid derivatives
US6974817B2 (en) 2001-06-20 2005-12-13 Pfizer Inc. Sulfonic acid derivatives
WO2003035627A1 (en) * 2001-10-22 2003-05-01 Pfizer Products Inc. Piperazine derivatives with ccr1 receptor antagonist activity
US7098212B2 (en) 2001-10-22 2006-08-29 Blumberg Laura C Piperazine derivatives
WO2004039376A1 (en) * 2002-10-30 2004-05-13 Pfizer Products Inc. Use of piperazine derivatives as ccr1 antagonists
WO2004039377A1 (en) * 2002-10-30 2004-05-13 Pfizer Products Inc. Use of piperazine sulfonic acid derivatives as ccr1 antagonists for the treatment of fibrosis, alzheimer disease and other disorders
WO2004055031A1 (en) * 2002-12-13 2004-07-01 Pfizer Products Inc. Phosphorus-containing piperazine derivatives as ccr1 antagonists
NL1025010C2 (en) * 2002-12-13 2004-10-14 Pfizer Prod Inc New phosphorus-containing derivatives.
US7671215B2 (en) 2003-05-16 2010-03-02 Lek Pharmaceuticals, D.D. Process for the preparation of compounds having an ace inhibitory action
WO2005016344A1 (en) * 2003-08-14 2005-02-24 Pfizer Limited Piperazine derivatives for the treatment of hiv infections
US7687503B2 (en) 2003-12-23 2010-03-30 Sanofi-Aventis Derivatives of 1-piperazine-and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme
FR2864080A1 (en) * 2003-12-23 2005-06-24 Sanofi Synthelabo New 1-carboxy-piperazine or -homopiperazine derivatives, useful for treatment and prevention of e.g. pain and cancer, are inhibitors of fatty acid amide hydrolase
KR101276427B1 (en) 2003-12-23 2013-06-19 사노피 Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same in therapeutics
US8114866B2 (en) 2003-12-23 2012-02-14 Sanofi-Aventis Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme
WO2005070910A3 (en) * 2003-12-23 2005-10-13 Sanofi Aventis Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the faah enzyme
JP4833080B2 (en) * 2003-12-23 2011-12-07 サノフイ−アベンテイス Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, methods for their preparation and their use as inhibitors of FAAH enzymes
WO2005070910A2 (en) * 2003-12-23 2005-08-04 Sanofi-Aventis Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the faah enzyme
WO2005077372A1 (en) * 2004-02-06 2005-08-25 Schering Aktiengesellschaft Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma
US7339059B2 (en) 2004-02-25 2008-03-04 Active Biotech Ab Benzofurans and indols
AU2005223422B2 (en) * 2004-02-26 2010-06-24 Sanofi-Aventis Derivatives of alkylpiperazine- and alkylhomopiperazine- carboxylates, preparation method thereof and use of same as FAAH enzyme inhibitors
US7973042B2 (en) 2004-02-26 2011-07-05 Sanofi-Aventis Derivatives of alkylpiperazine- and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors
US7482346B2 (en) 2004-02-26 2009-01-27 Sanofi-Aventis Derivatives of alkylpiperazine and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors
FR2866888A1 (en) * 2004-02-26 2005-09-02 Sanofi Synthelabo New 1-alkyl-(homo)piperazine-4-carboxylate ester derivatives, are fatty acid amidohydrolase inhibitors useful e.g. for treating pain, cancer or neurodegenerative, cardiovascular, inflammatory or allergic disease
WO2005090322A1 (en) * 2004-02-26 2005-09-29 Sanofi-Aventis Derivatives of alkylpiperazine- and alkylhomopiperazine- carboxylates, preparation method thereof and use of same as faah enzyme inhibitors
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
US11667613B2 (en) 2019-09-26 2023-06-06 Novartis Ag Antiviral pyrazolopyridinone compounds

Also Published As

Publication number Publication date
NO20024649L (en) 2002-09-27
MXPA02009645A (en) 2003-03-10
CZ20023154A3 (en) 2003-11-12
WO2001072728B1 (en) 2003-01-09
MA26887A1 (en) 2004-12-20
PE20011309A1 (en) 2001-12-29
EA200200873A1 (en) 2003-04-24
NZ521290A (en) 2004-10-29
HUP0300567A2 (en) 2003-09-29
ZA200207827B (en) 2003-09-30
HUP0300567A3 (en) 2003-11-28
EP1268455A2 (en) 2003-01-02
CA2404626A1 (en) 2001-10-04
EA006079B1 (en) 2005-08-25
AU2001239469A1 (en) 2001-10-08
KR20020084273A (en) 2002-11-04
HRP20020785A2 (en) 2004-12-31
UA73553C2 (en) 2005-08-15
BG107091A (en) 2003-04-30
IS6546A (en) 2002-09-10
JP2003528867A (en) 2003-09-30
SV2002000356A (en) 2002-06-07
TNSN01047A1 (en) 2005-11-10
US20040058932A1 (en) 2004-03-25
AR033813A1 (en) 2004-01-07
WO2001072728A3 (en) 2002-07-18
EE200200567A (en) 2004-06-15
WO2001072728A9 (en) 2002-10-10
US6649611B2 (en) 2003-11-18
PL358618A1 (en) 2004-08-09
NO20024649D0 (en) 2002-09-27
IL151923A0 (en) 2003-04-10
CN1450999A (en) 2003-10-22
BR0109703A (en) 2003-02-04
YU69902A (en) 2005-07-19
AP2002002637A0 (en) 2002-09-30
PA8514401A1 (en) 2002-02-21
SK13652002A3 (en) 2004-01-08
DZ3306A1 (en) 2001-10-04
US20020107255A1 (en) 2002-08-08
OA12239A (en) 2003-12-08

Similar Documents

Publication Publication Date Title
US6649611B2 (en) Piperazine derivatives
US20050250790A1 (en) Novel sulfonic acid derivatives
US20020119961A1 (en) Bridged piperazine derivatives
US20040034034A1 (en) Novel piperazine derivatives
EP1534677A1 (en) Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
EP1945606A1 (en) Alkylcarbamoyl naphthalenyloxy- octenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and preparation thereof
DE10130374A1 (en) Substituted N-acyl aniline derivatives, their preparation and their use as medicines
US20040116441A1 (en) Methods of using sulfonic acid derivatives
TANIGUCHI et al. Agents for the Treatment of Overactive Detrusor. VIII. Synthesis and Pharmacological Properties of 4, 4-Diphenyl-2-cycloalkenylamines Including FK584 and 3, 3-or 4, 4-Diphenylcycloalkylamines
AU2002337408A1 (en) Piperazine derivatives with CCR1 receptor antagonist activity
WO2003095439A1 (en) Methods for manufacture of dihydro-furan-2-one derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-699/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 521290

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2001 107091

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001239469

Country of ref document: AU

Ref document number: IN/PCT/2002/00890/DE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20020640

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 02083307

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 200200873

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: PV2002-3154

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 13652002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 151923

Country of ref document: IL

Ref document number: 2001914083

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2404626

Country of ref document: CA

Ref document number: 2002/02248

Country of ref document: TR

Ref document number: 1200200883

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 1020027012974

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018076165

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2001 570640

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009645

Country of ref document: MX

Ref document number: P20020785A

Country of ref document: HR

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 18, DESCRIPTION, REPLACED BY CORRECT PAGE 18

WWP Wipo information: published in national office

Ref document number: 1020027012974

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001914083

Country of ref document: EP

B Later publication of amended claims
WWP Wipo information: published in national office

Ref document number: PV2002-3154

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 521290

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 521290

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 1020027012974

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2001914083

Country of ref document: EP